

Last updated: 17Jan2022

SUSAN P.C. COLE, PHD, FRSC, FCAHS
CURRICULUM VITAE AND BIBLIOGRAPHY

	<i>page</i>
• Education, Honours & Professional Experience	1
• Research Funding & Patents/Licenses	5
• Teaching & Trainee Supervision	9
• Invited Presentations	22
• Service & Administration	34
• Peer-Reviewed Publications	43
• Abstracts/Conference Presentations	66

Citizenship: Canadian (born Toronto, ON, Canada)

Contact: Division of Cancer Biology & Genetics
 Queen's University Cancer Research Institute
 10 Stuart St., Rm 312, Kingston, ON, Canada K7L 3N6
tel: 613-533-2636; *fax:* 613-533-6830
e-mail: spc.cole@queensu.ca
ORCID 0000-0001-6571-6884; *ResearcherID* I-6389-2017
http://qcri.queensu.ca/cancer_biology_genetics/faculty/cole_susan_pc

H-INDEX 86; I10-INDEX 216; CITATIONS 31,900 [GOOGLE SCHOLAR JANUARY 2022]

EDUCATION

1972-1976 Queen's University at Kingston
 BSc (Honours, Biochemistry), 1976

1977-1981 Queen's University at Kingston
 PhD (Pharmacology), 1981
 (*Advisor:* Dr. G.S. Marks)

1981-1982 Postdoctoral Fellow
 Laboratory of Molecular Carcinogenesis
 National Institutes of Health, Bethesda, MD, USA
 (*Advisors:* Drs. H.V. Gelboin, J. Fagan, A. Peacock and M. Seidman)

1982-1985 Research Associate/Senior Postdoctoral Fellow
 Department of Microbiology & Immunology, Queen's University
 (*Advisor:* Dr. J.C. Roder)

DISTINCTIONS (*Honours, Prizes & Awards*)

2022-present Allie Vibert "Vi" Douglas Distinguished University Professor Emerita,
 Queen's University

2020 Jeanne Manery Fisher Memorial Lecture Award – Canadian Society for
 Molecular Biosciences

2019-2021 Allie Vibert "Vi" Douglas Distinguished University Professorship, Queen's
 University

2017-present Honorary Professor, Central South University, Changsha, Hunan, PRC

- 2017-2019 American Association for Cancer Research (AACR) International – Canada, Board of Directors
- 2016-2018 AACR Regional Advisory Subcommittee on Canada
- 2016 Featured in AACR *Cancer Research* 75th Anniversary Celebration website as among top 62 most highly cited authors in 75 years
- 2015 MRP – listed on Council of Ontario Universities (COU) Top 50 Discoveries in University Research Spanning 100 Years
- 2015-2017 Chair, Division for Cancer Pharmacology, American Society of Pharmacology and Experimental Therapeutics (*inaugural*)
https://www.aspet.org/Cancer_Pharmacology_home/
- 2015 6th Annual Hogarty Family Foundation Lecturer, University at Albany Cancer Research Center
- 2014-2018 Honorary Director, Jinan University Clinical Medical Research Institute (Cancer Institute), Guangzhou, Guangdong, PRC
- 2013-2021 Honorary Professor, Jinan University, Guangzhou, Guangdong, PRC
- 2012 PARTEQ Innovations 25th Anniversary Award for “Most Licensed Technology”
- 2012 Queen Elizabeth II Diamond Jubilee Medal
(*national honour in recognition of contributions to Canada*)
- 2011 Fellow of The Canadian Academy of Health Sciences (CAHS) (*elected*)
(*national honour in recognition of outstanding performance in the academic health sciences*)
- 2008 Tier I Canada Research Chair (*renewal*)
- 2008 Pfizer Senior Scientist Award of the Pharmacological Society of Canada
- 2007 National Cancer Institute of Canada Diamond Jubilee Award
(*national honour for outstanding contributions to cancer research*)
- 2006, 2011, 2016 Queen’s University Bracken Chair in Genetics and Molecular Medicine
(*inaugural, renewals*)
- 2005 Robert L. Noble Prize of the Canadian Cancer Society/National Cancer Institute of Canada
- 2003 British Medical Association Medical Book Competition - Commended in the Basic and Clinical Sciences category for *ABC PROTEINS: From Bacteria to Man* (co-editor)
- 2002 Ontario Distinguished Researcher Award
- 2001 Tier I Canada Research Chair (*initial*)
- 2000 Fellow of The Royal Society of Canada, Academy of Science (*elected*)
- 1999 C.W. Gowdey Distinguished Lecturer, University of Western Ontario
- 1996 Monbusho Visiting Professorship, Kyushu University, Japan
- 1994 Queen’s University Prize for Excellence in Research
(*highest university award for research contributions*)
- 1991 Merck-Frosst Award of the Pharmacological Society of Canada
- 1988 Mihran and Mary Basmajian Award for Excellence in Biomedical Research Faculty of Medicine, Queen’s University at Kingston
- 1985-2008 Career Scientist, Ontario Cancer Treatment and Research Foundation (*now* Cancer Care Ontario) (*salary award*)
- 1982 National Cancer Institute of Canada Postdoctoral Fellowship (*declined*)
- 1981 Fogarty International Fellowship, National Institutes of Health (USA)
- 1979 Annual Graduate Student Award of the Pharmacological Society of Canada

POSITIONS HELD

2022-present	Allie Vibert “Vi” Douglas Distinguished University Professor Emerita, Queen’s University
2019-2021	Allie Vibert “Vi” Douglas Distinguished University Professor, Queen’s University
2013	Researcher in Residence, PARTEQ Innovations (<i>inaugural</i>)
2010-2012	Deputy Provost, Queen’s University (<i>inaugural</i>)
2006-2021	Queen’s University Bracken Chair in Genetics and Molecular Medicine (<i>inaugural, renewed 2011, 2016</i>)
2001-2015	Canada Research Chair in Cancer Biology (Tier I)
1985-2008	Scientist, Cancer Care Ontario (<i>formerly OCTRF</i>)
2004-2010	Professor (<i>Adjunct, Group I</i>) Department of Chemistry, Queen’s University at Kingston
2022-2025	Professor (<i>Adjunct, Group I</i>)
1995-2021	Professor (<i>primary, tenured</i>)
1990-1995	Associate Professor
1988-1990	Assistant Professor Department of Pathology & Molecular Medicine, Queen’s University
2011-2021	Professor (<i>cross-appointed</i>) Department of Biomedical and Molecular Sciences, Queen’s University
1995-2011	Professor
1989-1995	Associate Professor Department of Pharmacology & Toxicology
1994-2021	Professor (<i>cross-appointed</i>)
1989-1994	Associate Professor
1985-1989	Assistant Professor Department of Oncology, Queen’s University at Kingston
1983-1989	Assistant Professor Department of Microbiology & Immunology, Queen’s University
1976-1977	Research Technologist University of Alberta Cancer Research Unit, Edmonton, Alberta (<i>Supervisors: Drs. L. Brox and J.F. Henderson</i>)

LEAVES FROM TEACHING & ADMINISTRATIVE RESPONSIBILITIES

Maternity Leaves: April-May 1985; August-December 1987; December 1989-May 1990

Academic Leaves: July-December 2003; July-December 2004; July-December 2013; January-June 2020

Administrative Leave: January-June 2013

EDITORIAL RESPONSIBILITIES

- Editorial Advisory Board, *Molecular Pharmacology*, 2013-2016; 2016-2019
- Deputy and Senior Editor, *Molecular Cancer Therapeutics*, 2000-2012
- Editorial Board, *Journal of Biological Chemistry*, 2002-2007
- Associate Editor, *Cancer Research*, 1999-2002
- Co-editor with I.B. Holland, K. Kuchler and C.F. Higgins. *ABC Proteins: From Bacteria to Man* (Academic Press), 2000-2003 (2003 British Medical Association Competition - Commended in the Basic and Clinical Sciences category)
- Editorial Advisory Board, *Journal of Pharmacology and Experimental Therapeutics*, 1999

PROFESSIONAL MEMBERSHIPS

- American Association for Cancer Research (AACR) (#4183) (*elected – Board of Directors 1996-99; Nominating Committee 2002-04*), 1983-present
- American Society for Biochemistry and Molecular Biology (ASBMB) (#12562), 1999-present
- American Society for Pharmacology and Experimental Therapeutics (ASPET) (#5716), 1997-present; Chair, Division for Cancer Pharmacology, 2015-17
- Canadian Academy of Health Sciences (*elected 2011*)
- Canadian Society for Molecular Biosciences (CSMB) (#413), 1998-present
- Canadian Society of Pharmacology and Therapeutics (CSPT), 2008-2018
- International Society for the Study of Xenobiotics (ISSX)
- International Society for Extracellular Vesicles (ISEV), 2016-17
- International Transmembrane Transporter Society (ITTTS) (*Councillor 2014-21*), 2014-21
- Pharmacological Society of Canada (PSC) (*elected Councillor 1995-98*), 1989-2008
- Royal Society of Canada, Academy of Science (#31026) (*elected 2000*)
- Society of Toxicology (SOT), 2004-2010

BOARD MEMBERSHIPS

- Board of Directors, AACR International – Canada, 2016-2019 (*invited*)
- Board of Trustees, Queen's University, 2008-2010 (*elected by alumni*)
- Board of Directors, PARTEQ Innovations Inc., Kingston, 1999-2002; 2002-2005; 2005-2006 (*invited*)
- Board of Directors, American Association for Cancer Research, 1996-1999 (*elected*)
- Scientific Advisory Board, Active Pass Pharmaceuticals, Vancouver, 2001-2007 (*invited*)
- Board of Directors, Thor Cancer 1 Dx Inc, 2015-2018 (*invited*)

CONSULTING

- ISIS Pharmaceuticals, Carlsbad, CA (1993-97)
- Eli Lilly Pharmaceutical Company, Indianapolis, IN (1995-2002)
- Monsanto/Searle, St. Louis, MO (1996)
- Merck-Frosst, Montréal (2000)
- Boehringer-Ingelheim Pharmaceuticals, Inc., Ridgeway, CT (2001)

RESEARCH FUNDING & PATENTS/LICENCES

PEER-REVIEWED GRANTS, CONTRACTS and AWARDS

EXTERNAL

As Principal Investigator:

1985	• S.P.C. Cole	OCTRF	Operating (<i>start-up</i>)	\$19,018
1985-87	• S.P.C. Cole	MRC (MA-9355)	Operating	\$100,200
1985-88	• S.P.C. Cole B.G. Campling	NCIC (No. 455)	Operating	\$157,462
1987-96	• S.P.C. Cole	NCIC (No. 2049)	Operating	\$921,077
1988-90	• S.P.C. Cole	Cancer Research Society	Operating	\$68,000
1989-12	• S.P.C. Cole R.G. Deeley	MRC (MT-10519) CIHR (MOP-10519)	Operating	\$3,171,950
1992-94	• S.P.C. Cole R.G. Deeley	Cancer Research Soc.	Operating	\$76,000
1996-97	• S.P.C. Cole	NCIC (No. 7196)	Operating	\$97,000
1997-00	• B.G. Campling S.P.C. Cole R.G. Deeley	NCIC (Terry Fox Program Project)	Operating	\$1,842,737
2000-03	• S.P.C. Cole R.G. Deeley M. Petkovich	NCIC (Terry Fox Program Project)	Operating	\$1,999,368
2003-06	• S.P.C. Cole	NCIC (No. 14219)	Operating	\$416,718
2001-08 2008-15	• S.P.C. Cole	CIHR	Canada Research Chair (Tier 1)	\$1,400,000 \$1,400,000
2010-11	• S.P.C. Cole	Prostate Cancer Fight Foundation	Operating	\$32,000
2010-15	• S.P.C. Cole	CIHR (MOP-106513)	Operating	\$663,619
2015-17	• S.P.C. Cole	Prostate Cancer Fight Foundation	Operating	\$31,456
2014-19	• S.P.C. Cole	CIHR (MOP-133584)	Operating	\$589,465
<i>Equipment/Maintenance/Infrastructure/Training Grants (as P-I):</i>				
1993	• S.P.C. Cole	NCIC	Equipment	\$26,825
1998-01	• S.P.C. Cole	MRC (MT-14055)	Studentship Voucher	\$62,766
2001	• S.P.C. Cole	CFI (No. 200994)	Infrastructure	\$124,866
2002	• S.P.C. Cole	Ontario Innovation Trust (OIT)	Infrastructure	\$124,866

2011-12	• S.P.C. Cole T.E. Massey R. Oleschuk	CFI Leaders Opportunity Fund (LOF) (No. 27270)	Infrastructure	\$399,938
2011-12	• S.P.C. Cole T.E. Massey R. Oleschuk	Ministry of Research & Innovation (MRI) New Opportunities Fund	Infrastructure	\$400,000
2014-19	• S.P.C. Cole T.E. Massey R. Oleschuk	CFI Infrastructure Operating Fund (IOF) (No. 27270)	Operating	\$119,981
<i>Contract (as P-I):</i>				
1993-97	• S.P.C. Cole R.G. Deeley	ISIS Pharmaceuticals	Contract	\$225,000
1995-97	• S.P.C. Cole R.G. Deeley	Centocor Diagnostics	Contract	\$100,000
1995	• S.P.C. Cole R.G. Deeley	Glaxo Pharmaceuticals	Contract	\$14,000
1996-97	• S.P.C. Cole R.G. Deeley	Monsanto/Searle	Contract	\$10,000
1997	• S.P.C. Cole	Bristol-Myers Squibb	Contract	\$3,000
2001-02	• S.P.C. Cole	Procter & Gamble	Contract	\$57,960
<i>As Co-Investigator:</i>				
1985-87	• P.G. Forkert S.P.C. Cole	Ontario Thoracic Society	Operating	\$28,000
1985-88	• A.R. Giles S.P.C. Cole <i>et al</i>	NIH (US)	Operating	\$531,226
1994-97	• R.G. Deeley S.P.C. Cole	NCIC (No. 4570)	Operating	\$341,250
2003-08	• R.G. Deeley S.P.C. Cole	CIHR (MOP-62824)	Operating	\$954,800
2003-08	• B. Bennett S.P.C. Cole C. Ward	CIHR (MOP-64337)	Operating	\$607,915
2009-14	• R.G. Deeley S.P.C. Cole	CIHR (MOP-97877)	Operating	\$980,680
2018-20	• Y. Cai S.P.C. Cole	Guangzhou Economic Technology Development Zone	Operating	\$274,000
<i>Equipment/Maintenance/Infrastructure/Training Grants (as Co-I):</i>				
1984	• J.C. Roder S.P.C. Cole	MRC	Equipment	\$22,000
1984	• J.C. Roder S.P.C. Cole	NSERC	Equipment	\$32,082
1985	• S.P.C. Cole	MRC	Equipment	\$15,092

1986-04	• B. Elliott S.P.C. Cole <i>et al</i>	MRC (MME-7827) CIHR (MT-7827)	Multi-user Equip/Maintenance	\$676,276
1987	• H.F. Pross S.P.C. Cole	Cancer Research Society	Equipment	\$7,154
1988	• H.F. Pross S.P.C. Cole	NCIC	Equipment	\$7,467
1990-91	• H.F. Pross S.P.C. Cole <i>et al</i>	MRC (ME-11102)	Equipment	\$47,000
2000	• T.G. Flynn S.P.C. Cole <i>et al</i>	CFI; OIT; Industry In- Kind Contributions	Infrastructure/ Equipment	\$8,962,571
2000	• J.L. Pater S.P.C. Cole <i>et al</i>	OIT	Infrastructure	\$4,473,600
2002-06	• G. Coté S.P.C. Cole <i>et al</i>	CIHR (STP-53905)	Training Grant in Proteomics	\$1,200,000
2002-09	• L. Mulligan S.P.C. Cole <i>et al</i>	CIHR (STP-53913)	Training Grant in Cancer	\$2,100,000
2005-06	• P. Greer S.P.C. Cole <i>et al</i>	CIHR (MME-74989)	Multi-user Equip/ Maintenance	\$92,165
2005-08	• A. Mak S.P.C. Cole <i>et al</i>	CIHR (MME-54191)	Multi-user Equip/ Maintenance	\$273,000
2005-10	• B.E. Elliott S.P.C. Cole <i>et al</i>	CIHR (MME-74988)	Multi-user Equip/ Maintenance	\$300,370
2006-11	• P.L. Davies S.P.C. Cole <i>et al</i>	CIHR (PRG-80162)	Research Resource	\$1,022,222
2009-15	• L. Mulligan S.P.C. Cole <i>et al</i>	CIHR (STP-53913)	Training Grant in Cancer	\$1,950,000
<i>Contract (as Co-I):</i>				
1998-02	• R.G. Deeley S.P.C. Cole	Eli Lilly	Contract	\$620,000
<i>Declined:</i>				
1985-87	• S.P.C. Cole B.G. Campling	MRC (MA-7941)	Operating	\$100,915
1987-89	• S.P.C. Cole	MRC (MA-9355)	Operating	\$108,000
1997-05	• S.P.C. Cole	MRC (MT-14055)	Operating	\$1,088,790
2000-03	• S.P.C. Cole	NCIC	Operating	\$450,000
2000-03	• R.G. Deeley S.P.C. Cole	NCIC	Operating	\$450,000
2000-05	• R.G. Deeley S.P.C. Cole	MRC	Operating	\$980,000
2003-08	• R.G. Deeley S.P.C. Cole	NCIC	Operating	\$750,000

INTERNAL

As Principal Investigator:

1984	• S.P.C. Cole	Queen's University Dean's MRC	Operating	\$4,725
1985	• S.P.C. Cole	Clare Nelson Bequest- KGH	Operating	\$9,000
1988	• S.P.C. Cole	Clare Nelson Bequest- KGH	Operating	\$9,000
2014	• S.P.C. Cole	Clare Nelson Bequest- KGH	Operating	\$10,000
1984	• S.P.C. Cole	Ontario Thoracic Society Block Grant	Equipment	\$6,978
1987	• S.P.C. Cole	Queen's Appeal Committee	Equipment	\$8,371
1992	• S.P.C. Cole S.E.L. Mirski	Clare Nelson Bequest- KGH	Equipment	\$6,442
1995	• S.P.C. Cole	Clare Nelson Bequest- KGH	Equipment	\$4,000

As Co-Investigator:

1985	• P.G. Forkert J.S. Elce S.P.C. Cole	Queen's University Principal's Development Fund	Operating	\$5,000
1986	• R.A. Whitney S.P.C. Cole	Clare Nelson Bequest- KGH	Operating	\$9,600
1987	• P.G. Forkert S.P.C. Cole	Deans' MRC	Operating	\$5,000
1990	• H.F. Pross S.P.C. Cole	Clare Nelson Bequest- KGH	Operating	\$6,880
1987	• S.P.C. Cole S.E.L. Mirski	Ontario Thoracic Society Block Grant	Equipment	\$8,371
1987	• J.H. Gerlach S.P.C. Cole et al	Queen's Lottery Funding	Equipment	\$30,895
1995	• A. Boag S.P.C. Cole et al	KGH	Equipment	\$11,179
2018	• T.E. Massey S.P.C. Cole	Spear and Start Fund, Queen's	Operating	\$29,000

PATENTS

[assigned to Queen's University]

- Multidrug Resistance Gene (International Publication No. WO 94/10303, issued 1994/05/11; U.S. Patent No. 5,489,519, issued 1996/02/06; Australian Patent No. 671160, issued 1996/12/03; Australian Patent No. 682140, issued 1998/01/08; Canadian Patent No. 2,147,372, issued 2004/04/06; Japanese Patent No. 3,682,926, issued 2005/06/03; European Patent No. 0666911B9, issued 2008/04/02).
- Isolated Nucleic Acid Molecules Encoding Multidrug Resistance Proteins (U.S. Patent No. 5,766,880; issued 1998/06/16)

- Methods for Identifying Multidrug Resistant Tumor Cells (U.S. Patent No. 5,882,875; issued 1999/03/16)
- Methods for Conferring Multidrug Resistance on a Cell (U.S. Patent No. 5,891,724; issued 1999/04/06)
- Methods for Identifying Chemosensitizers (U.S. Patent No. 6,001,563; issued 1999/12/14)
- Multidrug Resistance Proteins (U.S. Patent No. 6,025,473; issued 2000/02/15)
- Antibodies to a Multidrug Resistance Protein (U.S. Patent No. 6,063,021; issued 2000/05/16)

LICENSING AGREEMENTS

[Career Total: 28] [through PARTEQ Inc.]

- Abnova (2012-present)
- Alexis Biochemicals Corporation (2003-2009)
- Avigen, Inc. (1993-1997)
- BASF Research Corp. (1994-1996)
- BD Biosciences (formerly Pharmingen) (2001-present)
- Becton Dickinson and Company (now Corning) (2004-2016)
- BioLegend (formerly Covance Antibody Services) (2002-present)
- Cadus Pharmaceutical Corp. (1993-1998)
- Centocor, Inc. (1995-2000)
- Eli Lilly and Company (1993-2006)
- Enzo Life Sciences AG (2008-present)
- Genetex (2008-present)
- Genetic Therapy, Inc. (1994-1998)
- GenoMembrane Inc. (2008-2010)
- IDEC Pharmaceuticals Corp. (1993-1994)
- Indiana University (Bloomington) (2009-present)
- Ingenex, Inc. (1993-1998)
- ISIS Pharmaceuticals Inc. (1993-2000)
- MBL International (2008-present)
- Millipore Sigma (formerly Chemicon International Inc and Sigma Aldrich.) (2001-present)
- Netherlands Cancer Institute (2009-present)
- Novus Biologicals, LLC (2009-present)
- R&D Systems, Inc. (now Bio-Techne) (2002-present)
- Ricerca Biosciences, LLC (2012-present)
- Santa Cruz Biotechnology, Inc. (2001-present)
- Signet Laboratories, Inc. (2002)
- Solvo Biotechnologies Inc. (now Citoxlab) (2005-2017)
- Stichting Research Fonds Pathologie (2009-present)
- United States Biological (2008-present)

TEACHING & TRAINEE SUPERVISION

UNDERGRADUATE TEACHING & SUPERVISION

Teaching:

- CANC440/0.5 - Cancer Biology & Therapeutics (course development), 2007-08

- CANC440/0.5 - Cancer Biology & Therapeutics (lectures, seminars), 2009, 2010
- CANC440/3.0 - Cancer Biology & Therapeutics (lectures, seminars), 2014-2021
- CANC440/3.0 - Cancer Biology & Therapeutics – Course Co-coordinator, 2017, 2021
- CANC440/3.0 – Cancer Biology & Therapeutics – Course Coordinator, 2018, 2019
- PATH425/3.0 - Current Topics in Human Genetics (1 h lecture, 4 h seminar), 2015 (x 2), 2016, 2017

- PHAR416/0.5 - Xenobiotic Disposition & Toxicity (lectures), 2001-02; 2005-08
- PHAR450/0.5 - Principles of General Pharmacology II (lectures), 1998-2002; 2005-09
- PHAR340/0.5 - Principles of General Pharmacology I (lectures), 1996; 2004-10
- PHAR411/0.5 - Principles of Pharmacology & Toxicology (lectures), 1984, 86, 88, 90, 92, 94-00 (*course discontinued 2001*)
- PHAR411/0.5 - Principles of Pharmacology & Toxicology - Course Coordinator 1990, 92, 94 (*course discontinued 2001*)
- PHAR420/1.0 - Principles of Pharmacology (lectures, tutorial), 1988-89; 1991-96 (*course discontinued 1996*)
- PHAR520/1.0 - Medical Pharmacology (lectures, lab, tutorial), 1991, 92 (*course discontinued 1992*)
- PHAR230/0.5 - Pharmacology for the Health Sciences (lectures), 1991
- PHAR420/1.0 Laboratory Demonstrator, 1977-81

- MICR520/1.0 (for medical students), 1984-86
- MICR120/1.0 (lectures), 1985-86
- MICR432/0.5 (lectures), 1985-86

- CHEM112/1.0, Laboratory Demonstrator, 1974-76; 1978-80

Supervision (>40 completed):

CANC499/9.0 or 12.0:

2015-2016 E.E. Smith (winner of the Cancer Biology Undergraduate Research Prize)
 2017-2018 A. Lauzon

PHAR499/1.5; PHAR499/9.0:

1991-1995 K. Almquist, B. Smith, J. Ross (with B. Bennett), A.J. Lang
 1992-1993 K. Ernst
 1997-1998 L. Organ
 1998-1999 B. Levac
 2000-2001 K.W.J. Lee
 2001-2002 J.C. Bielawski
 2002-2003 N.S. Kanji
 2003-2004 J.D.H. Leung
 2004-2005 S. Ikeda
 2005-2006 M.X. Luo
 2006-2007 M.K. DeGorter (winner of undergraduate research prized; Vanier Scholar)
 2008-2009 L.C.M. Hawkins
 2013-2014 M.A. Csandl

2016-2017 E. St. George (with T. Massey)

PATH420/499/1.5:

1992-1993 D.R. Hipfner
 1993-1994 S. McGill
 1994-1995 Z. Schwartz
 1996-1997 H.J. Cummings, T. Subissati
 2000-2001 Z. Kaderali
 2002-2003 Q. Li
 2008-2009 Y. Sun

BCHM421/422/2.0:

2000-2001 J. Bates
 2001-2002 A. Smaggus, C. Polson, C. Montgomery
 2002-2003 S. Woods
 2003-2004 J. Chiu, J. Cao

BCHM421/422/12.0:

2012-2013 L. Sinai

MICR440/1.5:

1983-1986, 1988 R. Cheng, L. Dunphy, P. Paterson, E. Osborne, S. Miner

SUMMER STUDENTS:

1984 S. Buchanan (MRC summer studentship) (with J. Roder)
 1985 R. Cheng (with J. Roder)
 1987 H. Downes (NSERC summer studentship)
 1988 H. Downes (Thomas M. and Louise A. Brown Research Scholarship)
 K. Thompson
 1989 F. Dicke
 1990 F. Dicke (PMAC summer studentship); K. Almquist
 1991 K.C. Almquist
 1992 D.R. Hipfner; K.C. Almquist (PMAC summer studentship)
 1994 R. Comley; S. Gauldie
 1995 R. Comley; S. Ahmad; D. Fenech (PMAC summer studentship)
 1996 A. Lang; E. Leslie
 1997 H. Cummings; J. Ooi (PMAC summer studentship)
 1998 B. Levac (PMAC summer studentship); M. McFadden
 2000 J. Bryant
 2001 J. Bielawski
 2002 A. Saltzman; N. Kanji
 2003 J.H. Foley
 2004 S. Nandra; S. Ikeda
 2005 S. Nandra; J. Poh
 2006 A. Lau; K. Starr
 2007 M. DeGorter
 2008 L.C.M. Hawkins
 2013 M.A. Csandl
 2015 E.E. Smith

2016 E.E. Smith (QCRI Craig Jury summer studentship)
 2017 A. Lauzon

CO-OP STUDENTS:

2019 J.M. Steele (University of Waterloo)

VOLUNTEERS:

2011-12 G. Mullins

GRADUATE and POSTDOCTORAL TEACHING & SUPERVISION:**Teaching:**

- BMED860/3.0 - Fundamentals of Research, 2014-15
- PHAR812/1.0 - Methodology in Pharmacology & Toxicology (*evaluation/grading of research proposals; laboratory; lecture*), 1990-07
- PHAR811/0.5 - Principles of Pharmacology & Toxicology (*lectures, journal clubs, essay supervision, evaluations*), 1984, 86, 88, 90, 92; 1994-00
- PHAR811/0.5 - Principles of Pharmacology & Toxicology - Course Coordinator, 1990, 92, 94 (*course discontinued 2001*)
- PHAR811/0.5 - Topics in Drug Discovery & Development, 2002, 06, 08
- PATH823/0.5 - Cancer Biology (*lectures, journal club, essay supervision*), 1986, 92, 94, 96, 98, 2000
- PATH822/0.5 - Experimental Cancer Therapeutics, 2007, 2009, 2019, 2021
- PATH827/1.0 - Research Project in Pathology, 2003-07, 2009-10, 2010-11, 2016, 2019-20
- Immunology Graduate Courses (*lectures, seminar leader*), 1983-87, 1989

Supervision Summary:

- *Graduate Student Supervision:*
 - 18 MSc, 13 PhD theses completed (3 co-supervised)
- *Postdoctoral Fellow Supervision:*
 - 31 completed (1 co-supervised)
- *Graduate Student Committees:*
 - Thesis Advisory Committees (*since 2001*): 28
 - PhD Comprehensive Examining Committees (*since 1993*): 27
 - Queen's Thesis Examining Committees (*since 1993*): 76 (19 as Chair)
 - External PhD Thesis Examiner (*since 1993*): 10

GRADUATE STUDENTS:**MSc**

1985-1988 S.A. Mohamdee - MSc (Microbiology & Immunology)
Thesis: Monoclonal Antibodies Against the Multidrug Resistant Human Ovarian Carcinoma Cell Line, 2780.AD645
 [current position: high school science teacher, Belleville, ON]

1987-1989 B. Campigotto - MSc (Microbiology & Immunology)
 (R.S. McLaughlin Fellowship 1987; Ontario Thoracic Society 1988)

- Thesis:* Modulation of Major Histocompatibility Complex Antigen Expression in a Drug Sensitive and a Drug Resistant Human Small Cell Lung Cancer Cell Line
 [last known position: secondary school teacher, Ontario]
- 1988-1991 M.J. Pinkoski - MSc (Pathology); (PhD, University of Alberta)
 (Cancer Research Society Graduate Fellowship 1989-91)
Thesis: Identification of a Resistance Associated Antigen in a Multidrug Resistant Small Cell Lung Carcinoma Cell Line
 [last known position: Adjunct Professor, University of Alberta, Edmonton, AB]
- 1989-1991 K. Krebes - MSc (Microbiology & Immunology)
Thesis: Small Cell Lung Cancer Multidrug Resistance-Associated Antigens on Peripheral Blood Mononuclear Cells
 [last known position: Staff Scientist, DuPont, USA]
- 1990-1992 C.D. Evans - MSc (Pharmacology & Toxicology)
 (Queen's University Graduate Fellowship 1990)
Thesis: Multidrug Resistance in Small Cell Lung Cancer: The Role of Topoisomerase II
 [last known position: Acting Vice-President, Emergency Management, Public Health Agency Canada, Ottawa, ON]
- 1993-1995 Q. Yu - MSc (Pharmacology & Toxicology)
 (Queen's University Graduate Fellowship 1993)
Thesis: Molecular Characterization of a Mutant Topoisomerase II α mRNA in the Drug Resistant Lung Cancer Cell Line, H209/V6
 [current position: see below]
- 1995-1996 S.R. Wright - MSc (Pathology) (*not completed*) (*primary supervisor:* R.G. Deeley)
 (Ontario Graduate Scholarship 1995)
 [current position: Family physician, Waterloo, ON]
- 1998-2000 M.J. Savoie - MSc (Pharmacology & Toxicology)
Thesis: Role of mRNA Stability in Reduced Topoisomerase II β Expression in a Drug Resistant Lung Cancer Cell Line
 [current position: Manager, Office of Compliance and Oversight, Canadian Cancer Trials Group, Kingston, ON]
- 2001-2003 D. Situ - MSc (Pathology & Molecular Medicine)
Thesis: Functional Consequences of Charged Amino Acid Substitutions In and Around Transmembrane Helices in the Third Membrane Spanning Domain of MRP1
 [current position: Toxicology Evaluator, Health Canada, Ottawa, ON]
- 2002-2004 K.F. Clark - MSc (Pathology & Molecular Medicine) (PhD 2013, UPEI)
Thesis: Examining the Extracellular Topology of Multidrug Resistance Protein 1 (MRP1): A Substituted Cysteine Accessibility Method
 [current position: Research Scientist & Assistant Professor, Atlantic Veterinary College, Lobster Science Centre UPEI]
- 2004-2006 M. Chan - MSc (Pharmacology & Toxicology); (PhD 2013, Queen's)
 (Queen's Cancer Research Institute - CIHR Transdisciplinary Training Program in Cancer Research Graduate Award, 2004-06)

- Thesis: Mechanisms of Tumour Cell Death Induced by Novel Titanium-based Agents*
 [current position: see below]
- 2005-2007 C. (Y.M.) Chan - MSc (Pathology & Molecular Medicine)
Thesis: Functional Analysis of Single Nucleotide Polymorphisms in the Proximal Promoter Regions of the Multidrug Transporter Genes MRP1/ABCC1 and MRP4/ABCC4
 [current position: Research Project Manager, Saskatchewan Pulse Growers, Saskatoon, SK]
- 2006-2008 X. Wang - MSc (Pathology & Molecular Medicine)
Thesis: Biochemical Characterization of Nucleotide and Protein Interactions of Human Multidrug Resistance Protein 1 (MRP1/ABCC1)
 [current position: Scientist, Abmart, Shanghai, PRC]
- 2007-2009 S.V. Molinski - MSc (Pharmacology & Toxicology); (PhD 2015, University of Toronto)
 (Eldon Boyd Fellowship 2007-08, 2008-09)
Thesis: Functional Analysis of an α -Helical Region in the Human Multidrug and Organic Anion Transporter MRP1
 [last known position: Applications Scientist, Cyclica Inc., Toronto]
- 2009-2011 R.L. Myette – MSc (Pathology & Molecular Medicine)
Thesis: Chalcogenopyrylium Dyes as Modulators of Multidrug Resistance Protein (MRP) 1, MRP2 and MRP4 Transport Activities
 [current position: medical resident in pediatric nephrology, University of Ottawa]
- 2014-2015 R.A. Millott - MSc (Biomedical & Molecular Sciences) (*withdrew*)
 (Ontario Graduate Scholarship 2014-2015; CIHR Canada Graduate Scholarship; CUFW Memorial Fellowship 2015-16)
 [last known position: graduate student, University of Alberta]
- 2014-2015 M.A. Csandl - MSc (Biomedical & Molecular Sciences)
 (Eldon Boyd Fellowship 2014)
Thesis: Effect of Leukotriene Modifiers (LTMs) on Organic Anion Transport by Multidrug Resistance Proteins (MRPs)
 [current position: Optometrist, Kelowna, BC]
- 2016-2018 J.F. Power – MSc (Pathology & Molecular Medicine)
 (Terry Fox Research Institute Future Leader Studentship 2016; R.S. McLaughlin Fellowship 2017-18)
Thesis: The Role of Extracellular Vesicles in the Transfer of Multidrug Resistance in Human Ovarian Cancer Cells
 [current position: student, Algonquin College, ON]
- 2016-2018 E.E. Smith – MSc (Pathology & Molecular Medicine)
 (R.S. McLaughlin Fellowship 2016-17; Queen's Graduate Entrance Tuition Award 2016; Bracken Fellowship 2017-18)
Thesis: The Regions Connecting the Membrane-spanning and Nucleotide-binding Domains of Multidrug Resistance Protein 1 (MRP1) are Functionally Distinct
 [current position: Technical Officer, National Research Council, Montreal]

PhD

- 1991-1998 E.U. Kurz - PhD (Pharmacology & Toxicology) (*primary supervisor*)
(R.S. McLaughlin Fellowship 1991; MRC Studentship 1992-1997; Colorado Cancer Society Fellowship 1999; Alberta Heritage Foundation Fellowship 2001)
Thesis: Studies of Molecular Mechanisms Regulating Transcription of the Human Multidrug Resistance Protein (MRP) Gene
[*current position*: Associate Professor and Associate Dean, Dept. of Pharmacology & Therapeutics, University of Calgary]
- 1995-1998 Q. Yu - PhD (Pharmacology & Toxicology)
(Fogarty International Fellowship, NIH 1998)
Thesis: Molecular Analyses of Topoisomerase II α Alterations in a Drug Resistant Lung Cancer Cell Line
[*current position*: Senior Group Leader, Cancer Biology and Pharmacology, Genome Institute of Singapore]
- 1993-1998 K.C. Almquist - PhD (Pathology) (*not completed*)
[*last known position*: Research Associate, Guelph University]
- 1993-1998 D.R. Hipfner - PhD (Pathology)
(Queen's University Graduate Fellowship 1993; MRC Studentship 1994-1998; Queen's University – Division I (Life Sciences) Outstanding Thesis 1999; MRC Postdoctoral Fellowship 1998-2001; EMBL Fellowship 1998-2001; Human Frontiers Fellowship 1998-2002)
Thesis: Structural and Functional Analysis of the Multidrug Resistance Protein, MRP, Using Monoclonal Antibodies
[*current position*: Associate Research Professor, Director of Epithelial Cell Biology Research Unit, Institut de Recherches Cliniques de Montréal (IRCM)]
- 1995-2000 M. Gao - PhD (Pathology) (*primary supervisor*: R.G. Deeley)
(Queen's University Graduate Fellowship 1997-2000)
Thesis: Structure and Function Analysis of the Human Multidrug Resistance Protein 1, MRP1
[*current position*: Senior Research Investigator II, Bristol-Myers Squibb, NJ]
- 1996-2001 A.J. Lang - PhD (Pharmacology & Toxicology)
Thesis: Human Topoisomerase II: Investigation of Human *TOP2A* and *TOP2B* Structure and Regulation (CIHR Studentship 1998-2001)
[*current position*: Manager, Medical Information, Janssen Pharmaceuticals, Toronto]
- 1997-2002 E.M. Leslie - PhD (Pharmacology & Toxicology)
(Ontario Graduate Scholarship 1997, 1998; CIHR Doctoral Award 1999-2002; CIHR Postdoctoral Fellowship 2002-2005; Davies Charitable Foundation Fellowship 2002)
Thesis: Substrate Specificity and Structure-Function Relationships of Human Multidrug Resistance Protein 1 (MRP1)
[*current position*: AIHS Scholar, Associate Professor (with tenure) of Physiology and Laboratory Medicine & Pathology, University of Alberta]
- 1998-2004 C.J. Oleschuk - PhD (Pharmacology & Toxicology)
(CIHR Doctoral Award 1998-2001; Ontario Graduate Scholarship 2001-2002; Clinical Chemistry Fellowship, McMaster University 2004-2006)
Thesis: Structure-Function Studies of the Multidrug Resistance Proteins

- [*current position*: Clinical Biochemist, Department of Pathology & Molecular Medicine; Kingston Health Science Centre, Kingston, ON]
- 1997-2005 K.E. Weigl - PhD (Pathology & Molecular Medicine)
(McLaughlin Fellowship 2001-2003)
Thesis: Biochemical Investigations of MRP1: Analysis of Glycosylation and Topology
[*current position*: Laboratory Head, Enzyme Analytics, Abbott Products GmbH, Hannover, Germany]
- 2001-2007 I.J. Létourneau - PhD (Pharmacology & Toxicology)
(Frank Carrel Fellowship 2001, 2002; Ontario Graduate Scholarship 2003-2004; CIHR Doctoral Award, 2004-2007; FRSQ PDF 2009-2012)
Thesis: Pharmacogenetic, Functional and Toxicological Studies of the Human Multidrug and Organic Anion Transporters MRP1, MRP2 and MRP3
[*current position*: Associate, Institut national d'excellence en santé et en services sociaux, Québec, QC]
- 2004-2008 G. Potter - PhD (Chemistry) (*primary supervisor*: M.C. Baird)
Thesis: A Novel Series of Titanocene Dichloride Derivatives: Synthesis, Characterization and Assessment of Their Cytotoxic Properties
[*current position*: Research Engineer, Borealis AG, Austria]
- 2005-2011 A.J. Slot - PhD (Pathology & Molecular Medicine)
(Robert John Wilson Fellowship 2005-2007; R.S. McLaughlin Fellowship 2007-2008; CIHR Doctoral Award, 2007-2010)
Thesis: Modulation of Human Multidrug Resistance Proteins by Reactive Quinone-based Glutathione Conjugates
[*last known position*: Acting Associate Director, Health Canada, Ottawa]
- 2009-2012 M.Z. Perry – PhD (Pathology & Molecular Medicine) (*withdrew*)
[*current position*: Study Co-ordinator, Hospital for Sick Children, Toronto]
- 2006-2013 M. Chan - PhD (Pharmacology & Toxicology)
(Robert John Wilson Fellowship 2006-2008; R.S. McLaughlin Fellowship 2008-2009)
Thesis: Studies of the Misprocessing Mutations R1202D and E1204K in the Drug and Organic Anion Transporter, MRP1 (*ABCC1*) in Cultured HEK Cells
[*last known position*: McKinsey Management Consulting, USA]
- 2009-2015 M.F. Miah – PhD (Pathology & Molecular Medicine)
(Robert John Wilson Fellowship 2009-2011; CIHR Banting and Best Graduate Scholarship 2011-2013; Ontario Graduate Scholarship 2010-2011)
Thesis: Investigations into the Plasma Membrane Trafficking of Multidrug Resistance Protein 4 (ABCC4/MRP4)
[*current position*: Senior Consultant, Canadian Imperial Bank of Commerce, Toronto]

POSTDOCTORAL FELLOWS

- 1985-1990 S.E.L. Mirski (PhD, McMaster University) (maternity leave 8/86-1/87)
[*current position*: Biosafety Officer, Queen's University, Kingston]
- 1990-1992 G. Bhardwaj (MB, India)
[*current position*: Gastroenterologist, FL]
- 1990-1992 J.E. Mackie (PhD, Queen's University)
(MRC Postdoctoral Fellowship, 1990-92)

- [*current position*: Assistant Professor, Trent/Fleming School of Nursing, Trent University, Peterborough, ON]
- 1992-1994 A.J. Stewart (PhD, Newcastle, UK)
(Cancer Research Society Inc. Fellowship, 1992-94)
[*last known position*: Principal, AJS Consulting Inc., Vancouver]
- 1994-1995 Y. Canitrot (PhD, Perpignan, France)
(League Nationale Française Contre le Cancer Fellowship, 1994-95)
[*current position*: Scientist, INSERM, Toulouse, France]
- 1995-1997 I. Neverova (PhD, Moscow University)
[*last known position*: Adjunct Assistant Professor, Dept. Physiology, Queen's University]
- 1996-1997 M. Yamazaki (PhD, Toho University, Japan)
[*last known position*: Manager, Clinical Development Department I, R&D Division, Daiichi Sankyo, Tokyo, Japan]
- 1993-1998 D.W. Loe (PhD, Guelph University)
[*current position*: Managing Director and Analyst, Healthcare & Biotechnology, Leede Jones Gable, Toronto]
- 1996-1998 S.L. Olsen (PhD, Melbourne University, Australia)
(International Agency for Cancer Research Fellowship, 1996-97)
[*last known position*: Research Associate, Fiona Elsey Cancer Research Laboratory, Ballarat University, Australia]
- 1998-2000 W. Qiu (PhD, Shanghai Institute of Entomology, China)
[*last known position*: Research Associate, Hospital for Sick Children, Toronto]
- 1998-2001 K.-i. Ito (MD, Kanazawa University; PhD, Kyushu University, Japan)
[*current position*: Professor and Chair, Dept. of Surgery (II), Shinshu University, Matsumoto, Japan]
- 1999-2001 Y.M. Qian (PhD, Hong Kong University) (*primary supervisor*: R.G. Deeley)
[*last known position*: Bristol Myer Squibb, USA]
- 1997-2002 Q. Mao (PhD, Berne University, Switzerland)
[*current position*: Associate Professor (with tenure), Dept. of Pharmaceutics, University of Washington, Seattle, WA]
- 2001-2002 C.N. Lok (PhD, Hong Kong University)
[*current position*: Research Assistant Professor, Dept. of Chemistry, The University of Hong Kong]
- 2001-2002 E. Burns (PhD, University of North Carolina)
[*last known position*: Patent agent, Ottawa]
- 2001-2003 K. Koike (MD, PhD, Kyushu University, Japan)
[*last known position*: Assistant Professor, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan]
- 2002-2004 C. Moreau (PhD, University of Grenoble, France)
(Fondation pour la Recherche Médicale Fellowship, 2002-03; Cancer Research Society Postdoctoral Fellowship, 2003-04)
[*current position*: Scientist, CNRS Institut de Biologie Structurale, Grenoble, France]
- 2000-2004 A. Haimeur (PhD, Laval University)
(Queen's University Postdoctoral Fellowship, 2000-01 (*declined*); MRC/CIHR Postdoctoral Fellowship, 2000-03)

- [*last known position*: Assistant Professor, Centre de recherche en Infectiologie de l'Université Laval; Consultant]
- 2000-2005 G. Conseil (PhD, Institut de Biologie et Chimie des Protéines, Université Claude Bernard de Lyon, France) (maternity leave 11/04-03/05)
(League Nationale Française Contre le Cancer Fellowship; 2000-01; CIHR Postdoctoral Fellowship, 2001-04; Cancer Research Society Postdoctoral Fellowship, 2001-03 (*declined*))
- [*current position*: Research Associate, Queen's University]
- 2003-2006 J.P. Wyles (PhD, Dalhousie University)
(NCIC - Terry Fox Foundation Research Fellowship, 2004-07)
[*current position*: Secondary school science teacher, BC]
- 2004-2006 P. Wu (PhD, Tianjin University, PRC)
[*last known position*: Scientist, Johnson & Johnson Pharmaceutical Research & Development, Raritan, NJ]
- 2004-2006 A. Nakajima (MD, PhD, Kyoto University, Japan)
(George Christian Hoffman Fellowship, 2004-06)
[*current position*: Assistant Professor, Toyooka Public Hospital, Toyooka, Japan]
- 2004-2007 A.J. Rothnie (PhD, Oxford University, UK)
(CIHR Postdoctoral Fellowship, 2006-07)
[*current position*: Senior Lecturer, School of Life and Health Sciences, Aston University, Birmingham, UK]
- 2006-2008 K. Maeno (MD, PhD, Shinshu University, Japan)
[*current position*: Associate Professor, Dept. of Surgery (II), Shinshu University, Matsumoto, Japan]
- 2005-2009 Md. T. Hoque (PhD, Tokyo Institute of Technology, Japan)
[*current position*: Senior Research Associate, Faculty of Pharmacy, University of Toronto]
- 2007-2012 S.H. Iram (PhD, University of Illinois at Urbana-Champaign, USA)
[*current position*: Assistant Professor, Dept. of Chemistry and Biochemistry, South Dakota State University, Brookings, SD, USA]
- 2010-2013 Á. Hernández (PhD, Madrid Autonomous University, Spain)
[*current position*: Scientist, Viralgen Vector Core, Spain]
- 2010-2013 Y. Hassan (PhD, University of Nebraska-Lincoln, USA)
[*current position*: Visiting Fellow, Guelph Food Research Centre]
- 2012-2014 C. Gao (PhD, Shanghai Institute of Materia Medica, Shanghai, PRC)
[*current position*: Associate Director, Alliance Pharma, Philadelphia, PA, USA]
- 2014-2016 M. Joshi (PhD, University of Munich, Germany)
[*current position*: Research Associate, Ottawa Institute of Systems Biology, University of Ottawa]
- 2015-2016 M.F. Miah (PhD, Queen's University)
[*current position*: Senior Consultant, Canadian Imperial Bank of Commerce, Toronto]

VISITING SCIENTISTS AND STUDENTS

- 1994-1995 D. Lautier, PhD (Scientist, INSERM at Toulouse, France)

- 06/1995 M. Filipits, PhD [*last known position*: Associate Professor, Institute of Cancer Research, Medical University of Vienna, Austria)
- 06-07/2000 H. Nakamura and T. Nanko (MD students, Shinshu University Medical School, Matsumoto, Japan)
- 2000-2001 S. Conrad (PhD candidate, University of Kaiserlautern, Germany)
[*last known position*: Quality Expert for Medical Device Development, Novartis Pharma AG, Basel, Switzerland]
- 06/2003 J.D. Campbell (PhD candidate, Oxford University, UK)
[*last known position*: Medical student, UBC]
- 08/2004 R. Callaghan, PhD (Professor, Oxford University, UK)
- 09/2004 A. Ivetac (PhD candidate, Oxford University, UK)
- 07-08/2006 K. Starr (undergraduate research project, Nottingham University, UK)
- 05-08/2012 M.T.D. Yu, PhD (Research Officer, University of New South Wales, Australia)
- 09-12/2014 A. Blauz, PhD (Postdoctoral Fellow, Department of Molecular Biophysics, University of Lodz, Poland)
- 03-09/2016 K. Ziems (Post-graduate student, University Medicine Greifswald, Germany)
- 01-04/2019 K.M. Hanssen (Post-graduate student, University of New South Wales, Australia)

GRADUATE STUDENT COMMITTEES

Thesis Examining Committees (since 1993):

1993 PhD	S. Daly	Biochemistry, University of Western Ontario
1994 PhD	H. Hao	Biology
1994 PhD	D. Marks	University of Technology, Sydney (Australia)
1994 MSc (Chair)	R.D. Dovell	Community Health & Epidemiology
1994 MSc	C. Cuthbert	Biochemistry
1995 PhD	R. Nigam	Pharmacology & Toxicology
1995 mini-MSc	J.J. McGuire	Pharmacology & Toxicology
1995 MSc	S.H. Im	Pharmacology & Toxicology
1995 MSc	Q. Yu	Pharmacology & Toxicology
1996 MSc	S.J. Matthews	Pharmacology & Toxicology
1996 MSc	J. White	Pathology
1996 MSc	H. Liu	Pharmacology & Toxicology
1997 PhD	I. Jordan	Biochemistry, University of Ottawa
1997 mini-MSc	M. Gao	Pathology
1997 PhD (Chair)	C. Gee	Biology
1998 mini-MSc	A.J. Lang	Pharmacology & Toxicology
1998 PhD	J.P. McPherson	Pharmacology, University of Toronto
1998 MA (Chair)	N. Viau	Psychology
1998 PhD	Q. Yu	Pharmacology & Toxicology
1998 PhD	E.U. Kurz	Pharmacology & Toxicology
1998 PhD	J. White	Pathology
1998 mini-MSc	E.M. Leslie	Pharmacology & Toxicology
1998 PhD	D.R. Hipfner	Pathology
1999 PhD	B.D. Stride	Biochemistry
1999 PhD	J.J. McGuire	Pharmacology & Toxicology
1999 mini-MSc	K. E. Weigl	Pathology
1999 PhD (Chair)	N.C. Doubleday	Biology

2000 PhD	J. Dheekollu	Biochemistry, University of Hyderabad (India)
2000 mini-MSc	B. Brown	Pathology
2000 MSc	B. Yang	Physiology
2000 mini-MSc	D. Greer	Pathology
2000 PhD	M. Gao	Pathology
2000 MSc	M. Savoie	Pharmacology & Toxicology
2001 PhD	K. Al-Batayneh	Biology
2001 MSc	T. Voskoglou- Nomikos	Community Health & Epidemiology
2001 MSc	H. Dunkerley	Pharmacology & Toxicology
2001 PhD	A.J. Lang	Pharmacology & Toxicology
2002 mini-MSc	D. Néhmé	Microbiology & Immunology
2002 PhD	E.M. Leslie	Pharmacology & Toxicology
2002 mini-MSc	I.J. Létourneau	Pharmacology & Toxicology
2003 mini-MSc	J. Wan	Pharmacology & Toxicology
2003 MSc	D. Situ	Pathology & Molecular Medicine
2004 PhD	S. Dallas	Pharmaceutical Sciences, University of Toronto
2004 PhD	C.J. Oleschuk	Pharmacology & Toxicology
2004 PhD	F. Visser	Oncology, University of Alberta
2004 MSc	K.F. Clark	Pathology & Molecular Medicine
2005 PhD	C. Paul	Microbiology & Immunology
2005 mini-MSc	D. Richardson	Pathology & Molecular Medicine
2005 MSc	D.H. Lam	Physiology
2005 PhD	K.E. Weigl	Pathology & Molecular Medicine
2005 mini-MSc	L. Mok	Pathology & Molecular Medicine
2006 MSc	M. Chan	Pharmacology & Toxicology
2006 mini-MSc	E. Tung	Pharmacology & Toxicology
2006 PhD (Chair)	J. Wicke	Physical & Health Education
2006 MSc	A. Boros	Pathology & Molecular Medicine
2007 MSc	S. Organ	Pathology & Molecular Medicine
2007 PhD	I.J. Létourneau	Pharmacology & Toxicology
2007 PhD	J. Wan	Pharmacology & Toxicology
2007 MSc	C. (Y.M.) Chan	Pathology & Molecular Medicine
2007 MSc	R. Singh	Pharmacology & Toxicology
2008 PhD (Chair)	P. Lungchukiet	Biology
2008 PhD	G. Potter	Chemistry
2008 mini-MSc (Chair)	M. Golder	Pathology & Molecular Medicine
2008 MSc	X. Wang	Pathology & Molecular Medicine
2009 mini-MSc (Chair)	J. Chen	Pathology & Molecular Medicine
2012 PhD	S. Fischer	Environmental Toxicology, Swiss Federal Institute of Aquatic Science & Technology (Switzerland)
2012 PhD	J. Park	Pharmacology & Physiology, Western University
2013 PhD	M. Chan	Pharmacology & Toxicology
2014 MSc (Chair)	L. Bathurst	Pathology & Molecular Medicine

2014 PhD (Chair)	X. Han	Biology
2015 PhD (Chair)	P. Ferrazzi	Rehabilitation Therapy
2015 MSc	M.A. Csandl	Biomedical & Molecular Sciences
2015 PhD	M.F. Miah	Pathology & Molecular Medicine
2016 PhD (Chair)	A. Felker	Anatomy & Cell Biology
2016 PhD (Chair)	L. Schumann	Psychology
2017 PhD (Chair)	M.J.-Y. Lee	Biochemistry (Biomedical & Molecular Sciences)
2017 mini-MSc (Chair)	J. Wong	Pathology & Molecular Medicine
2018 MSc	J.F. Power	Pathology & Molecular Medicine
2018 MSc	E.E. Smith	Pathology & Molecular Medicine
2018 PhD	M. Alnakhli	Molecular Medicine & Pathology, Flinders University (Australia)
2018 PhD (Chair)	A.C. Parr	Neuroscience
2019 PhD (Chair)	T.D. Vance	Biochemistry (Biomedical & Molecular Sciences)
2019 PhD (Chair)	J. Mackeil	Biomedical & Molecular Biosciences
2020 MSc	L. Wu	Pathology & Molecular Medicine
2021 PhD (Chair)	L. Haslam-Larmer	Aging and Health

PhD Comprehensive Exam Committees (since 1993):

1993	M. Lundie	Pharmacology & Toxicology
1993	Z.-G. Lui	Pharmacology & Toxicology
1993	B. Savas	Microbiology & Immunology
1994	E. Rafeiro	Pharmacology & Toxicology
1995	P. Donnelly	Pharmacology & Toxicology
1996,1998,1999	G. Lafreniere	Pharmacology & Toxicology
1997	K. Kimura	Pharmacology & Toxicology
1997	K. Al-Batayneh	Biology
1998	A. Keightley	Pathology
1998	H. Liu	Pharmacology & Toxicology
1999	A. Tam	Pharmacology & Toxicology
1999	S. Wong	Pharmacology & Toxicology
1999	T. Bushfield	Pharmacology & Toxicology
2000	C. Davidson	Pathology
2000	T. Hale	Pharmacology & Toxicology
2001	L. Bedard	Pharmacology & Toxicology
2002	D. Néhmé	Microbiology & Immunology
2003	C. Paul	Microbiology & Immunology
2004	J. Wan	Pharmacology & Toxicology
2005	D. Richardson	Pathology & Molecular Medicine
2005, 2006	L. Mok	Pathology & Molecular Medicine
2007 (Chair)	J. Hannan	Pharmacology & Toxicology
2008	M. Komolova	Pharmacology & Toxicology
2008	H. Badham	Pharmacology & Toxicology
2008 (Chair)	M. Golder	Pathology & Molecular Medicine
2018 (Chair)	T. Azad	Pathology & Molecular Medicine
2018 (Chair)	J. Wong	Pathology & Molecular Medicine

Thesis Advisory Committees (compiled since 2001):

1995-2001	K. Al-Batayneh, PhD	Biology
1996-2001	A. Tam, PhD	Pharmacology & Toxicology
1997-2003	R. St. Onge, PhD	Pathology & Molecular Medicine
1997-2004	C. Westlake, PhD	Biochemistry
1998-2005	M. Muredda, PhD	Biochemistry
1999-2001	H. Dunkerley, MSc	Pharmacology & Toxicology
2000-2006	D. Nehmé, PhD	Microbiology & Immunology
2000-2004	L. Bedard, PhD	Pharmacology & Toxicology
2001-2002	K. Neumann, MSc	Biology
2001-2005	C. Paul, PhD	Microbiology & Immunology
2002-2007	J. Affleck, PhD	Biology
2002-2007	J. Wan, PhD	Pharmacology & Toxicology
2003-2005	S. Dowlatshahi, MSc	Pharmacology & Toxicology
2003-2009	D. Richardson, PhD	Pathology & Molecular Medicine
2003-2009	A. Theis, MSc	Pathology & Molecular Medicine
2004-2006	P. Wang, MSc	Physiology
2004-2008	G. Potter, PhD	Chemistry (co-supervisor)
2004-2010	M. Sierant, PhD	Biochemistry
2004-2010	L. Mok, PhD	Pathology & Molecular Medicine
2004-2011	E. Tung, PhD	Pharmacology & Toxicology
2004-2011 (<i>incomplete</i>)	S. Wang, MSc	Pharmacology & Toxicology (co-supervisor)
2005-2007	P. Bandler, MSc	Pathology & Molecular Medicine
2005-2007	R. Singh, MSc	Pharmacology & Toxicology
2006-2009	A. Hampton, MSc	Pharmacology & Toxicology
2007-2012	A. Reid, MSc	Pharmacology & Toxicology
2008	R. Sullivan, PhD	Anatomy & Cell Biology
2010-2017	M. Crupi, PhD	Pathology & Molecular Medicine
2019-2021	S. Kheitan, MSc	Pathology & Molecular Medicine

INVITED PRESENTATIONS (career total 227)**1980-90 (8)**

- Laboratory of Molecular Carcinogenesis, Bldg. 37, NCI, NIH, Bethesda, MD, November 1980
- Department of Health and Human Services, Bldg. 10, NIH, Bethesda, MD, November 1980
- OCFRF, London Regional Cancer Centre, London, ON, September 1984
- OCFRF, Toronto-Bayview Centre, Sunnybrook Medical Centre, Toronto, October 1984
- Canadian Society of Laboratory Technologists, St. John's, NL, June 19, 1986
- Department of Radiation Oncology, Arizona Cancer Center, Tucson, AZ, January 21, 1988
- OCFRF Research Meeting, Ottawa Regional Cancer Centre, Ottawa, ON, May 15, 1989
- 3rd IASLC Lung Tumor Biology Workshop, Robinson College, Cambridge University, UK, August 1990

1991 (4)

- Merck-Frosst Award Lecture, 34th Annual Meeting of the Canadian Federation of Biological Societies, Kingston, ON, June 9, 1991

- Symposium on “Frontiers in Cancer Biology II: Lung Cancer”, Cancer Center of the Medical College of Wisconsin, Milwaukee, WI, October 5, 1991
- CME Day, Division of Surgery Annual Clinical Day, Peterborough Civic Hospital and St. Joseph’s General Hospital, Peterborough, ON, November 11, 1991
- Department of Biochemistry, University of Saskatchewan, Saskatoon, SK, November 26, 1991

1992 (6)

- L’Hôtel Dieu de Québec, Centre de Recherche, Québec City, QC, March 13, 1992
- Terry Fox Workshop, Niagara-on-the-Lake, ON, March 25-27, 1992
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, June 24, 1992
- Stritch School of Medicine, Loyola University Medical Center, Chicago, IL, October 2, 1992
- ISIS Pharmaceuticals, Carlsbad, CA, October 19, 1992 (with R. Deeley)
- Institute of Parasitology, McGill University, Montréal, QC, December 4, 1992

1993 (17)

- London Regional Cancer Centre, London, ON, January 7, 1993
- Department of Biochemistry, University of Western Ontario, London, ON, January 8, 1993
- Department of Pharmacology, University of Ottawa, Ottawa, ON, January 12, 1993
- Department of Molecular Therapeutics, Memorial Sloan-Kettering Cancer Center, New York, NY, February 2, 1993
- Lederle Laboratories, Pearl River, NY, February 3, 1993
- BASF Laboratories, Cambridge, MA, February 10, 1993 (with R. Deeley)
- Citywide Oncology Rounds, The Toronto Hospital, University of Toronto, February 19, 1993 (with R. Deeley)
- City of Hope Medical Center, Duarte, CA, March 8, 1993
- Arizona Cancer Center, Tucson, AZ, March 9, 1993
- 4th IASLC Lung Tumor Biology Workshop, Airlie, VA, April 14, 1993
- General Motors Cancer Research Foundation International Symposium on “Resistance Against Anticancer Drugs: Molecular Mechanisms and Clinical Opportunities”, Toronto, ON, May 7, 1993
- Symposium on “Molecular Mechanisms of Drug Resistance”, 84th Annual Meeting of the American Association for Cancer Research, Orlando, FL, May 19, 1993
- 3rd International IASLC Workshop on “Lung Tumor Antigens and Differentiation Antigens”, Zürich, Switzerland, September 9 and 10, 1993
- The Upjohn Company, Kalamazoo, MI, September 14, 1993
- National Cancer Center Research Institute & Hospital, Tokyo, Japan, November 12, 1993
- Current Progress on Drug Resistance, US-Japan Cooperative Agreement, Tokyo, Japan, November 15, 1993
- Manitoba Institute of Cell Biology, Winnipeg, MB, November 25, 1993, *Ortho Biotech Visiting Lecturer*

1994 (11)

- Department of Cancer Biology, The Cleveland Clinic Foundation, Cleveland, OH, January 11, 1994
- Cleveland Clinic Cancer Center Ground Rounds, The Cleveland Clinic Foundation, Cleveland, OH, January 11, 1994
- Grand Rounds, Division of Hematology and Oncology, School of Medicine, Wayne State University, Detroit, MI, January 12, 1994

- Multidisciplinary Lung Cancer Conference, School of Medicine, Wayne State University, Detroit, MI, January 13, 1994
- BiochemPharma Inc., Montréal, QC, February 18, 1994 (with R. Deeley)
- 4th Winternational Symposium on Cellular and Molecular Biology, “The Molecular Biology of Membrane Proteins”, Banff, AB, March 11, 1994
- James Brown Cancer Center, Louisville, KY, March 28, 1994
- Toronto-Bayview Regional Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, May 24, 1994
- Gordon Research Conference on “Chemotherapy of Experimental and Clinical Cancer”, Colby Sawyer College, NH, July 26, 1994
- Joint Meeting of the American Association for Cancer Research and Academia Sinica on “Modern Developments in Cancer Therapeutics”, Taipei, Taiwan, November 8, 1994
- Genetic Therapy Institute, Gaithersburg, MD, December 20, 1994 (with R. Deeley)

1995 (11)

- Department of Biology, Concordia University, Montréal, QC, January 6, 1995
- INEX Pharmaceuticals, Vancouver, January 20, 1995 (with R. Deeley)
- Unité de santé et environnement, Laval University, Ste-Foy, Québec, February 2, 1995
- Departments of Pharmacology and Biochemistry, Wayne State University, Detroit, MI, May 5, 1995
- Oncor Diagnostics, Malvern, PA, June 15, 1995 (with R. Deeley)
- Eli Lilly Pharmaceutical Company, Indianapolis, IN, June 28, 1995 (with R. Deeley)
- Symposium on “Drug Resistance Issues in Cancer Chemotherapy”, 19th International Congress of Chemotherapy, Montréal, QC, July 17, 1995
- Lung Cancer: Strategies for the 21st Century, University of Toronto, Faculty of Medicine, Toronto, ON, September 29, 1995
- ISIS Pharmaceuticals, Carlsbad, CA, October 20, 1995 (with R. Deeley)
- American Association for Cancer Research Special Conference, “Novel Strategies Against Resistant Cancers”, Ft. Myers, FL, November 20, 1995
- University of Maryland Cancer Center, Baltimore, MD, November 30, 1995

1996 (11)

- Institute of Molecular and Cellular Biosciences, University of Tokyo, Japan, January 29, 1996
- Symposium on “Drug Resistance”, Department of Biochemistry, Kyushu University, Fukuoka, Japan, January 31, 1996 (*sponsor*: Monbusho International Scientific Research Program) (*plenary speaker*)
- Institute for Cancer Research, Kagoshima University, Kagoshima, Japan, February 1, 1996
- Gordon Research Conference on “Drug Carriers in Biology and Medicine”, Ventura, CA, February 25, 1996
- Loeb Research Institute, Ottawa, ON, March 25, 1996
- Johns Hopkins Oncology Centre, Baltimore, MD, May 6, 1996
- MRC Membrane Biology Group, University of Toronto, Toronto, ON, May 13, 1996
- Monsanto/Searle, St. Louis, MO, June 26, 1996
- Department of Chemistry and Biochemistry, University of Guelph, ON, September 25, 1996
- EORTC International Meeting “Anticancer Targets and Strategies for the Twenty-first Century”, Castres, France, October 10, 1996

- International Conference on “Glutathione and Glutathione-linked Enzymes in Human Cancer and Other Diseases”, Hilton Head, SC, November 1, 1996

1997 (6)

- Ontario Cancer Institute, Princess Margaret Hospital, Toronto, ON, January 9, 1997
- Hollings Cancer Center, Charleston, SC, January 24, 1997
- 2nd Annual John Doull Toxicology Symposium, Kansas City Medical Center, Kansas City, KS, May 9, 1997 (*Keynote Speaker*)
- Mini-symposium on “Dose Intensity and Drug Resistance in Lung Cancer”, 8th World Lung Cancer Conference, Dublin, Ireland, August 14, 1997
- Symposium on “Lung Cancer – New Aspects”, University of Vienna Medical School, Vienna, Austria, September 22, 1997 (*sponsor: Novartis (plenary speaker)*)
- 4th International Symposium on “Cytostatic Drug Resistance”, Humboldt University, Berlin, Germany, September 26, 1997

1998 (9)

- Molecular Therapeutics, Memorial Sloan Kettering Cancer Center, New York, NY, January 20, 1998
- Department of Microbiology & Immunology, University of Western Ontario, London, ON, January 29, 1998
- 8th Fisher Winternational Symposium on Cellular and Molecular Biology, “Membrane Proteins in Health and Disease”, Banff, AB, April 5, 1998
- Cancer Center, University of Illinois at Chicago, Chicago, IL, May 4, 1998
- Department of Pharmacology, University of Tennessee, Memphis, TN, May 6, 1998
- 10th NCI-EORTC Symposium on “New Drugs in Cancer Therapy”, Amsterdam, The Netherlands, June 16, 1998
- Symposium on “Multiple Drug Resistance Genes and Gene Transfer”, IUPHAR, XIIIth International Congress of Pharmacology, Munchen, Germany, July 27, 1998
- Eli Lilly Pharmaceutical Company, Indianapolis, IN, August 25, 1998 (with R. Deeley)
- SmithKline & Beecham, Collegeville, PA, September 15, 1998

1999 (7)

- 2nd FEBS Advanced Lecture Course, ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease, Gosau, Austria, February 24, 1999 (*plenary speaker*)
- C.W. Gowdey Distinguished Lectureship, Department of Pharmacology & Toxicology, University of Western Ontario, London, ON, March 18-19, 1999
- Meet the Expert Sunrise Session on “Drug Resistance”, 90th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, April 11, 1999
- Hematology – Oncology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, May 7, 1999
- 2nd FASEB Conference on “Transport ATPases”, Snowmass, CO, July 7, 1999
- Symposium on “Drug Efflux Pumps: Challenges and Opportunities for Drug Delivery”, Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, LA, November 15, 1999
- Roswell Park Cancer Institute, Buffalo, NY, December 14, 1999

2000 (10)

- Symposium on “Transporters in Host Defence Mechanisms”, Tokyo, Japan, January 19, 2000

- Department of Biochemistry, Kyushu University, Fukuoka, Japan, January 24, 2000
- Department of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, March 30, 2000
- Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, March 31, 2000
- Symposium on "Cytotoxic Chemotherapy: Marking the Transition to the New Millennium", 91st Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April 4, 2000
- Division of Cell Biology, Hospital for Sick Children, Toronto, ON, May 12, 2000
- Gordon Research Conference on "Chemotherapy of Experimental and Clinical Cancer", Oxford, UK, September 19, 2000
- Faculty of Pharmacy, University of Toronto, ON, October 12, 2000
- Québec Breast Cancer Symposium, Montréal, QC, October 27, 2000
- Merck-Frosst Centre for Therapeutic Research, Montréal, QC, December 7, 2000 (with R. Deeley)

2001 (6)

- Department of Tumour Biochemistry, German Cancer Center, Heidelberg, Germany, March 12, 2001
- Department of Drug Metabolism and Pharmacokinetics, Boehringer-Ingelheim Pharmaceuticals, Inc., Ridgeway, CT, April 17, 2001
- Symposium on "Biology of Cellular Invasiveness: Pathos of Convergence in Pregnancy and Malignancy", Queen's University, Kingston, ON, June 1, 2001
- 3rd FASEB Conference on "Transport ATPases", Snowmass, CO, July 18, 2001
- Symposium on "Childhood Cancer: From Mechanisms to Therapeutics", Children's Cancer Institute of Australia, Sydney, Australia, October 8, 2001 (*keynote speaker*)
- 33rd Meeting of the International Society of Paediatric Oncology (SIOP), Brisbane, Australia, October 11, 2001 (*keynote speaker*)

2002 (10)

- Department of Biology, McMaster University, Hamilton, ON, January 31, 2002
- Department of Pharmacology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, February 11, 2002
- Eli Lilly Pharmaceutical Company, Indianapolis, IN, February 15, 2002 (with R. Deeley)
- CSBMCB 45th Annual Meeting and 12th Winternational Symposium on "Membrane Proteins: Implications for Therapeutics", Banff, AB, March 24, 2002
- American Association for Cancer Research (AACR) 93rd Annual Meeting, San Francisco, CA, April 8, 2002
- Symposium on "Advances in Understanding Transport of Drugs and Toxicants", ASPET, Annual Meeting of the Societies of Experimental Biology, New Orleans, LA, April 23, 2002
- Symposium on "The Role of Transporters in Drug Metabolism", IUPHAR, XIVth International Congress of Pharmacology, San Francisco, CA, July 2002
- Department of Biochemistry, National University of Singapore, September 16, 2002
- Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan, September 20, 2002
- 22nd International Symposium "Xenobiotics and Host Responses" of the University of Occupational and Environmental Health, Kitakyushu, Japan, September 24, 2002

2003 (8)

- Joint Meeting – Symposium on “ABC Proteins” and the 5th Conference on “ABC Proteins and Ion Channels – From Gene to Disease”, Kyoto, Japan, January 25, 2003
- Faculty of Pharmaceutical Sciences, Kanazawa University, Japan, January 28, 2003
- 4th FEBS Advanced Lecture Course “ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease”, Gosau, Austria, March 4, 2003
- Gordon Research Conference on “Multi-Drug Efflux Systems”, Ventura, CA, March 10, 2003
- Grand Rounds, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, April 25, 2003 (*CME credit*)
- Northeastern Ontario Regional Cancer Centre (NEORCC), Sudbury, ON, June 6, 2003
- Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford University, Oxford, UK, August 21, 2003
- Auckland Cancer Society Research Center, University of Auckland, New Zealand, October 31, 2003

2004 (13)

- Institute of Parasitology, MacDonald Campus, McGill University, Ste. Anne de Bellevue, QC, January 30, 2004
- ASPET Symposium on “Toxicological and Health Implications of GSH Transport and Metabolism”, Experimental Biology 2004, Washington, DC, April 18, 2004
- Laboratory of Cell Biology, NCI, NIH, Bethesda, MD, April 20, 2004
- Department of Pharmaceutical Sciences, University of Toronto, ON, April 23, 2004
- Department of Biopharmaceutical Sciences, University of Illinois at Chicago, Chicago, IL, April 28, 2004
- Indiana University Cancer Center, Indianapolis, IN, April 29, 2004
- Department of Biopharmaceutical Sciences, Pharmaceutical Sciences & Pharmacogenomics Graduate Program, University of California at San Francisco, San Francisco, CA, May 12, 2004
- Institut de Recherches Servier, Croissy sur Seine, France, June 9, 2004
- 9th Symposium of the Institut de Chimie des Substances Naturelles (ICSN), “Cancer: Targets, Molecules and Therapies”, CNRS, Gif-sur-Yvette, France, June 11, 2004
- Department of Pharmacology, Cambridge University, UK, July 12, 2004
- H. Lee Moffitt Cancer Center & Research Institute - 3rd Biennial Meeting “Molecular Targets for Cancer Therapy”, St. Petersburg Beach, FL, October 5, 2004 (*CME credit*)
- ABC Gene Workshop, NCI-NIH, Frederick, MD, October 21, 2004
- Department of Medical Sciences-Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, November 1, 2004

2005 (10)

- 2nd Korean Pharmacogenomic Research Network International Symposium, Seoul, Korea, March 18, 2005 (*declined*)
- Markey Cancer Center Distinguished Visitor, University of Kentucky, Lexington, KY, April 28, 2005
- Division of Drug Delivery and Disposition, School of Pharmacy, University of North Carolina, Chapel Hill, NC, May 6, 2005
- 13th Meeting on Pollution Responses in Marine Organisms, Alessandria, Italy, June 19, 2005 (*plenary lecturer*)

- VIth Conference on Cerebral Vascular Biology, CVB 2005, Münster, Germany, June 25-29, 2005 (*declined*)
- John Roder 25th Anniversary Symposium, Mount Sinai Hospital, Toronto, ON, June 25, 2005.
- 12th Annual MDIBL Environmental Health Sciences Symposium, “Molecular Evolution of Chemical Defense Mechanisms”, Mount Desert Island Biological Laboratory, Salisbury Cove, ME, July 14, 2005
- Symposium on “Mechanisms of ABC Transporters”, BioScience 2005 - Biochemical Society 2nd Major Annual Scientific Meeting, Glasgow, UK, July 21, 2005 (*declined*)
- 2nd Annual North American ABC Genetic Workshop, NCI-NIH, Frederick, MD, September 29, 2005
- Robert L. Noble Award Lecture, Queen’s University, Kingston, ON, November 16, 2005 (with R. Deeley)

2006 (9)

- Keystone Symposium, “Eicosanoids in Inflammation and Chronic Diseases”, Park City, UT, January 11, 2006 (*CME credit*)
- Translational Cancer Research Unit, University of Western Ontario, London, ON, January 19, 2006 (*CME credit*)
- FEBS Special Meeting on ABC Proteins - ABC 2006, Innsbruck, Austria, March 9, 2006 (*Final Keynote address*)
- Merck Research Laboratories, Westpoint, PA, April 18, 2006
- Merck Research Laboratories, Rahway, NJ, April 19, 2006
- Gordon Research Conference on “Mechanisms of Toxicity”, Colby College, Waterville, ME, July 25, 2006.
- MDR1-20 Symposium, National Cancer Institute, National Institutes of Health, Bethesda, MD, September 20, 2006.
- Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea, December 14, 2006
- The 3rd International Symposium of Korea Biomedical Genomic Research Association and National Genome Research Institute, Seoul, Korea, December 15, 2006

2007 (8)

- Royal Society of Canada Kingston Regional Seminar, Queen’s University, March 31, 2007
- Mayo Clinic College of Medicine, Scottsdale, AZ, May 3, 2007
- Symposium on “Transporters and Barrier Function”, 7th Cerebral Vascular Biology (CVB 2007) International Conference, Ottawa, ON, June 25, 2007 (*declined*)
- Workshop on “Drug Transport to the Fetus”, 13th International Federation of Placenta Associations (IFPA) & 2nd Placenta Association of the Americas Conference, Kingston, ON, August 18, 2007 (*declined*)
- National Institute of Environmental Health Sciences (NIEHS), U.S. National Institutes of Health (NIH) Distinguished Lecture Series, Research Triangle Park, NC, September 11, 2007
- International Meeting on “ABC Transport Proteins in Environmental Health and Toxicology”, Siena, Italy, October 20, 2007 (*plenary speaker*)
- Symposium on “Novel Interventions Preventing Treatment Failure”, *Making Connections: A Canadian Cancer Research Conference Celebrating NCIC’s 60th Anniversary*, Toronto, ON, November 16, 2007 (*CME credit*)
- College of Pharmacy, University of Arizona, Tucson, AZ, November 27, 2007

2008 (10)

- Science Research for Health Day, CIHR Synapse Youth Mentorship, University of Ontario Institute of Technology (UOIT), Oshawa, ON, February 18, 2008 (*keynote speaker*) (*declined*)
- Symposium on “ABC Proteins in Multidrug Resistance and Pharmacology”, 2nd FEBS Special Meeting: ATP-Binding Cassette (ABC) Proteins: from Multidrug Resistance to Genetic Diseases, Innsbruck, Austria, March 4, 2008 (*plenary speaker*)
- ASPET Centennial Symposium on “ABC Transporters: From Drug Resistance to Drug Response”, Experimental Biology 2008, San Diego, CA, April 8, 2008
- ASPET Symposium on “Drug Metabolism, Bioactivation and Chemical-induced Toxicities: Lessons Learned and Contemporary Issues”, Experimental Biology 2008, San Diego, CA, April 8, 2008
- Symposium on “Pharmacogenomics of Drug Disposition”, 5th International Symposium of KPGRN and 14th Annual Meeting of PRACP, Busan, Korea, April 9-11, 2008 (*declined*)
- Grand Rounds, Department of Clinical Pharmacology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, May 29, 2008 (*CME credit*)
- Gordon Research Conference on Drug Metabolism, Plymouth, NH, July 6-11, 2008 (*declined*)
- Pfizer Senior Scientist Award Lecture, CPT2008, Québec, QC, July 28, 2008
- Symposium on “Transporters: Relevance to Drug Disposition and Disease”, IXth World Conference on Clinical Pharmacology and Therapeutics (CPT2008), Québec, QC, July 30, 2008
- Symposium on “Glutathione Transferases”, Uppsala University, Sweden, August 21, 2008

2009 (5)

- Shinshu University, Matsumoto, Japan, May 22, 2009 (*cancelled H1N1*)
- The 5th Takeda Science Foundation Symposium in PharmaSciences, “Bioactive Lipid Molecules and Transporters”, Tokyo, Japan, May 26, 2009
- Fourth iCeMS International Symposium on Integrated Cell-Material Sciences, “Integrated Physical/Chemical Biology of the Cell: from Genes to Membrane Systems”, Kyoto, Japan, May 28, 2009
- Membrane Protein Research Group, University of Alberta, Edmonton, AB, October 22, 2009 (*CME credit*)
- Department of Pharmacology and Therapeutics, University of Calgary, Calgary, AB, October 23, 2009

2010 (4)

- 3rd FEBS Special Meeting, “ATP-Binding Cassette (ABC) Proteins: from Multidrug Resistance to Genetic Diseases”, Innsbruck, Austria, March 4, 2010
- Symposium on “Transporter Biology: Impact on Drug Distribution and Organ Toxicity”, Gordon Research Conference on Drug Metabolism, Holderness, NH, July 15, 2010
- Symposium on “Multidrug Resistance and Transporters”, Joint Meeting of the Australian Society for Biophysics and Australian Physiological Society, Adelaide, Australia, November 29, 2010
- Children’s Cancer Institute Australia, Sydney, Australia, December 9, 2010

2011 (6)

- Visiting Professor Program, Medical University of South Carolina (MUSC) Hollings Cancer Center, Charleston, SC, February 11, 2011

- Symposium on “Frontiers in Epithelial Transport 2011”, Yonsei University, Seoul, Korea, April 15, 2011
- Dept. of Pharmaceutical Oncology, Kyushu University, Fukuoka, Japan, April 18, 2011
- Institute for Integrated Cell-Material Sciences, Kyoto University, Japan, April 22, 2011
- Institute for Cancer Research, University of North Texas Health Science Center, Fort Worth, TX, May 4, 2011 (*declined*)
- Gordon Research Conference on Multidrug Efflux Systems, Les Diablerets, Switzerland, June 12-17, 2011 (*declined*)

2012 (5)

- 4th FEBS Special Meeting, “ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Diseases”, Innsbruck, Austria, March 8, 2012 (*Final Keynote address*)
- Institute of Enzymology, Hungarian Academy of Sciences, Budapest, Hungary, May 7, 2012
- Department of Environmental Toxicology, Swiss Federal Institute of Aquatic Science and Technology, Dübendorf, Switzerland, May 9, 2012
- Canadian Medical Hall of Fame TD Discovery Day in Health Sciences, Queen’s University, Kingston, ON, May 16, 2012 (*Keynote Speaker*)
- Conference on “Membrane Transporters and Their Role in Human Disease”, University of New South Wales, Sydney, Australia, December 6, 2012 (*declined*)

2013 (5)

- Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, June 27, 2013
- European Union Conference “Role of MDR Proteins in Pharmacokinetics and Toxicology”, Ryn, Poland, September 3, 2013 (*Keynote Speaker*)
- 6th Annual SFB35 Symposium “Transmembrane Transporters in Health and Disease”, Vienna, Austria, September 23, 2013
- College of Pharmacy, Jinan University, Guangzhou, PRC, November 11, 2013
- First Affiliated Hospital, Jinan University, Guangzhou, PRC, November 12, 2013

2014 (2)

- University of Lodz, Poland, September 12, 2014
- Jinan University Clinical Medical Research Institute, Guangzhou, PRC, November 5, 2014

2015 (4)

- 6th Annual Hogarty Family Foundation Lecture, University at Albany Cancer Research Center, Albany, NY, March 26, 2015
- Department of Biomedical Sciences, University at Albany SUNY, Albany, NY, March 27, 2015
- Conference on Tumor Multidrug Resistance, College of Pharmacy, Jinan University, Guangzhou, PRC, November 7, 2015 (*Keynote Speaker*)
- Department of Physiology, McGill University, Montréal, QC, December 4, 2015

2016 (4)

- Advanced Medical Research Institute of Canada, Northeast Cancer Centre – Health Sciences North, Sudbury, ON, May 9, 2016
- Symposium: Celebrating 30 Years of Research on Multidrug Resistance and ABC Drug Transporters, National Cancer Institute, NIH, Bethesda, MD, September 23, 2016
- American Society of Nephrology Annual Meeting, Session on “Predicting Drug Disposition and Dosing in CKD: Not just a renal affair”. Chicago, IL, November 15-20, 2016 (*declined*)

- Symposium: Basic and Clinical Studies of ABC Transporters, College of Pharmacy, Jinan University, Guangzhou, PRC, November 7, 2016 (*Keynote Speaker*)

2017 (8)

- John Austin Society, Kingston, ON, January 19, 2017
- Gordon Research Conference on Multidrug Efflux Systems, Galveston, TX, March 26, 2017 (*Keynote Speaker*)
- Saturday Club, Queen's University, Kingston, ON, May 2, 2017
- Department of Biochemistry, University of Alberta, Edmonton, AB, September 21, 2017
- Symposium, College of Pharmacy, Jinan University, Guangzhou, Guangdong, PRC, November 5, 2017 (*Keynote Speaker*)
- Symposium, Cancer Research Institute, Central South University, Changsha, Hunan, PRC, November 8, 2017 (*Keynote Speaker*)
- Institute of Hydrobiology, Wuhan, Hubei, PRC, November 10, 2017
- Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, November 13, 2017

2018 (3)

- 61st Annual Meeting of the Canadian Society of Molecular Biosciences, Banff, AB, April 13, 2018
- Department of Pharmacology, Center of Drug Absorption and Transport, University Medicine Greifswald, Greifswald, Germany, June 18, 2018
- Symposium, Jinan University, Guangzhou, Guangdong, PRC, November 9, 2018 (*Keynote Speaker*)

2019 (1)

- Department of Biochemistry, Immunology & Microbiology, University of Ottawa, September 13, 2019

2020 (4)

- Department of Biochemistry and Molecular Biology, Tel Aviv University, Israel, March 12, 2020 (*cancelled – COVID-19*)
- Jeanne Manery Fisher Memorial Lecture Award, 63rd Annual Meeting of the Canadian Society of Molecular Biosciences, Ottawa, ON, June 10, 2020 (*cancelled – COVID-19*)
- Gordon Research Conference on Drug Metabolism, Holderness, NH, July 12-17, 2020 (*cancelled – COVID-19*)
- Symposium, Jinan University, Guangzhou, Guangdong, PRC, November 2020 (*Keynote Speaker*) (*cancelled – COVID-19*)

2021 (1)

- Gordon Research Seminar on Multidrug Efflux Systems, Galveston, TX, May 29-30, 2021 (*Keynote Speaker*) (*declined – COVID-19*)

2022 (1)

- Gordon Research Conference on Drug Metabolism “50th” Anniversary, Holderness, NH, July 10-15, 2022

Internal:

- Department of Oncology, Kingston Regional Cancer Centre, 1982
- Department of Pharmacology, Queen's University, 1983
- Department of Microbiology & Immunology, Queen's University, 1983
- Medical Grand Rounds, Cancer & Interferons, March 14, 1985 (*with E. Eisenhauer*)

- Department of Oncology, Kingston Regional Cancer Centre, October 24, 1985 (*with B.G. Campling*)
- Department of Biochemistry, Queen's University, November 29, 1985
- Department of Oncology, Kingston Regional Cancer Centre, April 17, 1986
- Department of Oncology, Kingston Regional Cancer Centre, April 2, 1987
- Basmajian Award Lecture, Queen's University, April 28, 1988
- Department of Pathology, Queen's University, January 24, 1989
- Department of Pharmacology & Toxicology, Queen's University, October 2, 1989
- Department of Microbiology & Immunology, Queen's University, February 26, 1992
- Department of Oncology, Queen's University, January 14, 1993
- Department of Biochemistry, Queen's University, February 26, 1993
- Kingston Regional Cancer Centre, "Cancer '93 – Challenges for Care and Cure", October 20, 1993
- Department of Pharmacology & Toxicology, Queen's University, October 17, 1994
- Workshop, School of Graduate Studies and Research, "The Challenges of Balancing Family Commitments and a Research Intensive Career – Costs and Rewards", January 25, 1995
- Prize for Excellence in Research Lecture, Queen's University, November 27, 1995
- Department of Physiology, Queen's University, September 30, 1996
- Department of Chemistry, Queen's University, February 24, 1997
- Presentation to MRC Council, "Drug Resistance in Cancer: From Bench to Bedside and Back Again", November 24, 1997 (*with B.G. Campling and R.G. Deeley*)
- Department of Microbiology & Immunology, Queen's University, February 4, 1998
- Education Seminar, Queen's University Biomedical Engineering Club, January 15, 2003
- Department of Pharmacology & Toxicology, Queen's University, March 23, 2004

CONFERENCES – INVITED PARTICIPATION (*other than as a speaker*)

1984-1993

- Co-Chair, Monoclonal Antibodies Workshop; Canadian Federation of Biological Societies, Saskatoon, June 1984
- Co-Chair, Session on Monoclonal Antibodies and Lung Cancer – Biology III. IV World Conference on Lung Cancer, Toronto, August, 1985
- Organizer and Co-Chairperson, Ontario Cancer Foundation Research Meeting, Donald Gordon Centre, Kingston, October 15-16, 1987
- Chair, Session on Multidrug Resistance, Gordon Research Conference on "Chemotherapy of Clinical and Experimental Cancer, July 1989
- Organizer and Chair, Symposium on "Resistance to Antineoplastic Agents", Pharmacological Society of Canada, Canadian Federation of Biological Societies, Kingston, June 9, 1991
- Co-Chair, Minisymposium on "New Mechanisms of Drug Resistance", 83rd Annual Meeting of the American Association for Cancer Research, San Diego, CA, May 21, 1992
- Co-Chair, Session on Cluster Analysis, 3rd International IASLC Workshop on Lung Tumor and Differentiation Antigens, Zürich, September 9, 1993

1994-2003

- Co-Chair, Poster Discussion Session on P-glycoprotein, 84th Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April 10, 1994

- Co-Chair, Symposium on “Drug Resistance Issues in Cancer Chemotherapy”, 19th International Congress of Chemotherapy, Montréal, July 17, 1995
- Co-Chair, Poster Discussion Session on Biology of MRP, 86th Annual Meeting of the American Association for Cancer Research, Washington, DC, April 23, 1996
- Co-Chair, Session on GSH/GST, Other Thiols and Thiol-proteins in Drug Resistance, International Conference on “Glutathione and Glutathione-linked Enzymes in Human Cancer and Other Diseases”, Hilton Head, SC, November 1, 1996
- Co-Chair, Session on Biology of Lung Cancer, 8th World Conference on Lung Cancer, Dublin, Ireland, August 14, 1997
- Chair, Session on Non-MDR Mechanisms of Drug Resistance, 4th International Symposium on “Cytostatic Drug Resistance”, Berlin, Germany, September 25, 1997
- Chair, Session on Cancer Research and Therapy, 1st Annual Meeting for Basic and Clinical Research Trainees, Faculty of Health Sciences, Queen’s University, Kingston, May 27, 1998
- Co-Chair and Organizer, Symposium on “Cytotoxic Chemotherapy: Marking the Transition to the New Millennium”, 91st Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April 4, 2000
- Adjudicator, Oral Presentations, 3rd Annual Meeting for Basic and Clinical Research Trainees, Faculty of Health Sciences, Queen’s University, Kingston, May 31, 2000
- Co-Moderator, Session on Genomics and Novel Therapeutics, Canadian Lung Cancer Research Workshop, Toronto, June 16-17, 2000
- Chair, Session on Drug Resistance, Gordon Research Conference on “Chemotherapy of Clinical and Experimental Cancer”, Oxford, UK, September 19, 2000
- Chair, Symposium on “Functions, Substrates, Mechanisms & Clinical Implications of MRPs, MXR and BSEP”, FEBS Advanced Lecture Course – ABC 2001, Gosau, Austria, March 7, 2001
- Co-Chair, Symposium on “The Role of Transporters in Drug Metabolism”, IUPHAR, XIVth International Congress of Pharmacology, San Francisco, CA, July 8, 2002
- Co-Chair, Session on Transporters of Xenobiotics, 22nd International Symposium on “Xenobiotics and Host Responses”, Kitakyushu, Japan, September 24, 2002
- Member, Professional Advancement Series Session, “How to Get Your Papers Published in the Best Scientific Journals: The Insiders’ View from the Editors”, 94th Annual Meeting of the American Association for Cancer Research, Washington, DC, July 2003
- Member, “Women in Cancer Research” (WICR) Networking Breakfast, 94th Annual Meeting of the American Association for Cancer Research, Washington, DC, July 13, 2003

2004-2013

- Co-Chair, Minisymposium on “Novel Mechanisms of Drug Resistance and Functional Characterization”, 95th Annual Meeting of the American Association for Cancer Research, Orlando, FL, March 29, 2004
- Chair, Session on “Natural Products and Anticancer Drugs”, 9th Symposium of the Institut de Chimie des Substances Naturelles (ICSN), “Cancer: Targets, Molecules and Therapies”, Gif-sur-Yvette, France, June 10, 2004
- Discussion Leader, Gordon Research Conference on “Multi-Drug Efflux Systems”, Magdalen College, Oxford University, UK, September 2005 (*declined*).
- Co-Organizer, FEBS Special Meeting - ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease, Innsbruck, Austria, March 4-10, 2006

- Co-Chair, 2007 Gordon Research Conference on “Multi-Drug Efflux Systems”, 2005-2006 (*elected*).
- Co-Organizer, FEBS Special Meeting - ATP-Binding Cassette (ABC) Proteins - ABC2008, Innsbruck, Austria, March 1-8, 2008.
- Speaker (and Co-Chair), Session on “Predicting and Preventing Drug Resistance”, AACR Centennial Conference: Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine, Monterey, CA, July 22, 2008 (*declined*)
- Chair, Session on “ABCC Proteins in Cystic Fibrosis and Drug Resistance”, 5th Annual North American ABC Gene Meeting, NCI-NIH, Frederick, MD, September 25, 2008
- Representative, 20th EORTC-NCI-AACR Scientific Committee for the Molecular Targets and Cancer Therapeutics symposium in Geneva, Switzerland, October 21-24, 2008
- Discussion Leader, Session on “MDR Efflux Pumps in Cell Biology”, Gordon Research Conference on “Multi-Drug Efflux Systems”, Galveston, TX, March 24, 2009
- Co-Organizer, FEBS Special Meeting – ABC2010, Innsbruck, Austria, February 27-March 6, 2010
- Discussion Leader, Session on “Transporter Biology: Impact on Drug Distribution and Organ Toxicity”, Gordon Research Conference on “Drug Metabolism”, Holderness, NH, July 15, 2010
- Co-Organizer, FEBS Special Meeting - ABC2012, Innsbruck, Austria, March 3-9, 2012

2014-present

- Co-Organizer, ABC2014 Special Meeting, Innsbruck, Austria, March 8-14, 2014
- Chair, Session on “ABC Proteins and Drug Disposition”, ABC2014 Special Meeting, Innsbruck, Austria, March 13, 2014
- Discussion Leader, Session on “Functional Interactions between Influx and Efflux Transporters in Health and Clinical Conditions”, Gordon Research Conference on “Multi-Drug Efflux Systems”, Barga, Lucca, Italy, April 27, 2015
- Co-Organizer, Conference on MDR in Tumors, Jinan University College of Pharmacy, Guangzhou, PRC, 7 November 2015
- Co-Organizer, Special Meeting - ABC 2016, Innsbruck, Austria, March 5-11, 2016
- Chair, Session on “ABC Proteins and Xenobiotic Disposition”, Special Meeting - ABC 2016, Innsbruck, Austria, March 10, 2016
- Co-Chair, ASPET President’s Symposium on “Precision Medicine in Anti-Cancer Pharmacotherapy”, Experimental Biology 2016 Annual Meeting, San Diego, CA, April 3, 2016
- Session Chair, Symposium: Celebrating 30 Years of Research on Multidrug Resistance and ABC Drug Transporters, National Cancer Institute, NIH, Bethesda, MD, September 23, 2016
- Co-Organizer, Symposium: Basic and Clinical Studies of ATP-Binding Cassette Transporters, Jinan University, Guangzhou, PRC, November 2016
- Co-Organizer, Symposium: Basic and Clinical Studies of ATP-Binding Cassette Transporters, Jinan University, Guangzhou, PRC, November 2017
- Co-Organizer, ABC2018 FEBS Special Meeting, Innsbruck, Austria, March 6-12, 2018
- Co-Organizer & Co-Chair, ASPET Symposium on “Can Metabolic Vulnerabilities in Tumors be Therapeutically Exploited?”, Experimental Biology 2018 Annual Meeting, San Diego, CA, April 24, 2018
- Co-Organizer, Workshop on ABC Membrane Proteins in Human Physiology and Disease, Jinan University, Guangzhou, PRC, 9 November 2018

- Discussion Leader, Session on “Learning from Drug Resistance Across Diseases”, Gordon Research Conference on “Multi-Drug Efflux Systems”, Barga, Lucca, Italy, April 28 –May 3, 2019 (*declined*)

SERVICE & ADMINISTRATION

COMMITTEES – Academic:

External:

- Scientific Officer, National Cancer Institute of Canada, Grants Panel B (Cell Biology and Metastasis), 1989
- Member, National Cancer Institute of Canada, Grants Panel G (Pharmacology, Carcinogenesis, Chemistry), 1991, 1992
- Member, Medical Research Council of Canada Strategic Planning Committee, 1992
- Member, OCFTRF Selection Committee for Chief Executive Officer of the Kingston Regional Cancer Centre, 1992
- Member, Program Committee, Preclinical Pharmacology/Experimental Therapeutics Subcommittee, American Association for Cancer Research 1992-1993
- Member, John Charles Polanyi Prizes Selection Committee, Ontario Council on Graduate Studies, 1993-1995
- Member, Special Memberships Committee, American Association for Cancer Research, 1993-1994
- Member, Canadian Scientific Advisory Committee, 19th International Congress of Chemotherapy, 1993-1995
- Member, Awards Committee, Cain Subcommittee, American Association for Cancer Research, 1994-1995
- Chair, Medical Research Council of Canada Site Review Team, Toronto, March 23, 1995
- Chair, Preclinical Pharmacology/Experimental Therapeutics Subcommittee, Program Committee, American Association for Cancer Research, 1995-1996
- Councillor, Pharmacological Society of Canada, 1995-1998
- Chair, John Charles Polanyi Prizes Selection Committee, Ontario Council on Graduate Studies, 1995-1996
- Member, Medical Research Council of Canada, Grants Committee Cancer “B”, 1995-1998
- Member, Ontario Graduate Scholarship Selection Panel (Pharmacology & Pharmacy), 1996
- Member, Awards Committee, Cain Subcommittee, American Association for Cancer Research, 1996-1997
- Member, Sustaining Membership Committee, American Association for Cancer Research, 1996-1997
- Chair, Cain Memorial Award Committee, American Association for Cancer Research, 1997
- Member, Ontario Graduate Scholarship Selection Panel (Human Biology), 1997
- Member, Canadian Breast Cancer Research Initiative Review Panel for Unconventional/Alternate Therapies, National Cancer Institute of Canada, 1997-1998
- Member, Site Review Team, Laboratory of Nutrition and Molecular Regulation, National Institutes of Health, Frederick, MD, April 27-29, 1998
- Member, Advisory Committee on Research (ACOR), National Cancer Institute of Canada, 1998-2001
- Member, Education Committee, American Association for Cancer Research, 1998-1999

- Member, ACOR Subcommittee for Travel Awards, National Cancer Institute of Canada, 1998-2001
- Member, Research Advisory Committee, Cancer Care Ontario (CCO), 1998-2003
- Member, NCI-NIH Site Review Team, Moffitt Cancer Center, Tampa, FL, January 27-28, 1999
- Member, Program Committee, AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics, 1999
- Member, Genomics Initiative Advisory Board, Ontario Research and Development Challenge Fund (ORDCF), 1999-2001
- Member, Scientific Advisory Board, FEBS Advanced Lecture Course – ABC 2001, Gosau, Austria, 2000-2001
- Member, Oversight Committee, Centre for Behavioural Research and Program Evaluation, National Cancer Institute of Canada, 2000-2002
- Member, Working Group, Highway to Life, Ontario Ministry of Energy, Science and Technology, 2000
- Member, Bruce F. Cain Memorial Award Selection Committee, American Association for Cancer Research, 2001
- Vice-Chair, Committee on Research, National Cancer Institute of Canada, 2001-2002
- Member, Annual Meeting Program Committee, American Association for Cancer Research, 2001-2002, 2007-2008
- Member, Scientific Advisory Board, Eli Lilly Canada-Cancer Care Ontario, Ontario Senior Fellow/Clinician Scientist Award, 2001-2002
- Member, Pezcoller Foundation – AACR Award Selection Committee, 2002
- Member, Scientific Advisory Board, FEBS Advanced Lecture Course, 2002-2006
- Member, Nominating Committee, American Association for Cancer Research, 2002-2004 (*elected*)
- Member, Nominating Committee, PARTEQ Innovations Inc., Kingston, ON, 2002-2004
- Member, SCOR Grant Advisory Committee, Department of Pharmaceutics, University of Washington, Seattle, WA, 2003-2006
- Member, Canada Research Chairs Program, College of Reviewers, 2003-present
- Member, External Advisory Board, Roswell Park Cancer Institute (RPCI), Buffalo, NY, 2004-2009
- Member, Human Resources Committee, PARTEQ Innovations Inc., Kingston, ON, 2004-2006
- Member, National Cancer Institute of Canada (NCIC) Awards of Excellence Selection Committee, 2006, 2007, 2008
- Member, Flavelle Medal Committee, Royal Society of Canada, 2007-2008, 2010
- Member, International Affairs Committee, American Association for Cancer Research, 2007-2010
- Member, Program Committee, Experimental and Molecular Therapeutics Section, American Association for Cancer Research, 2007-2008
- Member, Scientific Committee, 20th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics”, 2008
- Member, Awards Committee, Canadian Society of Pharmacology & Therapeutics, 2008-2010
- Member, Gairdner Foundation Medical Review Panel, 2009-2010

- Member, Fellowships – Post-PhD Committee, Canadian Institutes of Health Research (CIHR), 2009-2010
- Member, Terry Fox Research Institute Program Project Grant Steering Committee on Research Excellence (PPG SCORE), 2013-2017
- Member, Expert Panel, European Union Project, “Role of multidrug transporters in pharmacokinetics and toxicology – in vitro tests in pharmaceutical and clinical practice”, Ryn, Poland, September 2-3, 2013
- Councillor, International Transmembrane Transporter Society (ITTS), 2014-2018
- Chair, Division for Cancer Pharmacology, American Society of Pharmacology and Experimental Therapeutics (ASPET), 2015-2017
- Member, Council of Division Chairs, American Society of Pharmacology and Experimental Therapeutics (ASPET), 2015-2017
- Member, ASPET Annual Meeting Program Committee, 2015-2017
- Member, Selection Committee, AACR Award for Outstanding Achievement in Chemistry in Cancer Research, American Association for Cancer Research, 2015-17
- Member, Board of Directors, American Association for Cancer Research International - Canada, 2016-2019
- Past-Chair, Division for Cancer Pharmacology, American Society of Pharmacology and Experimental Therapeutics (ASPET), 2017-2019

Internal - University/Faculty:

- Member, University Biohazards Committee, 1986-1989; 1989-1990
- Member, Principal’s Search Committee, Dean of Graduate Studies and Research, 1988-1989
- Member, Committee on Women in Science and Engineering, 1989
- Member, Search Committee, Director of the Animal Care Service, 1990
- Member, Council of the School of Graduate Studies and Research, 1990-1993
- Member, Review Committee, Joseph S. Stauffer Research Professor of Pathology, 1992
- Member, Search Committee for Co-Director, Investigational New Drugs Program, NCIC Clinical Trials Group, 1993
- Member, Strategic Planning Steering Committee, Faculty of Medicine, 1994-1995
- Member, Principal’s Search Committee, Vice-Principal, Research, 1994-1995
- Member, Adjudication Committee, Principal’s Development Fund, 1995
- Member, Faculty of Medicine, Graduate Studies and Research Committee, 1995-1996
- Member, Search Committee for Co-Director Investigational New Drugs Program, NCIC Clinical Trials Group, 1996
- Member, Vice-Principal Research Committee on Policy for Research Grants, Contracts and Consulting Activities, 1997
- Member, Search Committee, Head of Community Health & Epidemiology, 1997
- Member, Search Committee, Bader Chair in Organic Chemistry, 1997
- Member, Research Advisory Committee, Faculty of Health Sciences, 1998
- Member, Principal’s Search Committee, Vice-Principal, Research, 1999-2000
- Member, Principal’s Review Committee, Dean of Faculty of Health Sciences, 2000
- Member, Scientific Management Committee, Protein Function Discovery Facility, Faculty of Health Sciences, 2000-unk
- Member, Advisory Committee on the Establishment of a Cancer Research Institute, Faculty of Health Sciences, 2000-2001

- Member, Chancellor's Research Award Committee, 2001, 2002
 - Member, Microarray Laboratory Management Committee, 2001-2005
 - Member, Vice-Principal Research Adhoc Committee on the Indirect Costs of Research, 2001
 - Member, Internal Academic Review Team, Department of Biochemistry, 2001-2002
 - Member, Advisory Research Committee, Subcommittee I (Life Sciences), 2001-2002
 - Member, Queen's University Senate, 2002-2005 (*elected*); 2005-2008 (*elected*)
 - Member, Queen's University Senate Agenda Committee, 2002-2003
 - Member, Queen's University Joint Board of Trustees/Senate Committee to Select the Next Principal, 2002-2004 (*elected*)
 - Member, Queen's University Senate Promotion Advisory Committee, 2003-2005
 - Member, Faculty Search Committee, Protein Function Discovery (PFD) Research Group, 2004-2005 (*elected*)
 - Chair, Faculty Search Committee, Division of Cancer Biology & Genetics, Queen's Cancer Research Institute, 2004
 - Member, Queen's University Senate Representative to the International Centre Council, 2004-2005
 - Member, Search Committee, Director of the National Cancer Institute of Canada, Clinical Trials Group and the Edith Eisenhower Chair in Clinical Cancer Research, 2004-2005 (*elected*)
 - Member, Queen's University Senate Committee on Academic Development (SCAD), 2005-2008
 - Member, Council of Ontario Universities (COU), Academic Colleague for Queen's University, 2005-2008 (*elected*)
 - Member, Committee on Government and Community Relations, Council of Ontario Universities, 2005-2006
 - Member, Committee on Relationships with Other Postsecondary Institutions, Council of Ontario Universities, 2006-2008
 - Member, David Smith Award Selection Committee, Council of Ontario Universities, 2006
 - Member, Staffing Advisory Subcommittee of Basic Science Council, Faculty of Health Sciences, 2007-2009
 - Member, Queen's University Senate Internal Academic Review Committee (IARC), 2007-2008.
 - Member, Queen's University Board of Trustees, 2008-2010 (*elected by alumni*)
 - Member, Queen's University Board of Trustees Finance Committee, 2009-2010
 - Member, Queen's University Senate Nominating Committee, 2010 (*elected*)
 - Member, Executive Committee, Queen's University Mass Spectrometry and Proteomics Unit, 2011
 - Member, Principal's Advisory Selection Committee, Provost and Vice-Principal (Academic), 2015
 - Member, Faculty of Health Sciences, Adjudication Committee for Canada 150 Chair Competition, 2017
- Internal - Departmental:***
- Chair, Seminar Program Committee, Department of Microbiology & Immunology, 1985-1987
 - Library Representative, Department of Microbiology & Immunology, 1986-1989
 - Member, Promotions Committee, Department of Oncology, 1986-1988, 1992

- Member, Search Committee, Department of Medicine, Division of Hematology, 1987-1988
- Member, Research Committee, Department of Oncology, 1986-1989
- Member, Library Committee, Department of Oncology, 1987-1988
- Member, Ethics Committees (4), Department of Oncology, 1988-1989
- Member, Retreat Agenda Committee, Department of Oncology, 1988-1989
- Member, Appointment, Promotion, Tenure and Leave Committee, Department of Pharmacology & Toxicology, 1990-1991, 1992
- Member, Ethics Committee, Department of Pathology, 1990
- Member, Research Advisory Committee, Department of Oncology, 1993-1997
- Member, Graduate Studies and Admissions Committee, Department of Pharmacology & Toxicology, 1993-1996
- Member, Graduate Studies Committee, Department of Pathology, 1997-2001
- Member, Faculty Search Committee, Department of Pathology, 1997-2001
- Member, Appointment, Promotion, Tenure and Leave Committee, Department of Pathology, 1998
- Member, Haust Trust Fund Committee, Department of Pathology, 1999-2003
- Member, Graduate Studies Committee, Department of Pathology & Molecular Medicine, 2005-2010
- Member, Curriculum Review Working Group, Department of Pathology & Molecular Medicine, 2006-2010
- Member, Queen's University Cancer Research Institute Executive Management Committee, 2009-2018
- Member, Research Advisory Committee, Department of Pathology & Molecular Medicine, 2009-2013
- Member, Graduate Program Committee, Department of Pathology & Molecular Medicine, 2016-2019
- Member, Undergraduate Education Working Group, Department of Pathology & Molecular Medicine, 2017-2018
- Member, Faculty Search Committee, Department of Pathology & Molecular Medicine, 2018
- Member, Faculty Search Committee, Department of Pathology & Molecular Medicine, 2019-present
- Member, Reappointment, Tenure and Promotion Committee, Department of Pathology, 2020-2021
- Member, Adjudication Committee, Gerald and Marion Marks Award in Pharmacology & Human Toxicology, Department of Biomedical and Molecular Sciences, 2021

Other:

- Member, KGH Block Term Grant Committee, Ontario Respiratory Disease Foundation, 1986-1990
- Member, KRCC, OCTRF Career Scientist Search Committee, 1986
- Member, KGH Clare Nelson Bequest Committee, 1989, 1990, 1991
- Member, KRCC, OCTRF Physicist Search Committee, 1989, 1990, 1991
- Member, KRCC, Cancer '94 Committee, Department of Oncology, 1994
- Reviewer, KGH Prostate Cancer Fight Foundation (PCFF), 2009

COMMITTEES – Academic Administration (as Deputy Provost) (partial list):

- Chair, Senate Committee on Academic Development (SCAD), 2010-2012
- Chair, Senate Internal Academic Review (IARC) Committee, 2010-2012
- Chair, University Teaching Space Committee, 2010-2011
- Chair, Queen’s University Chair in Teaching and Learning Selection Committee, 2010-2011
- Chair, Selection Committee for the Baillie Awards for Excellence in Secondary School Teaching, 2010-2011
- Chair, Provost’s Advisory Committee for the Review of University Archivist, 2011
- Member, Advisory Board, Agnes Etherington Art Centre, 2010-2012
- Member, Queen’s University Accessibility Committee (*delegated*), 2010-2012
- Member, Provost’s Enrolment Planning Task Force, 2010-2012
- Member, Retirees’ Association of Queen’s-Academic Partnership Committee, 2010-2012
- Member, Queen’s University Research Chairs Executive Committee, 2010-2012
- Member, Queen’s University Learning Commons (QLC) Planning Committee (*delegated*), 2010-2012
- Member, Board of Directors, McGill-Queen’s University Press, 2010-2012
- Member, Finance and Audit Committee, McGill-Queen’s University Press, 2010-2012
- Member, Search Committee for Chief Information Officer, 2011
- Member, Sub-committee of the Joint Committee on the Administration of the Agreements (JCAA) to administer the fund for Scholarly Research and Creative Works and Professional Development, 2011-2012
- Chair, Senate Cyclical Program Review (CPR) Committee, 2011-2012
- Chair, Provost’s Advisory Committee for the Review of the Director, Agnes Etherington Art Centre, 2012
- Member, Vice-Principal (Research) Advisory Committee for the Review of the Associate Vice-Principal (Research Operations), 2012
- Chair, Provost’s Working Group on Diplomas and Certificates, 2012

PROFESSIONAL DEVELOPMENT – Academic Administration:

- Measuring the Value of a Postsecondary Education, Higher Education Quality Council of Ontario (HEQCO) Workshop, Toronto, May 2011
- Senior University Administrators Course, Centre for Higher Education Research and Development, Banff, June 2011

REVIEWER FOR GRANTING AGENCIES

Alberta Heritage Foundation	Medical Research Council of Canada
Association for International Cancer Research (UK)	National Cancer Institute of Canada
Biotechnology and Biological Sciences Research Council (UK)	National Institutes of Health (National Cancer Institute, USA)
Canadian Institutes of Health Research	National Science Foundation (USA)
Canada Research Chair Program	Natural Sciences and Engineering Research Council
Cancer Research UK	Netherlands Organization for Scientific Research
Cancer Research Campaign (UK)	Ontario Thoracic Society
Cancer Research Society Inc.	Ontario Council of Graduate Studies Polanyi
Clare Nelson Bequest, KGH	

Connaught (University of Toronto)
 Dutch Cancer Society
 Florida Department of Health
 Government of Alberta
 Israel Science Foundation

Prizes
 Prostate Cancer Fight Foundation
 Terry Fox Research Institute

REFEREE FOR JOURNALS

Advances in Therapy
 Annals of Oncology
 Biochemical Pharmacology
 Biochemistry and Cell Biology
 Biochimica Biophysica Acta
 British Journal of Cancer
 British Journal of Pharmacology
 Canadian Journal of Physiology and
 Pharmacology
 Cancer Chemotherapy and Pharmacology
 Cancer
 Cancer Research
 Carcinogenesis
 Chemical Research in Toxicology
 Clinical Cancer Research
 Cytometry
 Drug Metabolism and Disposition
 European Journal of Biochemistry
 European Journal of Cancer and Clinical
 Oncology
 European Journal of Pharmaceutical Sciences
 FEBS Journal
 FEBS Letters
 Functional and Integrative Genomics
 Gastroenterology
 Gene
 Genomics

International Journal of Cancer
 International Journal of Radiation Oncology,
 Biology, Biophysics
 Journal of Bioenergetics and Biomembranes
 Journal of Biological Chemistry
 Journal of Clinical Investigation
 Journal of Experimental Medicine
 Journal of the National Cancer Institute
 Journal of Pharmacology and Experimental
 Therapeutics
 Journal of Physiology
 Leukemia Research
 Molecular Biology of the Cell
 Molecular Cancer Therapeutics
 Molecular Membrane Biology
 Molecular Microbiology
 Molecular Pharmacology
 Nutrition and Cancer
 Oncology Research/Cancer Communications
 Pharmacogenetics
 Pharmacogenetics Genomics
 Proceedings of the National Academy of
 Sciences (USA)
 Science
 Toxicological Sciences
 Toxicology
 Trends in Pharmacological Sciences

FACULTY APPRAISALS

Multiple internal and external faculty appraisals (confidential)

OTHER

- Listed in *Canadian WHO'S WHO*, University of Toronto Press (since 1994)
- Listed in *WHO's WHO of Canadian Women*
- WHMIS Training, Queen's University
- Equity Training and Familiarization Workshop, Queen's University, 1997, 2004
- Continuing Medical Education, Power Point Presentations, Queen's University, April 17, 2002
- Canadians for Health Research, Researcher of the Week, February 16, 2005
 (www.chrcrm.org/profile_susan_cole_que.htm)

- Faculty Development Creative Writing Workshop, Queen's University, October 16, 2013
- Profiled in American Society of Pharmacology & Experimental Therapeutics, ASPET Members Achieve!, September 2013 (<http://www.aspet.org/DrugMetabolism/aspnet-members-achieve/susan-cole/>)
- Appointments/RTPC Workshop, Queen's University, 24 October 2018
- Queen's University Security Fundamentals, 4 December 2018
- Queen's Cybersecurity Education and Awareness training, October 4, 2021

COMMUNITY

- Judge, Frontenac County Science Fair, 1983, 1984, 1985, 1988
- Interview, Floyd Patterson, CKWS-TV, Kingston, April 1985
- Interview, Rob Tripp, CFMK-FM, Kingston, April 1987
- Speaker, Terry Fox Run Breakfast, Northern Telecom, Kingston, August 1990
- Speaker, Canadian Cancer Society Fund-raising Breakfast, Kingston, September 1990
- Interview, Floyd Patterson, CKWS-TV, Kingston, September 1990
- Interview, Mike Poskovits, CKWS-TV, Kingston, December 1992
- Interview, Avis Favaro, CTV, Toronto, December 1992
- Interview, CBC Radio *Quirks and Quarks*, December 1992
- Interview, CKLC Radio, Kingston, December 1992
- Interview, CBC Radio *Noontime*, Ottawa, December 1992
- Featured in *Macleans* magazine, *Kingston Whig-Standard*, *Globe & Mail*, *London Free Press*, *Vancouver Sun*, *Ontario Medicine*, *Toronto Star*, *Medical Post*, *Canadian Medical Association Journal*, *Progress Against Cancer* (Canadian Cancer Society) – December 1992/January 1993)
- Speaker, Kingston General Hospital Business Partners Luncheon, April 20, 1994
- Interview, CKWS-TV, Kingston, Andrew Barnett, May 1, 1996
- Speaker, NCIC 50th Anniversary Celebrations, Kingston, June 3, 1996
- Interview, Austrian Public Radio, Vienna, Austria, September 22, 1997
- Featured in *Cancer Care* 3(2): 1999 (Cancer Care Ontario magazine)
- Featured in *Kingston Whig-Standard*, August 9, 2001; December 11, 2001; October 17, 2006; November 2007
- Featured in *A Sampling of Success Stories of Federal Investment in University Research*, Council of Ontario Universities, March 2003
- Speaker, Rotary Club, Cobourg, May 30, 2003
- Introduction, Queen's University Terry Fox Run, September 14, 2003
- Speaker, Canadian Cancer Society Research Symposium, Loyalist College, Belleville, ON, November 29, 2006
- Featured in *Times Union*, Albany, NY; interviewed by Claire Hughes, March 26, 2015
- Executive Committee, John Austin Society (Queen's University), April 2019 - present

PEER-REVIEWED FULL PUBLICATIONS

[Career Total to date: 248] (names of student, postdoctoral and other trainees are underlined)

H-INDEX = 86; I10-INDEX = 216; CITATIONS = 31,900 [GOOGLE SCHOLAR JANUARY 2022]

16 ARTICLES CITED >400 TIMES; 60 CITED 100-399 TIMES; 68 CITED 40-100 TIMES)

1. C. Pace-Asciak and **S. Cole**. Inhibitors of prostaglandin catabolism. I. Differential sensitivity of 9-PGDH, 13-PGR and 15-PGDH to low concentrations of indomethacin. *Experientia* 31: 143-145 (1975). PMID: 1112337
<https://doi.org/10.1007/BF01990669>
2. **S.P.C. Cole**, E.J. Vavasour and G.S. Marks. Drug-induced porphyrin biosynthesis. XIX. Potentiation of the porphyrin-inducing effects of SKF 525-A in the chick embryo liver by 3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine, an inhibitor of ferrochelatase. *Biochem. Pharmacol.* 28: 3533-3538 (1979). PMID: 533555
3. **S.P.C. Cole** and G.S. Marks. Structural requirements in dihydropyridines for ferrochelatase inhibition and δ -aminolevulinic acid synthetase induction. *Int. J. Biochem.* 12: 989-992 (1980). PMID: 7450160
4. P.R. Ortiz de Montellano, K.L. Kunze, **S.P.C. Cole** and G.S. Marks. Inhibition of hepatic ferrochelatase by the four isomers of *N*-methylprotoporphyrin IX. *Biochem. Biophys. Res. Commun.* 97: 1436-1442 (1980). PMID: 6894236
5. **S.P.C. Cole**, D.T. Zelt and G.S. Marks. Comparison of the effects of griseofulvin and 3, 5-diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine on ferrochelatase activity in the chick embryo liver. *Mol. Pharmacol.* 19: 477-480 (1981). PMID: 7266472
6. **S.P.C. Cole**, R.A. Whitney and G.S. Marks. Ferrochelatase-inhibitory and porphyrin-inducing properties of 3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine and its analogues in chick embryo liver cells. *Mol. Pharmacol.* 20: 395-403 (1981). PMID: 7300820
7. **S.P.C. Cole**, T.E. Massey, G.S. Marks and W.J. Racz. Effects of porphyrin-inducing drugs on ferrochelatase activity in isolated mouse hepatocytes. *Can. J. Physiol. Pharmacol.* 59: 1155-1158 (1981). PMID: 7317839
8. P.R. Ortiz de Montellano, K.L. Kunze, **S.P.C. Cole** and G.S. Marks. Differential inhibition of hepatic ferrochelatase by the isomers of *N*-ethylprotoporphyrin IX. *Biochem. Biophys. Res. Commun.* 103: 581-586 (1981). PMID: 7332558
9. **S.P.C. Cole**, G.S. Marks, P.R. Ortiz de Montellano and K.L. Kunze. Inhibition of ferrochelatase by *N*-methylprotoporphyrin IX is not accompanied by δ -aminolevulinic acid synthetase induction in chick embryo liver cell culture. *Can. J. Physiol. Pharmacol.* 60: 212-215 (1982). PMID: 6896292

10. G.S. Marks, D.T. Zelt and **S.P.C. Cole**. Alterations in the heme biosynthetic pathway as an index of exposure to toxins. *Can. J. Physiol. Pharmacol.* 60: 1017-1026 (1982). PMID: 6812933
11. **S.P.C. Cole** and G.S. Marks. A radiochemical assay for heme synthase activity; confirmation and supplement. *Enzyme* 28: 231-232 (1982).
12. G.S. Marks, S.B. Follows, D.T. Zelt and **S.P.C. Cole**. Patterns of porphyrin accumulation in response to chemicals in chick embryo liver cells. *Can. J. Physiol. Pharmacol.* 61: 546-553 (1983). PMID: 6883207
13. **S.P.C. Cole**, B.G. Campling, T. Atlaw, D. Kozbor and J.C. Roder. Human monoclonal antibodies. *Molec. Cell. Biochem.* 62: 109-120 (1984). PMID: 6087121
14. **S.P.C. Cole**, B.G. Campling, I.H. Louwman, D. Kozbor and J.C. Roder. A strategy for the production of human monoclonal antibodies reactive with lung tumor cells. *Cancer Res.* 44: 2750-2753 (1984). PMID: 6327024
15. **S.P.C. Cole** and G.S. Marks. Ferrochelatase and *N*-alkylated porphyrins. *Molec. Cell. Biochem.* 64: 127-137 (1984). PMID: 6390167
16. **S.P.C. Cole**, E.H. Vreeken and J.C. Roder. Antibody production by human x human hybridomas in serum-free medium. *J. Immunol. Meth.* 78: 271-278 (1985). PMID: 3989311
17. J.C. Roder, D. Kozbor, **S.P.C. Cole**, T. Atlaw, B.G. Campling and R.C. McGarry. The EBV-hybridoma technique. In, *Human Hybridomas and Monoclonal Antibodies* (eds. E.G. Engleman, S. Foug, J. Larrick, A. Raubitschek), Ch. 4, pp. 55-70, Plenum Press, New York, NY, 1985.
18. **S.P.C. Cole**, S. Mirski, R.C. McGarry, R. Cheng, B.G. Campling and J.C. Roder. Differential expression of Leu-7 antigen on human lung tumor cells. *Cancer Res.* 45: 4285-4290 (1985). PMID: 3928154
19. **S.P.C. Cole**, D. Kozbor and J.C. Roder. Strategies for production of human monoclonal antibodies. In, *Hybridoma Technology in the Biosciences and Medicine* (ed. T.A. Springer), Ch. 2, pp. 43-55, Plenum Press, New York, NY, 1985.
20. D. Kozbor, W. Abramow-Newerly, P. Tripputi, **S.P.C. Cole**, J. Weibel, J.C. Roder and C.M. Croce. Specific immunoglobulin production and enhanced tumorigenicity following ascites growth of human hybridomas. *J. Immunol. Meth.* 81: 31-42 (1985). PMID: 4020147
21. **S.P.C. Cole**, D. Kozbor and J.C. Roder. The EBV-hybridoma technique and its application to human lung cancer. In, *Monoclonal Antibodies and Cancer Therapy* (Vol. 27, UCLA Symposia on Molecular and Cellular Biology, New Series) (eds. R.A. Reisfeld and S.Sell), pp. 77-96, Alan R. Liss, Inc. New York, NY, 1985.

22. A.C. Peacock, S.L. Bunting, **S.P.C. Cole** and M. Seidman. Two dimensional electrophoretic display of restriction fragments from genomic DNA. *Analyt. Biochem.* 149: 177-182 (1985). PMID: 3000213
23. **S.P.C. Cole**, B.G. Campling, D.F. Dexter, J.J.A. Holden and J.C. Roder. Establishment of a human large cell lung tumor line (QU-DB) with metastatic properties in athymic mice. *Cancer* 58: 917-923 (1986). PMID: 3719556
24. J.C. Roder, **S.P.C. Cole** and D. Kozbor. The EBV-hybridoma technique. In, *Immunochemical Techniques* (eds. J.J. Langone and H. Van Vunakis), *Meth. Enzymol.* 121: 140-167, Academic Press, New York, NY, 1986. PMID: 3014265
25. D. Kozbor, J.C. Roder, M.E. Sierzega, **S.P.C. Cole** and C.M. Croce. Comparative phenotypic analysis of available hybridoma fusion partners. In, *Immunochemical Techniques* (eds. J.J. Langone and H. Van Vunakis), *Meth. Enzymol.* 121: 120-140, Academic Press, New York, NY, 1986. PMID: 3014264
26. **S.P.C. Cole**. Rapid chemosensitivity testing of human lung tumor cells using the MTT assay. *Cancer Chemother. Pharmacol.* 17: 259-263 (1986). *416 citations-01/2022. PMID: 3742711
27. P.G. Forkert, M.L. Vessey, J.S. Elce, S.S. Park, H.V. Gelboin and **S.P.C. Cole**. Localization of phenobarbital- and 3-methylcholanthrene- inducible cytochromes P-450 in mouse lung with monoclonal antibodies. *Res. Commun. Chem. Pathol. Pharm.* 53: 147-157 (1986). PMID: 3532243
28. B.G. Campling, **S.P.C. Cole**, T. Atlaw, D. Kozbor and J.C. Roder. The EBV-hybridoma technique and its applications. In, *Human Hybridomas: Diagnostic and Therapeutic Applications* (ed. A.J. Strelkauskas), Ch. 1, pp. 3-22, Marcel-Dekker, New York, NY, 1986.
29. B.G. Campling, **S.P.C. Cole**, T. Atlaw, D. Kozbor and J.C. Roder. Practical aspects of human-human hybridomas. In, *Monoclonal Antibodies: Production, Techniques and Applications* (ed. L.B. Schook), Ch. 1, pp. 3-23, Marcel-Dekker, New York, NY, 1987.
30. **S.P.C. Cole**. Monoclonal antibodies. *Can. Fam. Physician* 33: 369-372 (1987). PMID: 21263826
31. **S.P.C. Cole**, E.H. Vreeken, S.E.L. Mirski and B.G. Campling. Growth of human x human hybridomas in protein-free medium supplemented with ethanolamine. *J. Immunol. Meth.* 97: 29-35 (1987). PMID: 3493294
32. S.E.L. Mirski, J.H. Gerlach and **S.P.C. Cole**. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. *Cancer Res.* 47: 2594-2598 (1987). *418 citations-01/2022. PMID: 2436751
33. J.M. Trent, P.S. Meltzer, M.L. Slovak, A.B. Hill, W.S. Dalton, W.T. Beck and **S.P.C. Cole**. Cytogenetic and molecular biologic alterations associated with anthracycline resistance. In,

Mechanisms of Drug Resistance in Neoplastic Cells (eds. P.V. Woolley and K.D. Tew), Vol. 9, Ch. 17, pp. 259-276, Academic Press, New York, NY, 1988.

34. B.G. Campling, J. Pym, P.R. Galbraith and **S.P.C. Cole**. Use of the MTT assay for rapid determination of chemosensitivity of human leukemic blast cells. *Leukemia Res.* 12: 823-831 (1988). PMID: 3199842
35. **S.P.C. Cole**, H.F. Downes and M.L. Slovak. Effect of calcium antagonists on the chemosensitivity of two multidrug resistant human tumour cell lines which do not overexpress P-glycoprotein. *Br. J. Cancer* 59: 42-46 (1989). *133 citations-01/2022. PMID: 2569325
36. P.G. Forkert, M.L. Vessey, S.S. Park, H.V. Gelboin and **S.P.C. Cole**. Cytochromes P-450 in murine lung: an immunohistochemical study with monoclonal antibodies. *Drug Metab. Dispos.* 17: 551-555 (1989). PMID: 2573499
37. S.E.L. Mirski and **S.P.C. Cole**. Antigens associated with multidrug resistance in H69AR, a small cell lung cancer cell line. *Cancer Res.* 49: 5719-5724 (1989). PMID: 2571409
38. **S.P.C. Cole**, H.F. Downes, S.E.L. Mirski and D.R. Clements. Alterations in glutathione and glutathione-related enzymes in a multidrug resistant small cell lung cancer cell line. *Mol. Pharmacol.* 37: 192-197 (1990). *130 citations-01/2022. PMID: 1968221
39. **S.P.C. Cole**, S.A. Mohamdee and S.E.L. Mirski. A monoclonal antibody detecting a cell surface epitope on some drug resistant human tumour cell lines. *Br. J. Cancer* 62: 14-16 (1990). PMID: 1697186
40. **S.P.C. Cole**. Patterns of cross-resistance in a multidrug resistant small cell lung carcinoma cell line. *Cancer Chemother. Pharmacol.* 26: 250-256 (1990). *66 citations-01/2022. PMID: 1973363
41. **S.P.C. Cole**. The legacy of Terry Fox. *Queen's Quarterly* 97: 253-276 (1990).
42. B.G. Campling, J. Pym, H. Baker, **S.P.C. Cole** and M. Lam. Chemosensitivity testing of small cell lung cancer using the MTT assay. *Br. J. Cancer* 63: 75-83 (1991). PMID: 1846554
43. **S.P.C. Cole**, B.M.T. Campigotto, J.G. Johnson and B.E. Elliott. Differential growth inhibition and enhancement of major histocompatibility complex class I antigen expression by interferons in a small cell lung cancer cell line and its doxorubicin-selected multidrug-resistant variant. *Cancer Immunol. Immunother.* 33: 274-277 (1991). PMID: 1711927
44. **S.P.C. Cole**, E.R. Chanda, F.P. Dicke, J.H. Gerlach and S.E.L. Mirski. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. *Cancer Res.* 51: 3345-3352 (1991). *220 citations-01/2022. PMID: 1675932
45. S.E.L. Mirski and **S.P.C. Cole**. Multidrug resistance-associated antigens on drug-sensitive and -resistant human tumour cell lines. *Br. J. Cancer* 64: 15-22 (1991). PMID: 1677258

46. M.L. Slovak, S.E.L. Mirski, **S.P.C. Cole**, J.H. Gerlach, K.H. Yohem and J.M. Trent. Tumorigenic multidrug resistant HT1080 cells do not overexpress receptors for epidermal growth factor. *Br. J. Cancer* 64: 296-298 (1991). PMID: 1679997
47. **S.P.C. Cole**. The Merck-Frosst Award. Multidrug resistance in small cell lung cancer. *Can. J. Physiol. Pharmacol.* 70: 313-329 (1992). PMID: 1318157 (*invited, peer-reviewed*)
48. **S.P.C. Cole**^{||}, M.J. Pinkoski, G. Bhardwaj and R.G. Deeley. Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line. *Br. J. Cancer* 65: 498-502 (1992). PMID: 1314068 ^{||}*corresponding senior author*
49. **S.P.C. Cole**. Drug resistance and lung cancer. In, *Cancer: Concept to Clinic* (ed. J. Wood), Vol. 1, pp. 15-21, Medical Publishing Enterprises, Fairlawn, NJ (1992). (*invited*)
50. B. Savas, **S.P.C. Cole**, T.F. Akoglu and H.F. Pross. P-glycoprotein-mediated multidrug resistance and cytotoxic effector cells. *Nat. Immun.* 11: 177-192 (1992). PMID: 1358293
51. J.E. Gervasoni, Jr., R.N. Taub, M.T. Yu, D. Warburton, M. Sabbath, D.L. Coppock, J. D'Alessandri, S. Krishna, M. Rosado, M.A. Baker, J. Lutzky, E.R. Chanda, J.H. Gerlach, M.J. Pinkoski, **S.P.C. Cole** and A.A. Hindenburg. Homogeneously staining region in anthracycline-resistant HL-60/AR cells not associated with MDR1 amplification. *Cancer Res.* 52: 5244-5249 (1992). PMID: 1394128
52. **S.P.C. Cole**, G. Bhardwaj, J.H. Gerlach, J.E. Mackie, C.E. Grant, K.C. Almquist, A.J. Stewart, E.U. Kurz, A.M.V. Duncan and R.G. Deeley. Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. *Science* 258: 1650-1654 (1992). PMID: 1360704 ***3,996 citations-01/2022**. **S.P.C. Cole** and R.G. Deeley. Multidrug resistance-associated protein: sequence correction. *Science* 260: 879 (1993).
53. K.A. Krebes, S.E.L. Mirski, H.F. Pross and **S.P.C. Cole**. Peripheral blood mononuclear cells express antigens associated with multidrug resistance in a small cell lung cancer cell line. *Anticancer Res.* 13: 317-322 (1993). PMID: 7685987
54. B.G. Campling, K.A. Baer, H.M. Baker, Y.-M. Lam and **S.P.C. Cole**. Do glutathione and related enzymes play a role in drug resistance in small cell lung cancer? *Br. J. Cancer* 68: 327-335 (1993). PMID: 8102244
55. M.L. Slovak, J.P. Ho, G. Bhardwaj, E.U. Kurz, R.G. Deeley and **S.P.C. Cole**. Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. *Cancer Res.* 53: 3221-3225 (1993). ***206 citations-01/2022**. PMID: 8391919
56. J. Jirsch, R.G. Deeley, **S.P.C. Cole**, A.J. Stewart and D. Fedida. Inwardly rectifying K⁺ channels and volume-regulated anion channels in multidrug resistant small cell lung cancer cells. *Cancer Res.* 53: 4156-4160 (1993). PMID: 8395978

57. S.E.L. Mirski, C.D. Evans, K.C. Almquist, M.L. Slovak and **S.P.C. Cole**. Altered topoisomerase II α in a drug resistant small cell lung cancer cell line selected in VP-16. *Cancer Res.* 53: 4866-4873 (1993). *71 citations-01/2022. PMID: 8104687
58. C.E. Grant, G. Valdimarsson, D.R. Hipfner, K.C. Almquist, **S.P.C. Cole** and R.G. Deeley. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. *Cancer Res.* 54: 357-361 (1994). PMID: 8275468
59. P.W. Feldhoff, S.E.L. Mirski, **S.P.C. Cole** and D.M.M. Sullivan. Altered subcellular distribution of topoisomerase II α in a drug resistant human small cell lung cancer cell line. *Cancer Res.* 54: 756-762 (1994). PMID: 8306338
60. J.R. Zalberg, X.F. Hu, D.M. Wall, S. Mirski, **S. Cole**, G. Nadalin, M.D. Luise, J.D. Parkin, V. Vrazas, L. Campbell and P. Kantharidis. Cellular and karyotypic characterization of two doxorubicin resistant cell lines isolated from the same parental human leukemia cell line. *Int. J. Cancer* 57: 522-528 (1994). PMID: 7514153
61. B.J. Kuss, R.G. Deeley, **S.P.C. Cole**, C.L. Willman, K.J. Kopecky, S.R. Wolman, H.J. Eyre, S.A. Lane, J.K. Nancarrow, S.A. Whitmore and D.F. Callen. Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications. *Lancet* 343: 1531-1534 (1994). PMID: 7911871
62. C.D. Evans, S.E.L. Mirski, M.K. Danks and **S.P.C. Cole**. Reduced levels of topoisomerase II α and β in a multidrug resistant lung cancer cell line. *Cancer Chemother. Pharmacol.* 34: 242-248 (1994). PMID: 8004758
63. J.D. Jirsch, D.W. Loe, **S.P.C. Cole**, R.G. Deeley and D. Fedida. ATP is not required for anion current activated by cell swelling in multidrug-resistant lung cancer cells. *Amer. J. Physiol.* 267: 688-699 (1994). PMID: 7943197
64. **S.P.C. Cole**^{||}, K.E. Sparks, K. Fraser, D.W. Loe, C.E. Grant, G.M. Wilson and R.G. Deeley. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. *Cancer Res.* 54: 5902-5910 (1994). PMID: 7954421 ^{||}corresponding senior author *1025 citations-01/2022.
65. I. Leier, G. Jedlitschky, U. Buchholz, **S.P.C. Cole**, R.G. Deeley and D. Keppler. The MRP gene encodes an ATP-dependent export pump for leukotriene C₄ and structurally related conjugates. *J. Biol. Chem.* 269: 27807-27810 (1994). *1021 citations-01/2022. PMID: 7961706
66. D.R. Hipfner, S.D. Gauldie, R.G. Deeley and **S.P.C. Cole**. Detection of the M_r 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. *Cancer Res.* 54: 5788-5792 (1994). *245 citations-01/2022. PMID: 7954400
67. T. Sumizawa, Y. Chuman, H. Sakamoto, K. Iemura, K.C. Almquist, R.G. Deeley, **S.P.C. Cole** and S.-i. Akiyama. Non-P-glycoprotein-mediated multidrug resistant human KB cells

- selected in medium containing Adriamycin, cepharanthine and mezerein. *Somat. Cell Mol. Genet.* 20: 423-435 (1994). PMID: 7825064
68. K.C. Almquist, D.W. Loe, D.R. Hipfner, J.E. Mackie, **S.P.C. Cole**^{||} and R.G. Deeley. Characterization of the M_r 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cells. *Cancer Res.* 55: 102-110 (1995). *225 citations-01/2022. PMID: 7805019 ^{||}corresponding senior author
69. I. Brock, D.R. Hipfner, B.E. Nielsen, P.B. Jensen, R.G. Deeley, **S.P.C. Cole** and M. Sehested. Sequential co-expression of the multidrug resistance genes, MRP and *mdr1* and their products in VP-16 (etoposide) selected H69 small cell lung cancer cells. *Cancer Res.* 55: 459-462 (1995). PMID: 7834606
70. S.E.L. Mirski and **S.P.C. Cole**. Cytoplasmic localization of a mutant M_r 160,000 topoisomerase II α is associated with the loss of putative bipartite nuclear localization signals in a drug resistant human lung cancer cell line. *Cancer Res.* 55: 2129-2134 (1995). *90 citations-01/2022. PMID: 7743513
71. S. Hasegawa, T. Abe, S. Naito, S. Kotoh, J. Kumazawa, D.R. Hipfner, R.G. Deeley, **S.P.C. Cole** and M. Kuwano. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug resistant bladder cancer cell lines. *Br. J. Cancer* 71: 907-913 (1995). PMID: 7734314
72. J.R. Dimmock, P. Kumar, J.W. Quail, U. Pugazhenthii, J. Yang, M. Chen, R.S. Reid, T.M. Allen, G.Y. Kao, **S.P.C. Cole**, G. Batist, J. Balzarini and E. De Clercq. Synthesis and cytotoxic evaluation of some styryl ketones and related compounds. *Eur. J. Med. Chem.* 30: 209-217 (1995).
73. M.L. Slovak, J.P. Ho, **S.P.C. Cole**, R.G. Deeley, L. Greenberger, E.G.E. deVries, H.J. Broxterman, G.L. Scheffer and R.J. Scheper. The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. *Cancer Res.* 55: 4214-4219 (1995). PMID: 7671223
74. B.J. Kuss, R.G. Deeley, **S.P.C. Cole**, C.L. Willman, K.J. Kopecky, S.R. Wolman, H.I. Eyre and D.F. Callen. The biological significance of the multidrug resistance gene *MRP* in inversion 16 leukaemias. *Leuk. Lymph.* 20: 357-364 (1996). PMID: 8833390 (invited)
75. D.D. Ross, L.A. Doyle, C.A. Schiffer, E.J. Lee, C.E. Grant, **S.P.C. Cole**, R.G. Deeley, W. Yang and Y. Tong. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients. *Leukemia* 10: 48-55 (1996). PMID: 8558937
76. I. Leier, G. Jedlitschky, U. Buchholz, M. Center, **S.P.C. Cole**, R.G. Deeley and D. Keppler. ATP-dependent glutathione disulfide transport mediated by the MRP gene-encoded conjugate export pump. *Biochem. J.* 34: 433-437 (1996). *383 citations-01/2022. PMID: 8670053

77. **S.P.C. Cole**. Multidrug resistance in human lung cancer and topoisomerase II. In, *Lung Cancer: Principles and Practice* (eds. H.I. Pass, J.B. Mitchell, D.H. Johnson and A.T. Turrisi). Ch. 12, pp. 169-204, Lippincott-Raven, Philadelphia, PA (1996). (*invited*)
78. A.J. Stewart, Y. Canitrot, E. Baracchini, N.M. Dean, R.G. Deeley and **S.P.C. Cole**. Reduction in expression of the multidrug resistance protein, MRP, in human tumour cells by antisense phosphorothioate oligonucleotides. *Biochem. Pharmacol.* 51: 461-469 (1996). ***114 citations-01/2022**. PMID: 8619891
79. D.W. Loe, K.C. Almquist, R.G. Deeley and **S.P.C. Cole**. Multidrug resistance protein (MRP)-mediated transport of leukotriene C₄ and chemotherapeutic agents in membrane vesicles: demonstration of glutathione-dependent vincristine transport. *J. Biol. Chem.* 271: 9675-9682 (1996). ***659 citations-01/2022**. PMID: 8621643
80. D.W. Loe, K.C. Almquist, **S.P.C. Cole** and R.G. Deeley. ATP-dependent 17 β -estradiol 17-(β -D-glucuronide) transport by multidrug resistance protein (MRP): inhibition by cholestatic steroids. *J. Biol. Chem.* 271: 9683-9689 (1996). PMID: 8621644
81. D.W. Loe, R.G. Deeley and **S.P.C. Cole**. Biology of drug resistance associated with overexpression of the multidrug resistance protein, MRP. *Eur. J. Cancer* 32A: 945-957 (1996). ***526 citations-01/2022**. PMID: 8763335 (*invited, peer-reviewed*).
82. B.D. Stride, G. Valdimarsson, J.H. Gerlach, G.M. Wilson, **S.P.C. Cole** and R.G. Deeley. Structure and expression of the mRNA encoding the murine multidrug resistance protein (MRP), an ATP-binding cassette transporter. *Mol. Pharmacol.* 49: 962-971 (1996). PMID: 8649356
83. **S.P.C. Cole** and R.G. Deeley. Multidrug resistance associated with overexpression of MRP. In, *Drug Resistance* (ed. W.N. Hait). Ch. 2, pp. 39-62, Kluwer Academic Press, Norwell, MA (1996). [*Cancer Treat Res.* 87: 39-62, 1996] PMID: 8886448 (*invited*).
84. D.R. Hipfner, K.C. Almquist, B.D. Stride, R.G. Deeley and **S.P.C. Cole**. Location of a protease- hypersensitive region in the multidrug resistance protein (MRP) by mapping of the epitope of MRP-specific monoclonal antibody QCRL-1. *Cancer Res.* 56: 3307-3314 (1996). ***123 citations-01/2022**. PMID: 8764126
85. D. Lautier, Y. Canitrot, R.G. Deeley and **S.P.C. Cole**. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. *Biochem. Pharmacol.* 52: 967-977 (1996). ***331 citations-01/2022**. PMID: 8831715 (*invited review*)
**** Among top 1% articles cited in Biochem. Pharmacol. 1996-2006**
86. M. Gao, D.W. Loe, C.E. Grant, **S.P.C. Cole** and R.G. Deeley. Reconstitution of ATP-dependent LTC₄ transport by co-expression of both half-molecules of human MRP in insect Sf21 cells. *J. Biol. Chem.* 271: 27782-27787 (1996). PMID: 8910374

87. Y. Canitrot, I. Neverova, A.J. Stewart, N.M. Dean, C.F. Bennett, R.G. Deeley and **S.P.C. Cole**. MRP-associated multidrug resistance and its reversal by 2'-modified antisense oligonucleotides. *Anti-Cancer Drugs* 7 (suppl 3): 93-99 (1996).
88. B. Savas, **S.P.C. Cole**, T. Tsuruo and H.F. Pross. P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma. *J. Clin. Immunol.* 16: 348-357 (1996). PMID: 8946280
89. B.G. Campling, L.C. Young, K.A. Baer, Y-M Lam, R.G. Deeley, **S.P.C. Cole** and J.H. Gerlach. Expression of the *MRP* and *MDR1* multidrug resistance genes in small cell lung cancer. *Clin. Cancer Res.* 3: 115-122 (1997). PMID: 9815546
90. R.G. Deeley and **S.P.C. Cole**. Multidrug resistance in mammalian cells mediated by members of the ATP-binding cassette superfamily: The P-glycoproteins and MRP. In, *Molecular Genetics of Drug Resistance, Modern Genetics*, Vol. 3, (eds. J.D. Hayes and C.R. Wolf), Ch. 7, pp. 247-298, Harwood Academic, Langhorne, PA. (1997). (*invited*)
91. S.E.L. Mirski and **S.P.C. Cole**. Multidrug resistance in small cell lung cancer. In, *Drug Resistance in Oncology* (ed. S.D. Bernal), Ch. 2, pp. 27-75, Marcel Dekker, New York, NY (1997). (*invited*)
92. M. Nakagawa, A. Emoto, N. Nasu, T. Hanada, M. Kuwano, **S.P.C. Cole** and Y. Nomura. Clinical significance of multi-drug resistant associated protein and P-glycoprotein in patients with bladder cancer. *J. Urol.* 157: 1260-1265 (1997). PMID: 9120915
93. B.G. Campling, K.A. Baer, J.H. Gerlach, Y-M. Lam, **S.P.C. Cole** and S.E.L. Mirski. Topoisomerase II levels and drug response in small cell lung cancer. *Int. J. Oncol.* 10: 885-893 (1997).
94. Q. Yu, S.E.L. Mirski, K.E. Sparks and **S.P.C. Cole**. Two COOH-terminal truncated cytoplasmic mutant forms of topoisomerase II α in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing. *Biochemistry* 36: 5868-5877 (1997). PMID: 9153428
95. D.W. Loe, R.K. Stewart, T.E. Massey, R.G. Deeley and **S.P.C. Cole**. ATP-dependent transport of aflatoxin B₁ and its glutathione conjugates by the product of the *MRP* gene. *Mol. Pharmacol.* 51: 1034-1041 (1997). *238 citations-01/2022. PMID: 9187270
96. H.S.L. Chan, Y. Lu, T.M. Grogan, G. Haddad, D.R. Hipfner, **S.P.C. Cole**, R.G. Deeley, V. Ling and B.L. Gallie. Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. *Cancer Res.* 57: 2325-2330 (1997). PMID: 9192801
97. D.R. Hipfner, K.C. Almquist, E.M. Leslie, J.H. Gerlach, C.E. Grant, R.G. Deeley and **S.P.C. Cole**. Membrane topology of the multidrug resistance protein, MRP: a study of glycosylation-site mutants reveals an extracytosolic NH₂-terminus. *J. Biol. Chem.* 272: 23623-23630 (1997). *263 citations-01/2022. PMID: 9295302

98. B.D. Stride, C.E. Grant, D.W. Loe, D.R. Hipfner, **S.P.C. Cole** and R.G. Deeley. Pharmacological characterization of the murine and human orthologs of multidrug resistance protein in transfected human embryonic kidney cells. *Mol. Pharmacol.* 52: 344-353 (1997). PMID: 9281595
99. I. Wessel, P.B. Jensen, J. Falck, S.E.L. Mirski, **S.P.C. Cole** and M. Sehested. Loss of amino acids ¹⁴⁹⁰Lys-Ser-Lys¹⁴⁹² in the COOH-terminal region of topoisomerase II α in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization. *Cancer Res.* 57: 4451-4454 (1997). PMID: 9377550
100. C.E. Grant, E.U. Kurz, **S.P.C. Cole** and R.G. Deeley. Analysis of the intron-exon organization of the human multidrug resistance protein gene (MRP) and alternative splicing of its mRNA. *Genomics* 45: 368-378 (1997). PMID: 9344662
101. S.E.L. Mirski, J.H. Gerlach, H.J. Cummings, R. Zirngibl, P.A. Greer and **S.P.C. Cole**. Bipartite nuclear localization signals in the C-terminus of human topoisomerase II α . *Exp. Cell Res.* 237: 452-455 (1997). *65 citations-01/2022. PMID: 9434641
102. M.D. Norris, S.B. Bordow, P.S. Haber, G.M. Marshall, M. Kavallaris, J. Madafiglio, S.L. Cohn, H. Salwen, M.L. Schmidt, D.R. Hipfner, **S.P.C. Cole**, R.G. Deeley and M. Haber. Evidence that the N-myc oncogene regulates MRP gene expression in neuroblastoma. *Eur. J. Cancer* 33: 1911-1916 (1997). PMID: 9516823
103. R.G. Deeley and **S.P.C. Cole**. Function, evolution and structure of multidrug resistance protein (MRP). *Sem. Cancer Biol.* 8: 193-204 (1997). PMID: 9441948 (invited review)
104. H.S.L. Chan, T.M. Grogan, G. Haddad, D.R. Hipfner, R.G. Deeley and **S.P.C. Cole**. Standardization of a single-cell assay for sensitive detection of multidrug resistance protein (MRP) expression in normal and malignant cells in archival clinical samples. *J. Lab. Clin. Med.* 130: 297-306 (1997). PMID: 9341990
105. M. Lohoff, S. Prechtel, F. Sommer, M. Roellinghoff, E. Schmitt, G. Gradehandt, P. Rohwer, B.D. Stride, **S.P.C. Cole** and R.G. Deeley. A multidrug-resistance protein (MRP)-like transmembrane pump is highly expressed by resting murine T helper (Th) 2, but not Th1 cells, and is induced to equal expression levels in Th1 and Th2 cells after antigenic stimulation *in vivo*. *J. Clin. Invest.* 101: 703-710 (1998). PMID: 9449706
106. M. Gao, M. Yamazaki, D.W. Loe, C.J. Westlake, C.E. Grant, **S.P.C. Cole** and R.G. Deeley. Multidrug resistance protein: identification of regions required for active transport of leukotriene C₄. *J. Biol. Chem.* 273: 10733-10740 (1998). PMID: 9553138
107. D.R. Hipfner, M. Gao, G. Scheffer, R.J. Scheper, R.G. Deeley and **S.P.C. Cole**. Epitope mapping of monoclonal antibodies specific for the 190 kDa multidrug resistance protein, MRP. *Br. J. Cancer* 78: 1134-1140 (1998). *81 citations-01/2022. PMID: 9820168

108. C.E. Grant, G. Bhardwaj, **S.P.C. Cole** and R.G. Deeley. Cloning, transfer and characterization of MRP. *Meth. Enzymol.* 292: 594-607 (1998). PMID: 9711585 (*invited review*)
109. Y. Canitrot, F. Bichat, **S. Cole**, R. Deeley, J. Gerlach, G. Bastian, F. Arvelo and M. Poupon. Expression of the multidrug resistance genes (MRP) and (MDR1) in small cell lung cancer xenografts: relationship with clinical outcome. *Cancer Lett.* 130: 133-141 (1998). PMID: 9751266
110. **S.P.C. Cole** and R.G. Deeley. Multidrug resistance mediated by the ATP-binding cassette transporter protein, MRP. *BioEssays* 20: 931-940 (1998). PMID: 9872059 (*invited, peer-reviewed*)
111. S.R. Wright, A.H. Boag, B.G. Campling, G. Valdimarsson, D.R. Hipfner, **S.P.C. Cole** and R.G. Deeley. Immunohistochemical detection of multidrug resistance protein (MRP) in human lung cancer and normal lung. *Clin. Cancer Res.* 4: 2279-2289 (1998). PMID: 9748150
112. D.W. Loe, R.G. Deeley and **S.P.C. Cole**. Characterization of vincristine transport by the 190 kDa multidrug resistance protein, MRP: evidence for co-transport with reduced glutathione. *Cancer Res.* 58: 5130-5136 (1998). PMID: 9823323 *506 citations-01/2022.
113. A.J. Lang, S.E.L. Mirski, H.J. Cummings, Q. Yu, J.H. Gerlach and **S.P.C. Cole**. Structural organization of the human *TOP2A* and *TOP2B* genes. *Gene* 221: 255-266 (1998). *75 citations-01/2022. PMID: 9795238
114. T. Abe, T. Mori, Y. Wakabayashi, M. Nakagawa, **S.P.C. Cole**, K. Koike, M. Kuwano and S. Hori. Expression of multidrug resistance protein gene in patients with glioma after chemotherapy. *J. Neuro-Oncol.* 40: 11-18 (1998). PMID: 9874181
115. B. Savas, P.E. Kerr, H. Ustun, **S.P.C. Cole** and H.F. Pross. Lymphokine-activated killer cell susceptibility and multidrug resistance in small cell lung carcinoma. *Anticancer Res.* 18: 4355-4361 (1998). PMID: 9891492
116. L.C. Young, B.G. Campling, T. Voskoglou-Nomikos, **S.P.C. Cole**, R.G. Deeley and J.H. Gerlach. Expression of MRP-related genes in lung cancer: correlation with drug response. *Clin. Cancer Res.* 5: 673-680 (1999). PMID: 10100721
117. D.D. Ross, W.D. Yang, L.V. Abruzzo, W.S. Dalton, E. Schneider, H. Lage, M. Dietel, L. Greenberger, **S.P.C. Cole** and L.A. Doyle. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. *J. Nat. Cancer Inst.* 91: 429-433 (1999). *477 citations-01/2022. PMID: 10070941
118. **S.P.C. Cole**. Re: Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins. *J. Nat. Cancer Inst.* 91: 888 (1999). PMID: 10340910 (*letter*)
119. D.R. Hipfner, Q. Mao, W. Qiu, E.M. Leslie, M. Gao, R.G. Deeley and **S.P.C. Cole**. Monoclonal antibodies that inhibit the transport function of the 190 kDa multidrug resistance

- protein, MRP: localization of their epitopes to the nucleotide binding domains of the protein. *J. Biol. Chem.* 274: 15420-15426 (1999). *87 citations-01/2022. PMID: 10336431
120. J.P. Machiels, A.S. Govaerts, T. Guillaume, B. Bayat, A.M. Feyens, E. Lenoir, J.C. Goeminne, **S. Cole**, R. Deeley, M. Caruso, A. Bank, M. Symann and V. D'Hondt. Retrovirus-mediated gene transfer of the human multidrug resistance-associated protein into hematopoietic cells protects mice from chemotherapy-induced leukopenia. *Hum. Gene Ther.* 10: 801-811 (1999). PMID: 10210147
121. B.D. Stride, **S.P.C. Cole** and R.G. Deeley. Localization of a substrate specificity domain in the multidrug resistance protein. *J. Biol. Chem.* 274: 22877-22883 (1999). PMID: 10428874
122. S.E.L. Mirski, J.H. Gerlach and **S.P.C. Cole**. Sequence determinants of nuclear localization in the α and β isoforms of human topoisomerase II. *Exp. Cell Res.* 251: 329-339 (1999). *52 citations-01/2022. PMID: 10471318
123. Q. Mao, E.M. Leslie, R.G. Deeley and **S.P.C. Cole**. ATPase activity of purified and reconstituted multidrug resistance protein (MRP1) from drug-selected H69AR cells. *Biochim. Biophys. Acta* 1461: 69-82 (1999). PMID: 10556489
124. D.R. Hipfner, R.G. Deeley and **S.P.C. Cole**. Structural, mechanistic and clinical aspects of MRP1. *Biochim. Biophys. Acta* 1461: 359-376 (1999). *530 citations-01/2022. PMID: 10581367(invited, peer reviewed)
125. S.E.L. Mirski, K.E. Sparks, Q. Yu, A.J. Lang, N. Jain, B.G. Campling and **S.P.C. Cole**. A truncated cytoplasmic topoisomerase II α in a drug resistant lung cancer cell line is encoded by a *TOP2A* allele with a partial deletion of exon 34. *Int. J. Cancer* 85: 534-539 (2000). PMID: 10699927
126. S. Prechtel, M. Roellinghoff, R. Scheper, **S.P.C. Cole**, R.G. Deeley and M. Lohoff. The multidrug resistance protein 1: a functionally important activation marker for murine Th1 cells. *J. Immunol.* 164: 754-761 (2000). PMID: 10623820
127. D.W. Loe, R.G. Deeley and **S.P.C. Cole**. Verapamil stimulates glutathione transport by the 190 kDa multidrug resistance protein, MRP1. *J. Pharm. Exp. Ther.* 293: 530-538 (2000). *209 citations-01/2022. PMID: 10773025
128. M. Gao, H. Cui, D.W. Loe, C.E. Grant, K.C. Almquist, **S.P.C. Cole** and R.G. Deeley. Comparison of the functional characteristics of the nucleotide binding domains of multidrug resistance protein 1. *J. Biol. Chem.* 275: 13098-13108 (2000). PMID: 10777615
129. S.E.L. Mirski, T. Voskoglou-Nomikos, L.C. Young, R.G. Deeley, B.G. Campling, J.H. Gerlach and **S.P.C. Cole**. Simultaneous quantitation of topoisomerase II α and β isoform mRNAs in lung tumour cells and normal and malignant lung tissue. *Lab. Invest.* 80: 787-795 (2000). PMID: 10879730

130. D.W. Loe, C.J. Oleschuk, R.G. Deeley and **S.P.C. Cole**. Structure-activity studies of verapamil analogs that modulate transport of leukotriene C₄ and reduced glutathione by multidrug resistance protein MRP1. *Biochem. Biophys. Res. Commun.* 275: 795-803 (2000). ***73 citations-01/2022**. PMID: 10973801
131. Q. Mao, R.G. Deeley and **S.P.C. Cole**. Functional reconstitution of substrate transport by purified multidrug resistance protein MRP1 (ABCC1) in phospholipid vesicles. *J. Biol. Chem.* 275: 34166-34172 (2000). ***129 citations-01/2022**. PMID: 10948173
132. Y.M. Qian, W.C. Song, H. Cui, **S.P.C. Cole** and R.G. Deeley. Glutathione stimulates sulfated estrogen transport by multidrug resistance protein 1. *J. Biol. Chem.* 276: 6404-6411 (2001). PMID: 11102445
133. D.W. Zhang, **S.P.C. Cole** and R.G. Deeley. Identification of an amino acid residue in multidrug resistance protein (MRP) 1 critical for conferring resistance to anthracyclines. *J. Biol. Chem.* 276: 13231-13239 (2001). PMID: 11278596
134. E.M. Leslie, Q. Mao, C.J. Oleschuk, R.G. Deeley and **S.P.C. Cole**. Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and ATPase activities by interaction with dietary flavonoids. *Mol. Pharmacol.* 59: 1171-1180 (2001). ***291 citations-01/2022**. PMID: 11306701
**Among top 10 articles viewed in *Mol. Pharmacol.* October 2005
135. K. Ito, S.L. Olsen, W. Qiu, R.G. Deeley and **S.P.C. Cole**. Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport. *J. Biol. Chem.* 276: 15616-15624 (2001). ***164 citations-01/2022**. PMID: 11278867
136. M.F. Rosenberg, Q. Mao, A. Holzenburg, R.C. Ford, R.G. Deeley and **S.P.C. Cole**. The structure of the multidrug resistance protein 1 (MRP1/ABCC1): crystallization and single-particle analysis. *J. Biol. Chem.* 276: 16076-16082 (2001). ***187 citations-01/2022**. PMID: 11279022
137. L.C. Young, B.G. Campling, **S.P.C. Cole**, R.G. Deeley and J.H. Gerlach. Multidrug resistance proteins MRP3, MRP1 and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. *Clin. Cancer Res.* 7: 1798-1804 (2001). PMID: 11410522
138. R. Zirngibl, D. Schulze, S. Mirski, **S.P.C. Cole** and P. Greer. Subcellular localization analysis of the closely related Fps/Fes and Fer protein-tyrosine kinases suggests a distinct role for Fps/Fes in vesicular trafficking. *Exp. Cell Res.* 266: 87-94 (2001). PMID: 11339827
139. E.M. Leslie, R.G. Deeley and **S.P.C. Cole**. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. *Toxicology* 167: 3-23 (2001). ***438 citations-01/2022**. PMID: 11557126 (*invited, peer-reviewed*).
**In TOP 40 of articles cited in *Toxicology* 2001-2006

140. E.M. Leslie, K. Ito, P. Upadhyaya, S.S. Hecht, R.G. Deeley and **S.P.C. Cole**. Transport of the β -O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1/ABCC1): requirement for glutathione or a non-sulfur-containing analog. *J. Biol. Chem.* 276: 27846-27854 (2001). ***188 citations-01/2022**. PMID: 11375986
141. E.U. Kurz, **S.P.C. Cole** and R.G. Deeley. Identification of DNA-protein interactions in the 5' flanking and 5' untranslated regions of the human multidrug resistance protein (MRP1) gene: Evaluation of a putative antioxidant response element/AP-1 binding site. *Biochem. Biophys. Res. Commun.* 285: 981-990 (2001). ***64 citations-01/2022**. PMID: 11467849
142. D. Zhang, **S.P.C. Cole** and R.G. Deeley. Identification of a non-conserved amino acid residue in multidrug resistance protein (MRP) 1 important for determining substrate specificity: evidence for functional interaction between transmembrane helices 14 and 17. *J. Biol. Chem.* 276: 34966-34974 (2001). PMID: 11429411
143. K. Ito, C.J. Oleschuk, C. Westlake, M.Z. Vasa, R.G. Deeley and **S.P.C. Cole**. Mutation of Trp¹²⁵⁴ in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. *J. Biol. Chem.* 276: 38108-38114 (2001). PMID: 11500505
144. Y.M. Qian, W. Qiu, M. Gao, C.J. Westlake, **S.P.C. Cole** and R.G. Deeley. Characterization of binding of leukotriene C₄ by human multidrug resistance protein 1: evidence of differential interactions with NH₂- and COOH-proximal halves of the protein. *J. Biol. Chem.* 276: 38636-38644 (2001). PMID: 11507101
145. S. Conrad, H-M. Kauffmann, K-i. Ito, R. Deeley, **S.P.C. Cole** and D. Schrenk. Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. *J. Hum. Genet.* 46: 656-663 (2001). ***100 citations-01/2022**. PMID: 11721885
146. S. Conrad, H-M. Kauffmann, K-i. Ito, E.M. Leslie, R.G. Deeley, D. Schrenk and **S.P.C. Cole**. A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. *Pharmacogenetics* 12: 321-330 (2002). ***126 citations-01/2022**. PMID: 12042670
147. D-W. Zhang, **S.P.C. Cole** and R.G. Deeley. Determinants of the substrate specificity of multidrug resistance protein 1 (MRP1): role of amino acid residues with hydrogen bonding potential in predicted transmembrane helix 17. *J. Biol. Chem.* 277: 20934-20941 (2002). PMID: 11925441
148. Q. Mao, W. Qiu, K.E. Weigl, P.A. Lander, L.B. Tabas, R.L. Shepard, A.H. Dantzig, R.G. Deeley and **S.P.C. Cole**. GSH-dependent photolabeling of multidrug resistance protein MRP1 (ABCC1) by [¹²⁵I]-LY475776: evidence of a major binding site in the COOH-proximal membrane spanning domain. *J. Biol. Chem.* 277: 28690-28699 (2002). ***75 citations-01/2022**. PMID: 12034727

149. **S.P.C. Cole** and R.G. Deeley. Multidrug Resistance II - MRP and Related Proteins. In, *Encyclopedia of Cancer - Second Edition* (ed. J.R. Bertino), Vol. 3, pp. 255-267, Elsevier Science, San Diego, CA (2002). (*invited*)
150. Y-M. Qian, C.E. Grant, C.J. Westlake, D. Zhang, P.A. Lander, R.L. Shepard, A.H. Dantzig, **S.P.C. Cole** and R.G. Deeley. Photolabeling of human and murine multidrug resistance protein 1 with the high affinity inhibitor [¹²⁵I]LY475776 and azidophenacyl [³⁵S]glutathione. *J. Biol. Chem.* 277: 35225-35231 (2002). PMID: 12138119
151. A. Haimeur, R.G. Deeley and **S.P.C. Cole**. Charged amino acids in the sixth transmembrane helix of multidrug resistance protein 1 (MRP1/ABCC1) are critical determinants of transport activity. *J. Biol. Chem.* 277: 41326-41333 (2002). *85 citations-01/2022. PMID: 12186871
152. C-N. Lok, A.J. Lang, S.E.L. Mirski and **S.P.C. Cole**. Characterization of human topoisomerase II β (*TOP2B*) promoter activity: essential roles of the nuclear factor-Y (NF-Y) and specificity protein-1 (Sp1) binding sites. *Biochem. J.* 368: 741-751 (2002). PMID: 12197834
153. K. Koike, C.J. Oleschuk, A. Haimeur, S.L. Olsen, R.G. Deeley and **S.P.C. Cole**. Multiple membrane associated tryptophan residues contribute to the transport activity and substrate specificity of the human multidrug resistance protein, MRP1. *J. Biol. Chem.* 277: 49495-49503 (2002). *65 citations-01/2022. PMID: 12388549
154. R.G. Deeley and **S.P.C. Cole**. Multidrug resistance protein 1 (ABCC1). In, *ABC Proteins: From Bacteria to Man*. (eds. I.B. Holland, **S.P.C. Cole**, K. Kuchler and C.F. Higgins) Ch. 19, pp. 393-422, Academic Press Elsevier Science, London (2003).
155. E.M. Leslie, R.G. Deeley and **S.P.C. Cole**. Bioflavonoid stimulation of glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). *Drug Metab. Dispos.* 31: 11-15 (2003). *145 citations-01/2022. PMID: 12485947
156. C.J. Oleschuk, R.G. Deeley and **S.P.C. Cole**. Substitution of Trp¹²⁴² of TM17 alters substrate specificity of human multidrug resistance protein, MRP3. *Am. J. Physiol. Gastrointest. Liver Physiol.* 284: G280-289 (2003). PMID: 12388190
157. E.M. Leslie, R.J. Bowers, R.G. Deeley and **S.P.C. Cole**. Structural requirements for functional interaction of glutathione tripeptide analogs with the human multidrug resistance protein 1 (MRP1). *J. Pharmacol. Exp. Ther.* 304: 643-653 (2003). PMID: 12538817
158. E.M. Leslie, I.J. Létourneau, R.G. Deeley and **S.P.C. Cole**. Functional and structural consequences of cysteine substitutions in the NH₂-proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1). *Biochemistry* 42: 5214-5224 (2003). PMID: 12731862
159. I. Kogan, M. Ramjeesingh, C. Li, J.F. Kidd, Y. Wang, E.M. Leslie, **S.P.C. Cole** and C.E. Bear. CFTR directly mediates nucleotide-regulated glutathione flux. *EMBO J.* 22: 1981-1989 (2003). *232 citations-01/2022. PMID: 12727866

160. S.E.L. Mirski, J.C. Bielawski and **S.P.C. Cole**. Identification of functional nuclear export sequences in human topoisomerase II α and β . *Biochem. Biophys. Res. Comm.* 306: 905-911 (2003). PMID: 12821127
161. K. Nunoya, C.E. Grant, D. Zhang, **S.P.C. Cole** and R.G. Deeley. Molecular cloning and pharmacological characterization of rat multidrug resistance protein 1 (MRP1). *Drug Metab. Dispos.* 31: 1016-1026 (2003). PMID: 12867490
162. K. Neumann, K.M. Al-Batayneh, M.J. Kuiper, J. Parsons-Sheldrake, M.G. Tyshenko, W.F. Flintoff, **S.P.C. Cole** and V.K. Walker. A single point mutation in *Drosophila* dihydrofolate reductase confers methotrexate resistance to a transgenic CHO cell line. *Genome* 46: 707-715 (2003). PMID: 12897877
163. D-W. Zhang, H-M. Gu, M. Vasa, M. Muredda, **S.P.C. Cole** and R.G. Deeley. Characterization of the role of polar amino acid residues within predicted transmembrane helix 17 in determining the substrate specificity of multidrug resistance protein 3 (ABCC3). *Biochemistry* 42: 9989-10000 (2003). PMID: 12924948
164. K. Ito, K.E. Weigl, R.G. Deeley and **S.P.C. Cole**. Mutation of proline residues in the NH₂-terminal region of the multidrug resistance protein, MRP1 (ABCC1): effects on protein expression, membrane localization, and transport function. *Biochim. Biophys. Acta* 1615: 103-114 (2003). PMID: 12948592
165. L.F. Payen, M. Gao, C.J. Westlake, **S.P.C. Cole** and R.G. Deeley. Role of carboxylate residues adjacent to the conserved core Walker B motifs in the catalytic cycle of multidrug resistance protein 1 (ABCC1). *J. Biol. Chem.* 278: 38537-38547 (2003). PMID: 12882957
166. M. Muredda, K. Nunoya, R.A. Burtch-Wright, E.U. Kurz, **S.P.C. Cole** and R.G. Deeley. Cloning and characterization of the murine and rat mrp1 promoter regions. *Mol. Pharmacol.* 64: 1259-1269 (2003). PMID: 14573776
167. D-W. Zhang, H-M. Gu, D. Situ, A. Haimour, **S.P.C. Cole** and R.G. Deeley. Functional importance of polar and charged amino acid residues in transmembrane helix 14 of multidrug resistance protein 1 (MRP1/ABCC1): identification of an aspartate residue critical for conversion from a high to low affinity substrate binding state. *J. Biol. Chem.* 278: 46052-46063 (2003). PMID: 12954620
168. C.J. Westlake, Y-M. Qian, M. Gao, M. Vasa, **S.P.C. Cole** and R.G. Deeley. Identification of the structural and functional boundaries of the multidrug resistance protein 1 cytoplasmic loop 3. *Biochemistry* 42: 14099-14113 (2003). PMID: 14640677
169. J.D. Campbell, K. Koike, C. Moreau, M.S.P. Sansom, R.G. Deeley and **S.P.C. Cole**. Molecular modeling correctly predicts the functional importance of Phe⁵⁹⁴ in transmembrane helix 11 of the multidrug resistance protein, MRP1 (ABCC1). *J. Biol. Chem.* 279: 463-468 (2004). PMID: 14561746

170. K. Koike, G. Conseil, E.M. Leslie, R.G. Deeley and **S.P.C. Cole**. Identification of proline residues in the core cytoplasmic and transmembrane regions of multidrug resistance protein 1 (MRP1/ABCC1) important for transport function, substrate specificity, and nucleotide interactions. *J. Biol. Chem.* 279: 12325-12336 (2004). *77 citations-01/2022. PMID: 14722114
171. K. Koike, R.G. Deeley and **S.P.C. Cole**. Mapping of the MRPm5 epitope to the cytosolic region between transmembrane helices 13 and 14 in the drug and organic anion transporter, MRP1 (ABCC1). *Biochem. Biophys. Res. Commun.* 315: 719-725 (2004). PMID: 14975760
172. A. Haimeur, G. Conseil, R.G. Deeley and **S.P.C. Cole**. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. *Curr. Drug Metab.* 5: 21-53 (2004). *600 citations-01/2022. PMID: 14965249 (invited, peer-reviewed).
**One of Canada's Top 10 Hot Papers, April 2004-February 2006, <http://www.in-cites.com/countries/Canada-top10papers2006>)
173. A. Haimeur, G. Conseil, R.G. Deeley and **S.P.C. Cole**. Mutations of charged amino acids in or proximal to the transmembrane helices of the second membrane spanning domain differentially affect the substrate specificity and transport activity of the multidrug resistance protein, MRP1 (ABCC1). *Mol. Pharmacol.* 65: 1375-1385 (2004). *87 citations-01/2022. PMID: 15155831
174. Q. Mao, G. Conseil, A. Gupta, **S.P.C. Cole** and J.D. Unadkat. Functional expression of the human breast cancer resistance protein in *Pichia pastoris*. *Biochem. Biophys. Res. Commun.* 320: 730-737 (2004). PMID: 15240109
175. D-W. Zhang, K. Nunoya, M. Vasa, H-M. Gu, A. Theis, **S.P.C. Cole** and R.G. Deeley. Transmembrane helix 11 of multidrug resistance protein 1 (MRP1/ABCC1): Identification of polar amino acids important for substrate specificity and binding of ATP at nucleotide binding domain 1. *Biochemistry* 43: 9413-9425 (2004). PMID: 15260484
176. D. Situ, A. Haimeur, G. Conseil, K.E. Sparks, D. Zhang, R.G. Deeley and **S.P.C. Cole**. Mutational analysis of ionizable residues proximal to the cytoplasmic interface of membrane spanning domain 3 of the multidrug resistance protein, MRP1 (ABCC1): Glutamate 1204 is important for both the expression and catalytic activity of the transporter. *J. Biol. Chem.* 279: 38871-38880 (2004). PMID: 15208328
177. P.W. Causey, M.C. Baird and **S.P.C. Cole**. Synthesis, characterization and assessment of cytotoxic properties of a series of titanocene dichloride derivatives. *Organometallics* 23: 4486-4494 (2004).
178. C.J. Westlake, L. Payen, M. Gao, **S.P.C. Cole** and R.G. Deeley. Identification and characterization of functionally important elements in the multidrug resistance protein 1 COOH-terminal region. *J. Biol. Chem.* 279: 53571-53583 (2004). PMID: 15459206
179. G. Conseil, R.G. Deeley and **S.P.C. Cole**. Role of two adjacent cytoplasmic tyrosine residues in MRP1 (ABCC1) transport activity and sensitivity to sulfonylureas. *Biochem. Pharmacol.* 69: 451-461 (2005). PMID: 15652236

180. E.M. Leslie, R.G. Deeley and **S.P.C. Cole**. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2 and BCRP (ABCG2) in tissue defense. *Toxicol. Appl. Pharmacol.* 204: 216-237 (2005). ***1,563 citations-01/2022**. PMID: 15845415 (invited, peer-reviewed).
**Top cited article in *Toxicology and Applied Pharmacology* 2006, one of Elsevier's Top 20 Downloaded Articles on ScienceDirectTM 2007-2008)
181. I.J. Létourneau, R.J. Bowers, R.G. Deeley and **S.P.C. Cole**. Limited modulation of the transport activity of the human multidrug resistance proteins MRP1, MRP2 and MRP3 by nicotine glucuronide metabolites. *Toxicol. Lett.* 157: 9-19 (2005). PMID: 15795089
182. **S.P.C. Cole** and I.F. Tannock. Drug resistance. In, *The Basic Science of Oncology*, 4th edition [eds. I.F. Tannock, R.P. Hill, R.G. Bristow and L. Harrington]. Ch. 18, pp. 376-399, McGraw-Hill, New York (2005).
183. C.J. Westlake, **S.P.C. Cole** and R.G. Deeley. Role of the NH₂-terminal membrane spanning domain of MRP1/ABCC1 in protein processing and trafficking. *Mol. Biol. Cell* 16: 2483-2492 (2005). PMID: 15772158
184. L. Payen, M. Gao, C. Westlake, A. Theis, **S.P.C. Cole** and R.G. Deeley. Functional interactions between nucleotide binding domains and LTC₄ binding sites of multidrug resistance protein 1 (ABCC1). *Mol. Pharmacol.* 67: 1944-1953 (2005). PMID: 15755910
185. G. Conseil, R.G. Deeley and **S.P.C. Cole**. Polymorphisms of *MRP1 (ABCC1)* and related ATP-dependent drug transporters. *Pharmacogenet. Genomics* 15: 523-533 (2005). ***115 citations-01/2022**. PMID: 16006996 (invited, peer-reviewed).
186. I.J. Létourneau, R.G. Deeley and **S.P.C. Cole**. Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). *Pharmacogenet. Genomics* 15: 647-657 (2005). ***103 citations-01/2022**. PMID: 16041243
187. P. Wu, C.J. Oleschuk, Q. Mao, B.O. Keller, R.G. Deeley and **S.P.C. Cole**. Analysis of human multidrug resistance protein 1 (ABCC1) by matrix-assisted laser desorption ionization/time of flight mass spectrometry: toward identification of leukotriene C₄ binding sites. *Mol. Pharmacol.* 68: 1455-1465 (2005). PMID: 16105987
188. J.G. Affleck, K.M. Al-Batayneh, K. Neumann, **S.P.C. Cole** and V.K. Walker. *Drosophila* dihydrofolate reductase mutations confer antifolate resistance to mammalian cells. *Eur. J. Pharmacol.* 529: 71-78 (2006). PMID: 16325803
189. G. Conseil, R.G. Deeley and **S.P.C. Cole**. Functional importance of three basic residues clustered at the cytosolic interface of transmembrane helix 15 in the multidrug and organic anion transporter MRP1 (ABCC1). *J. Biol. Chem.* 281: 43-50 (2006). ***50 citations-01/2022**. PMID: 16230346

190. R.G. Deeley and **S.P.C. Cole**. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). *FEBS Lett.* 580: 1103-1111 (2006). ***316 citations-01/2022**. PMID: 16387301 (invited, peer-reviewed).
191. D-W. Zhang, K. Nunoya, M. Vasa, H-M. Gu, **S.P.C. Cole** and R.G. Deeley. Mutational analysis of polar amino acid residues within predicted transmembrane helices 10 and 16 of multidrug resistance protein 1 (ABCC1): effect on substrate specificity. *Drug Metab. Dispos.* 34: 539-546 (2006). PMID: 16415113
***ASPET James R. Gillette Drug Metabolism Best Paper of 2006*
192. A. Rothnie, R. Callaghan, R.G. Deeley and **S.P.C. Cole**. Role of GSH in estrone sulfate binding and translocation by the multidrug resistance protein 1 (MRP1, ABCC1). *J. Biol. Chem.* 281: 13906-13914 (2006). ***57 citations-01/2022**. PMID: 16565074
193. **S.P.C. Cole** and R.G. Deeley. Transport of glutathione and glutathione conjugates by MRP1. *Trends Pharmacol. Sci.* 27: 438-446 (2006). ***372 citations-01/2022**. PMID: 16820223 (invited, peer-reviewed).
194. R.G. Deeley, C. Westlake and **S.P.C. Cole**. Transmembrane transport of endo- and xenobiotics by membrane ATP-binding cassette multidrug resistance proteins. *Physiol. Rev.* 86: 849-899 (2006). ***879 citations-01/2022**. PMID: 16816140 (invited, peer-reviewed).
195. G.D. Potter, M.C. Baird, M. Chan and **S.P.C. Cole**. Cellular toxicities of new titanocene dichloride derivatives containing pendant cyclic alkylammonium groups. *Inorg. Chem. Commun.* 9: 1114-1116 (2006).
196. S.E.L. Mirski, K.E. Sparks, B. Friedrich, M. Kohler, Y-Y. Mo, W.T. Beck and **S.P.C. Cole**. Topoisomerase II binds importin α isoforms and exportin/CRM1 but does not shuttle between the nucleus and cytoplasm in proliferating cells. *Exp. Cell Res.* 313: 627-637 (2007). PMID: 17182034 ***Selected as a journal 'Highlight'*
197. G.D. Potter, M.C. Baird and **S.P.C. Cole**. A new series of titanocene dichloride derivatives bearing cyclic alkylammonium groups: assessment of their cytotoxic properties. *J. Organometall. Chem.* 692: 3508-3518 (2007).
198. I.J. Létourneau, A.J. Slot, R.G. Deeley and **S.P.C. Cole**. Mutational analysis of a highly conserved proline residue in MRP1, MRP2 and MRP3 reveals a partially conserved function. *Drug Metab. Dispos.* 35: 1372-1379 (2007). PMID: 17494643
199. J.P. Wyles, Z. Wu, S.E.L. Mirski and **S.P.C. Cole**. Nuclear interactions of topoisomerase II α and β with phospholipid scramblase 1. *Nucl. Acids Res.* 35: 4076-4085 (2007). PMID: 17567603
200. M.K. DeGorter, G. Conseil, R.G. Deeley, R.L. Campbell and **S.P.C. Cole**. Molecular modeling of the human multidrug resistance protein 1 (MRP1/ABCC1). *Biochem. Biophys. Res. Commun.* 365: 29-34 (2008). ***77 citations-01/2022**. PMID: 17980150

201. A.J. Slot, D.D. Wise, R.G. Deeley, T.J. Monks and **S.P.C. Cole**. Modulation of human MRP1 (ABCC1) and MRP2 (ABCC2) transport by endogenous and exogenous glutathione-conjugated catechol metabolites. *Drug Metab. Dispos.* 36: 552-560 (2008). PMID: 18079363
202. I.J. Létourneau, A. Nakajima, R.G. Deeley and **S.P.C. Cole**. Role of proline 1150 in functional interactions between the membrane spanning domains and nucleotide binding domains of the MRP1 (ABCC1) transporter. *Biochem. Pharmacol.* 75: 1659-1669 (2008). PMID: 18336795
203. Md. T. Hoque and **S.P.C. Cole**. Downregulation of NHERF1 increases expression and function of multidrug resistance protein 4 (MRP4). *Cancer Res.* 68: 4802-4809 (2008). *59 citations-01/2022. PMID: 18559527
204. P.E. Bandler, C.J. Westlake, C.E. Grant, **S.P.C. Cole** and R.G. Deeley. Identification of regions in human multidrug resistance protein (MRP) 2 required for apical membrane localization. *Mol. Pharmacol.* 74: 9-19 (2008). PMID: 18381564
205. A. Rothnie, G. Conseil, A.Y.T. Lau, R.G. Deeley and **S.P.C. Cole**. Mechanistic differences between GSH transport by MRP1 (ABCC1) and GSH modulation of MRP1-mediated transport. *Mol. Pharmacol.* 74: 1630-1640 (2008). PMID: 18759527
206. C.E. Grant, M. Gao, M.K. DeGorter, **S.P.C. Cole** and R.G. Deeley. Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). *Drug Metab. Dispos.* 36: 2571-2581 (2008). PMID: 18775981
207. L. Qin, J. Zheng, C.E. Grant, Z. Jia, **S.P.C. Cole** and R.G. Deeley. Residues responsible for the asymmetric function of the nucleotide binding domains of multidrug resistance protein (MRP) 1. *Biochemistry* 47: 13952-13965 (2008). PMID: 19063607
208. G. Conseil, A. Rothnie, R.G. Deeley and **S.P.C. Cole**. Multiple roles of charged amino acids in cytoplasmic loop 7 for expression and function of the multidrug and organic anion transporter MRP1 (ABCC1). *Mol. Pharmacol.* 75: 397-406 (2009). PMID: 19015228
209. Md. T. Hoque, G. Conseil and **S.P.C. Cole**. Involvement of NHERF1 in apical membrane localization of MRP4 in polarized kidney cells. *Biochem. Biophys. Res. Commun.* 379: 60-64 (2009). *55 citations-01/2022. PMID: 19073137
210. K. Maeno, A. Nakajima, G. Conseil, A. Rothnie, R.G. Deeley and **S.P.C. Cole**. Molecular basis for reduced estrone sulfate transport and altered modulator sensitivity of TM6 and TM17 mutants of MRP1 (ABCC1). *Drug Metab. Dispos.* 37: 1411-1420 (2009). *41 citations-01/2022. PMID: 19398503
211. S.H. Lee, M-S. Lee, J.H. Lee, S.W. Kim, R-H. Kang, M-J. Choi, S.J. Park, S.J. Kim, J.M. Lee, **S.P.C. Cole** and M.G. Lee. MRP1 polymorphisms associated with citalopram response in patients with major depression. *J. Clin. Psychopharmacol.* 30: 116-125 (2010). PMID: 20520284

212. M.F. Rosenberg, C.J. Oleschuk, P. Wu, Q. Mao, R.G. Deeley, **S.P.C. Cole** and R.C. Ford. Structure of a human multidrug transporter in an inward-facing conformation. *J. Struct. Biol.* 170: 540-547 (2010). PMID: 20109555
213. G.D. Potter, M.C. Baird and **S.P.C. Cole**. A new series of titanocene dichloride derivatives bearing chiral alkylammonium groups: assessment of their cytotoxic properties. *Inorg. Chim. Acta* 364: 16-22 (2010).
214. S.H. Iram and **S.P.C. Cole**. Expression and function of human MRP1 (ABCC1) is dependent on amino acids in cytoplasmic loop 5 and its interface with nucleotide binding domain 2. *J. Biol. Chem.* 286: 7202-7213 (2011). PMID: 21177244
215. M. Pajic, J. Murray, G.M. Marshall, **S.P.C. Cole**, M.D. Norris and M. Haber. ABCC1 G2012T single nucleotide polymorphism is associated with patient outcome in primary neuroblastoma and altered stability of the ABCC1 gene transcript. *Pharmacogenet. Genomics* 21: 270-279 (2011). PMID: 21317832
216. A.J. Slot, S.V. Molinski and **S.P.C. Cole**. Mammalian multidrug resistance proteins (MRPs). *Essays Biochem.* 50: 179-207 (2011). (invited, peer-reviewed) PMID: 21967058
217. S.H. Iram and **S.P.C. Cole**. Mutation of Glu⁵²¹ or Glu⁵³⁵ in cytoplasmic loop 5 cause differential misfolding in multiple domains of the multidrug and organic anion transporter MRP1 (ABCC1). *J. Biol. Chem.* 287: 7543-7555 (2012). PMID: 22232552
218. **S.P.C. Cole** and I.F. Tannock. Drug resistance. In, *The Basic Science of Oncology*, 5th edition [eds. I.F. Tannock, R.P. Hill, R.G. Bristow and L. Harrington]. Ch. 19, pp. 443-468, McGraw-Hill, New York, NY (2012). ISBN: 978-0-07-174520-8.
219. P.G. Sreekumar, C. Spee, S.J. Ryan, **S.P.C. Cole**, R. Kannan and D.R. Hinton. Mechanism of RPE cell death in α -crystallin deficient mice: A novel and critical role for MRP1-mediated GSH efflux. *PLoS ONE* 7: e33420 (2012). *57 citations-01/2022. PMID: 22442691
**TOP 25% Most Cited in *PloS ONE* (28 citations; 3,300 views – 08/2017)
220. S.P. Ebert, B. Wetzel, R.L. Myette, G. Conseil, **S.P.C. Cole**, G.A. Sawada, T.W. Loo, M.C. Bartlett, D.M. Clarke and M.R. Detty. Chalcogenopyrylium compounds as modulators of the ATP-binding cassette transporters P-glycoprotein (P-gp/ABCB1) and multidrug resistance protein 1 (MRP1/ABCC1). *J. Med. Chem.* 55: 4683-4699 (2012). PMID: 22533905
221. R.L. Myette, G. Conseil, S.P. Ebert, B. Wetzel, M.R. Detty and **S.P.C. Cole**. Chalcogenopyrylium dyes as differential modulators of organic anion transport by MRP1, MRP2 and MRP4. *Drug Metab. Dispos.* 41: 1231-1239 (2013). PMID: 23530018
222. G. Conseil and **S.P.C. Cole**. Two polymorphic variants of *ABCC1* selectively alter drug resistance and inhibitor sensitivity of the multidrug and organic anion transporter MRP1. *Drug Metab. Dispos.* 41: 2187-2196 (2013). PMID: 24080162

223. **S.H. Iram** and **S.P.C. Cole**. Differential functional rescue of Lys⁵¹³ and Lys⁵¹⁶ processing mutants of MRP1 (ABCC1) by chemical chaperones reveals different domain-domain interactions of the transporter. *Biochim. Biophys. Acta* 1838: 756-765 (2014). PMID: 24231430 (413 downloads 12/2014).
224. **S.P.C. Cole**. Targeting the multidrug resistance protein (MRP1, ABCC1): past, present and future. *Annu. Rev. Pharmacol. Toxicol.* 54: 95-117 (2014). *248 citations-01/2022. PMID: 24050699 (invited review) (1,546 downloads 10/2014; *214 citations 02/2021).
225. J. Park, J-O. Kwak, B. Riederer, U. Seidler, S.P.C. Cole, H.J. Lee and M.G. Lee. Na⁺/H⁺ exchanger regulatory factor 3 is critical for multidrug resistance protein 4-mediated drug efflux in the kidney. *J. Am. Soc. Nephrol.* 25: 726-736 (2014). PMID: 24436471
**Research Highlight, E.F. Carney. NHERF3 regulates MRP4-mediated efflux of drug molecules in the kidneys. *Nat. Rev. Nephrol.* 10: 183 (2014). PMID: 24492322
226. L. Cheung, C.L. Flemming, F. Watt, N. Masada, **D.M. Yu**, T. Huynh, **G. Conseil**, A. Tivnan, A. Polinsky, A.V. Gudkov, M.A. Munoz, A. Vishvanath, D.M. Cooper, M.J. Henderson, **S.P.C. Cole**, J.I. Fletcher, M. Haber and M.D. Norris. High-throughput screening identifies Ceefourin-1 and Ceefourin-2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4). *Biochem. Pharmacol.* 91: 97-108 (2014). PMID: 24973542
227. D. Jin, T.T. Ni, J. Sun, H. Wan, J.D. Amack, G. Yu, J. Fleming, C. Chiang, W. Li, A. Papierniak, S. Cheepala, **G. Conseil**, **S.P.C. Cole**, B. Zhou, I.A. Drummond, J.D. Schuetz, J. Malicki and T.P. Zhong. Prostaglandin signaling regulates ciliogenesis by modulating intraflagellar transport. *Nat. Cell Biol.* 16: 841-851 (2014). PMID: 25173977
**Highlighted in News & Views, P. Barbry, L.E. Zaragosi. An ABC of ciliogenesis. *Nat. Cell Biol.* 16: 826-827 (2014). PMID: 25174819
228. **S.P.C. Cole**. Multidrug resistance protein 1 (MRP1, ABCC1): A “multitasking” ABC transporter. *J. Biol. Chem.* 289: 30880-30888 (2014). *241 citations-01/2022. PMID: 25281745 (invited review)
229. **M.F. Miah**, **G. Conseil** and **S.P.C. Cole**. N-glycans do not affect plasma membrane localization of multidrug resistance protein 4 (MRP4) but selectively alter its prostaglandin E₂ transport activity. *Biochem. Biophys. Res. Commun.* 469: 954-959 (2016). PMID: 26721430
230. **M.A. Csandl**, **G. Conseil** and **S.P.C. Cole**. Cysteinyl leukotriene receptor 1/2 antagonists nonselectively modulate organic anion transport by multidrug resistance proteins (MRP1-4). *Drug Metab. Disp.* 44: 857-866 (2016). PMID: 27068271
231. **Y. Huang**, **S.P.C. Cole**, T. Cai and Y. Cai. Applications of nanoparticle drug delivery systems for the reversal of multidrug resistance in cancer. *Oncol. Lett.* 12: 11-15 (2016). PMID: 27347092 (review)
232. **C.B. Shukalek**, D.P. Swanlund, R.K. Rousseau, **K.E. Weigl**, **S.P.C. Cole** and E.M. Leslie. Arsenic triglutathione [As(GS)₃] transport by multidrug resistance protein 1 (MRP1/ABCC1)

is selectively modulated by phosphorylation of Tyr⁹²⁰/Ser⁹²¹ and glycosylation of Asn¹⁹/Asn²³. *Molec. Pharmacol.* 90: 127-139 (2016). PMID: 27297967

233. M. Banerjee, V. Marensi, G. Conseil, X.C. Le, **S.P.C. Cole** and E.M. Leslie. Polymorphic variants of MRP4/ABCC4 differentially modulate the transport of methylated arsenic metabolites and physiological organic anions. *Biochem. Pharmacol.* 120: 72-82 (2016). PMID: 27659809
234. X. Xia, **S.P.C. Cole**, T. Cai and Y. Cai. Effect of traditional Chinese medicine components on multidrug resistance in tumors mediated by P-glycoprotein. *Oncol. Lett.* 13: 3989-3996 (2017). PMID: 28588693
235. Q. Li, T. Cai, X. Xia, Y. Huang, **S.P.C. Cole**, and Y. Cai. A review of the structure, preparation, and application of NLCs, PNPs, and PLNs. *Nanomaterials* 7: E122 (2017). (review) PMID: 28554993
236. Q. Li, T. Cai, Y. Huang, X. Xia, **S.P.C. Cole**, and Y. Cai. The preparation and evaluation of cepharanthine-nanostructured lipid carriers in vitro and in vivo. *J. Biomater. Tissue Eng.* 7: 848-857 (2017). DOI: <https://doi.org/10.1166/jbt.2017.1642>
237. Q. Huang, T. Cai, Q. Li, Y. Huang, Q. Liu, B. Wang, C. Du, X. Xia, Q. Wang, J.C.C. Whitney, **S.P.C. Cole**, and Y. Cai. Preparation of psoralen polymer-lipid hybrid nanoparticles and their reversal of multidrug resistance in MCF-7/ADR cells. *Drug Deliv.* 25: 1056-1066 (2018). PMID: 29695174
238. B. Wang, T. Cai, Q. Liu, J.C.C. Whitney, M. Du, Q. Ma, R. Zhang, L. Yang, **S.P.C. Cole**, and Y. Cai. Preparation and evaluation of spirulina polysaccharide nanoemulsions. *Int. J. Mol. Med.* 42: 1273-1282 (2018). PMID: 29901081
239. Y. Yuan, P. Chiba, T. Cai, R. Callaghan, L. Bai, **S.P.C. Cole**, and Y. Cai. Fabrication of psoralen-loaded lipid-polymer hybrid nanoparticles and their reversal effect on drug resistance in cancer cells. *Oncol. Rep.* 40: 1055-1063 (2018). PMID: 29901161
240. K.E. Weigl, G. Conseil, A.J. Rothnie, M. Arama, Y. Tsfadia and **S.P.C. Cole**. An outward-facing aromatic amino acid is crucial for signaling between the membrane spanning and nucleotide binding domains of multidrug resistance protein 1 (MRP1; ABCC1). *Molec. Pharmacol.* 94: 1069-1078 (2018). PMID: 29976562
241. J.Y. Cao, G. Forcina, A. Poddar, T. Mileur, J. Lumb, M. Reid, C. Dovey, E. Stone, J. Wang, J. Locosale, **S.P.C. Cole**, J.E. Carette, and S.J. Dixon. A genome-wide haploid genetic screen identifies regulators of glutathione abundance and ferroptosis sensitivity. *Cell Rep.* 26: 1544-1556.e8 (2019). PMID: 30726737
242. G. Conseil, M. Arama-Chayoth, Y. Tsfadia and **S.P.C. Cole**. Structure-guided probing of the LTC₄ binding site in human multidrug resistance protein 1 (MRP1; ABCC1). *FASEB J.* 33: 10692-10704 (2019). PMID: 31268744

243. C.G. Gana, K.M. Hanssen, D.M.T. Yu, C.L. Flemming, M.S. Wheatley, G. Conseil, **S.P.C. Cole**, M.D. Norris, M. Haber, and J.I. Fletcher. MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells. *Biochem. Pharmacol.* 168: 237-248 (2019). PMID: 31302132
244. E.E. Smith, G. Conseil, and **S.P.C. Cole**. Conservative amino acids in the region connecting membrane spanning domain 1 to nucleotide binding domain 1 are essential for expression of the MRP1 (ABCC1) transporter. *PLoS One* 16: e0246727 (2021). PMID: 33571281
245. J.D. Pearson, K. Huang, M. Pacal, S.R. McCurdy, S. Lu, A. Aubry, T. Yu, K.M. Wadosky, L. Zhang, T. Wang, A. Gregorieff, M. Ahmad, H. Dimaras, E. Langille, **S.P.C. Cole**, P.P. Monnier, B.H. Lok, M. Tsao, N. Akeno, D. Schramek, K.A. Wikenheiser-Brokamp, E.S. Knudsen, A.K. Witkiewicz, J.L. Wrana, D.W. Goodrich, and R. Bremner. Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. *Cancer Cell* 39:1115-1134.e12 (2021). PMID: 34270926
246. F. Szeri, V. Corradi, F. Niaziarimi, S. Donnelly, G. Conseil, **S.P.C. Cole**, D.P. Tieleman, K. van de Wetering. Mutagenic analysis of the putative ABCC6 substrate-binding cavity using a new homology model. *Int. J. Mol. Sci.* 22: 6910 (2021). PMID: 34199119
247. G. Conseil and **S.P.C. Cole**. Amino acids in the first cytoplasmic loop of the core structure of the ABCC1 (Multidrug Resistance Protein 1; MRP1) organic anion transporter are essential for expression. *Int. J. Mol. Sci.* 22: 9710 (2021). PMID: 34575890
248. K.M. Hanssen, M.S. Wheatley, D.M.T. Yu, G. Conseil, M.D. Norris, M. Haber, **S.P.C. Cole**, and J.I. Fletcher. GSH facilitates the binding and inhibitory activity of novel multidrug resistance protein 1 (MRP1) modulators. *FEBS J. (FJ-21-1043.R1 in press Jan2022)*

MANUSCRIPTS SUBMITTED

•

MANUSCRIPTS IN PREPARATION

- G. Conseil and **S.P.C. Cole**. Structure-guided probing of the bipartite LTC₄ binding site in human multidrug resistance protein 1 (MRP1). Part 2.
- G. Conseil, K. Ziems, M. Banerjee, E.M. Leslie, and **S.P.C. Cole**. Identification of *ABCC4* polymorphisms that disrupt membrane trafficking of the human MRP4 organic anion and drug transporter.
- B.D. Whitlock, G. Conseil, D.P. Swanlund, X.C. Le, J.D. Schuetz, **S.P.C. Cole**, and E.M. Leslie. Differential substrate specificity of the human and mouse multidrug resistance protein 4 (ABCC4/MRP4) orthologs.

CONFERENCE ABSTRACTS/POSTERS/PRESENTATIONS**[Career Total: 322]**

1. **S.P.C. Cole** and G.S. Marks. Potentiation of the porphyrin-inducing effects of SKF 525-A by DDC, an inhibitor of ferrochelatase. *Proc. Can. Fed. Biol. Soc.* 22: 127 (1979).
2. **S.P.C. Cole** and G.S. Marks. Structural requirements in dihydropyridines for ferrochelatase inhibition and ALA-synthetase induction. First International Argentine Meeting on Porphyrins and Porphyrins. Buenos Aires, Argentina. October 1979.
3. **S.P.C. Cole** and G.S. Marks. δ -aminolevulinic acid synthetase-inducing and ferrochelatase-inhibiting properties of DDC and its analogs in the chick embryo liver. *Proc. Can. Fed. Biol. Soc.* 23: 110 (1980).
4. S.B. Follows, D.T. Zelt, **S.P.C. Cole** and G.S. Marks. Patterns of porphyrin accumulation in response to chemicals in chick embryo liver cells. *Proc. Can. Fed. Biol. Soc.* 24: 862 (1981).
5. G.S. Marks, R.A. Whitney and **S.P.C. Cole**. Effect of 3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine (DDC) and its analogues on ferrochelatase activity and porphyrin accumulation. VIII International Congress of Pharmacology. Tokyo, Japan. August 1981.
6. **S.P.C. Cole**, P.R. Ortiz de Montellano, K.L. Kunze and G.S. Marks. Inhibition of hepatic ferrochelatase by *N*-methylprotoporphyrin. *Pharmacologist* 23: 248 (1981).
7. M. Seidman, S. Bunting, **S. Cole** and A.C. Peacock. Use of two restriction enzymes in the two-dimensional gel electrophoretic analysis of DNA. Ninth North American Physarum Conference. Dallas, TX. June 1983.
8. B. Campling, **S.P.C. Cole** and J. Roder. An approach to the production of human monoclonal antibodies to lung cancer antigens. OCTRIF Clinical Cancer Research Conference. Lake Couchiching, ON. September 1983.
9. **S.P.C. Cole**, B.G. Campling, I.H. Louwman and J.C. Roder. Production of human monoclonal antibodies reactive with lung tumour cell lines. Cellular and Molecular Biology of Neoplasia Symposium. Honey Harbour, ON. October 1983.
10. J.C. Roder, D. Kozbor, **S. Cole** and T. Atlaw. Recent advances in human hybridoma technology. *Proc. Can. Fed. Biol. Soc.* 27: S89a (1984).
11. **S.P.C. Cole**. Production of human monoclonal antibodies to lung tumour antigens. *Proc. Can. Fed. Biol. Soc.* 27: S89b (1984). (*invited speaker*)
12. **S.P.C. Cole**, S. Mirski, R.C. McGarry, R. Cheng, B.G. Campling and J.C. Roder. HNK-1 (Anti-Leu-7) monoclonal antibody reactivity with human lung tumour cells and melanoma cells. Second Terry Fox Cancer Conference: Epigenetic Regulation of Cancer. Vancouver, BC. August 1984.
13. B. Campling, **S.P.C. Cole** and J. Roder. Production of human monoclonal antibodies to lung tumor antigens. Annual Meeting of the Royal College of Physicians and Surgeons of Canada. September 1984.
14. J. Roder, D. Kozbor, T. Atlaw and **S. Cole**. New developments in the EBV- hybridoma system as applied to mycobacterium leprae, tetanus toxin and human lung cancer antigens. Interface-Human Hybridomas and Synthetic Peptides: Horizons in Clinical Medicine. Kauai, HI. October 1984 (*invited*).
15. J.C. Roder, T. Atlaw, **S.P.C. Cole** and D. Kozbor. Recent advances in the EBV-hybridoma technique. *J. Cell. Biochem. Suppl.* 9A: 47 (1985) (*invited*).
16. B.G. Campling, **S.P.C. Cole** and J.C. Roder. Human monoclonal antibodies to human tumour cells. *Proc. Amer. Assoc. Cancer Res.* 26: 290 (1985).

17. R. Cheng, S. Mirski, R.C. McGarry, B.G. Campling, J.C. Roder, J.J. Rusthoven and **S.P.C. Cole**. The antigenic determinant recognized by HNK-1 (anti-Leu-7) monoclonal antibody is shared by human lung and prostatic tumour cells. *Proc. Can. Fed. Biol. Soc.* 28: 270 (1985).
18. J.S. Elce, J.R. Paterson and **S.P.C. Cole**. Human monoclonal auto-antibodies to human sperm cell antigens. The Biochemical Society Meeting. Oxford, U.K. July 1985. *Biochem. Soc. Trans.* 14: 96-97 (1986).
19. M.L. Vessey, **S.P.C. Cole**, J.S. Elce, H.V. Gelboin, S.S. Park and P.G. Forkert. Immunohistochemical localization of 3-methylcholanthrene-induced cytochrome P450s in mouse lung. *Proc. Can. Fed. Biol. Soc.* 29: 134 (1986).
20. **S.P.C. Cole**. Human monoclonal antibodies. 7th Annual Congress of the Canadian Society of Laboratory Technologists. St. John's, NL. June 15-20, 1986 (*invited speaker*).
21. **S.P.C. Cole**, E.H. Vreeken and B.G. Campling. Growth of human x human hybridomas in serum free and protein free medium. 6th International Congress of Immunology. Toronto, ON. July 1986. Abstract 3.16.12.
22. J.C. Roder, D. Kozbor, T. Atlaw and **S. Cole**. Development of the EBV hybridoma system and its application to tetanus, human lung cancer and leprosy. 6th International Congress of Immunology. Toronto, ON. July 1986. Abstract 3.16.7.
23. J. Trent, P. Meltzer, M. Slovak, A. Hill, W. Beck and **S. Cole**. Cytogenetic and molecular biological alterations associated with anthracycline resistance. 9th Annual Bristol-Myers Symposium on Cancer Research. Mechanisms of drug resistance in neoplastic cells. Washington, DC October 15-16, 1986 (*invited*).
24. B. Campling, J. Pym, P.R. Galbraith and **S.P.C. Cole**. Use of the MTT test for rapid determination of sensitivity of human leukemic blast cells to a wide variety of chemotherapeutic agents. *Blood* 68, Suppl. 1: 220a (1986).
25. **S.P.C. Cole** and S.E.L. Mirski. Monoclonal antibodies to a multidrug resistant small cell lung cancer cell line. *Proc. Amer. Assoc. Cancer Res.* 28: 1104 (1987).
26. P. Meltzer, M. Coccia, M. Slovak, W. Dalton, W. Beck, **S. Cole** and J. Trent. Multidrug resistance (MDR) resulting from exposure to doxorubicin (Dox): evidence for genetic mechanisms not associated with P-glycoprotein amplification. *Proc. Amer. Assoc. Cancer Res.* 28: 1179 (1987).
27. B.G. Campling, J. Pym and **S.P.C. Cole**. Use of the MTT test for rapid chemosensitivity testing of human small cell lung cancer cell lines. *Proc. Amer. Soc. Clin. Oncol.* Abst. 33 (1987).
28. P.G. Forkert, M.L. Vessey, S.S. Park, H.V. Gelboin and **S.P.C. Cole**. Immunohistochemical detection of cytochromes P-450 in mouse lung with monoclonal antibodies. *Proc. Can. Fed. Biol. Soc.* 30: 114 (1987).
29. B.G. Campling, J. Pym, P.R. Galbraith and **S.P.C. Cole**. An automated colorimetric assay of chemosensitivity of human tumour cells. Annual Meeting of the Royal College of Physicians and Surgeons of Canada. September 1987.
30. J. Roder, D. Kozbor, T. Atlaw and **S. Cole**. Development of the EBV hybridoma system and its application to tetanus, human lung cancer and leprosy. 2nd Biotechnology Symposium of the University of Montreal. Montreal, QC, April 11-12, 1986. *Exp. Biol.* 46: 59 (1987) (*invited*).
31. M.L. Slovak, P.S. Meltzer, W.S. Dalton, W. Beck and **S. Cole**. Cytogenetic and molecular genetic alterations associated with the development of anthracycline resistance. Second International Workshop on Chromosomes in Solid Tumors. Tucson, AZ. January 18-20, 1987. *Cancer Genetics and Cytogenetics* 28: 29 (1987).

32. S.E.L. Mirski and **S.P.C. Cole**. Characterization of a multidrug resistant human small cell lung cancer cell line. 11th OCTRIF Clinical Cancer Research Conference. Lake Couchiching, ON. September 1987.
33. **S.P.C. Cole**, H.F. Downes and M.L. Slovak. Effect of calcium antagonists on multidrug resistant tumor cell lines which lack P-glycoprotein. *Proc. Amer. Assoc. Cancer Res.* 29: 1235 (1988).
34. E.J. Osborne, **S.P.C. Cole** and W.J. Mackillop. The effect of elevated temperatures on adriamycin uptake and cytotoxicity in two human ovarian carcinoma cell lines in vitro. Radiation Research Annual Meeting, Philadelphia, PA. April 16-21, 1988.
35. **S.P.C. Cole**, H.F. Downes and S.E.L. Mirski. Glutathione (GSH) levels are diminished but GSH-S-transferase and reductase activities are elevated in the multidrug resistant small cell lung cancer cell line, H69AR. *Proc. Amer. Assoc. Cancer Res.* 30: 2027 (1989).
36. S.E.L. Mirski and **S.P.C. Cole**. Antigens associated with the development of resistance in H69AR, a multidrug resistant small cell lung cancer cell line. *Proc. Amer. Assoc. Cancer Res.* 30: 2043 (1989).
37. B. Savas, **S.P.C. Cole**, T. Tsuruo and H.F. Pross. Lymphokine-activated killer cells and multidrug resistance. Canadian Society of Immunology, 4th Annual Meeting, Abst. 7-4, March 1990.
38. **S.P.C. Cole**. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line. 3rd IASLC Lung Tumour Biology Workshop, Cambridge, UK. August 6-9, 1990. (*invited speaker*)
39. B. Savas, **S. Cole**, T. Tsuruo, J. Lemontt and H. Pross. P-glycoprotein and lymphokine-activated killer cells. 12th International RES Congress, 27th Annual Meeting of the Society Leukocyte Biology, 20th Leukocyte Culture Conference, Heraklion, Crete, Greece. October 1990. *J. Leuk. Biol.* 48 (Suppl. 1): 37 (1990).
40. **S.P.C. Cole**, E.R. Chanda and J.H. Gerlach. Circumvention of multidrug resistance in a small cell lung cancer cell line. AACR Special Conference in Cancer Research. Membrane Transport in Multidrug Resistance, Development, and Disease. Banff, AB. March 10-14, 1991.
41. K.A. Krebes, H.F. Pross and **S.P.C. Cole**. Cross-reactivity of a monoclonal antibody (MAb) specific for the multidrug resistant small cell lung cancer (SCLC) cell line H69AR with peripheral blood mononuclear cells (PBMCs). *Proc. Amer. Assoc. Cancer Res.* 32: 2206 (1991).
42. S.E.L. Mirski, F.P. Dicke and **S.P.C. Cole**. Non-P-glycoprotein-mediated multidrug resistance in the small cell lung cancer (SCLC) cell line, H69AR. *Proc. Amer. Assoc. Cancer Res.* 32: 2196 (1991).
43. H. Pross, B. Savas, **S. Cole**, T. Tsuruo, J. Lemontt and P. Kerr. Lymphokine activated killer cell sensitivity of drug-resistant P-glycoprotein-negative and P-glycoprotein-positive cell lines. 7th International Workshop on Natural Killer Cells, Stockholm, Sweden. June 4-7, 1991. *Nat. Immun. Cell Growth Regl.* 10: 127-128 (1991).
44. **S.P.C. Cole**. Non-P-glycoprotein-mediated drug resistance in a lung cancer cell line. *Can. Fed. Biol. Soc.* 34: 220 (1991) (*invited speaker*).
45. S.E.L. Mirski, K.C. Almquist and **S.P.C. Cole**. Topoisomerase II alterations in the drug resistant small cell lung cancer cell lines H69AR, MAR/V6 and H209/V6. *Can. Fed. Biol. Soc.* 34: 382 (1991).
46. M.J. Pinkoski, G. Bhardwaj, J.E. Mackie, R.G. Deeley and **S.P.C. Cole**. Elevated expression of calpactin I (heavy chain) in a multidrug resistant small cell lung cancer cell line. *Can. Fed. Biol. Soc.* 34: 383 (1991).
47. K.A. Krebes, S.E.L. Mirski, H.F. Pross and **S.P.C. Cole**. Expression of multidrug resistance-associated antigens on peripheral blood mononuclear cells. *Can. Fed. Biol. Soc.* 34: 8 (1991).

48. B.G. Campling, K.A. Baer, H.M. Baker, Y.-M. Lam and **S.P.C. Cole**. Do glutathione and related enzymes play a role in drug resistance in small cell lung cancer? Annual Meeting of the Royal College of Physicians and Surgeons of Canada. September 1991.
49. S.E.L. Mirski, C.D. Evans, K.C. Almquist and **S.P.C. Cole**. Alterations in topoisomerase II and drug accumulation in the drug resistant small cell lung cancer cell line H209/V6. 13th OCTRIF Clinical Cancer Research Conference. Lake Couchiching, ON. October 1991.
50. S.E.L. Mirski, K.C. Almquist, C.D. Evans, B.G. Campling, and **S.P.C. Cole**. Topoisomerase II alterations in the drug resistant small cell lung cancer cell line H209/V6. 6th World Conference on Lung Cancer, Melbourne, Australia, November 1991. *Lung Cancer* 7 (Suppl.): 507 (1991).
51. B.G. Campling, K.A. Baer, H.M. Baker, Y.-M. Lam and **S.P.C. Cole**. Do glutathione and related enzymes play a role in drug resistance in small cell lung cancer? 6th World Conference on Lung Cancer, Melbourne, Australia, November 1991. *Lung Cancer* 7 (Suppl.): 103 (1991).
52. **S.P.C. Cole**, M.J. Pinkoski, G. Bhardwaj, J.E. Mackie and R.G. Deeley. Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line. Molecular Oncology as a Basis for New Strategies in Cancer Therapy. 2nd Joint AACR/JCA Conference. Honolulu, HI. February 10-14, 1992.
53. C.D. Evans, S.E.L. Mirski, M.K. Danks, W.T. Beck and **S.P.C. Cole**. Alterations in topoisomerase II in multidrug resistance in the small cell lung cancer cell line H69AR. *Proc. Amer. Assoc. Cancer Res.* 33: 2694 (1992).
54. S.E.L. Mirski, C.D. Evans, K.C. Almquist and **S.P.C. Cole**. A novel topoisomerase II in the drug resistant small cell lung cancer (SCLC) cell line H209/V6. *Proc. Amer. Assoc. Cancer Res.* 33: 2695 (1992).
55. B.G. Campling, H.M. Baker, J. Pym, J.H. Gerlach, **S.P.C. Cole** and Y-M. Lam. Patterns of drug responsiveness in small cell lung cancer (SCLC). *Proc. Amer. Assoc. Cancer Res.* 33: 2932 (1992).
56. **S.P.C. Cole**, G. Bhardwaj, J.H. Gerlach, J.E. Mackie, C.E. Grant, K.C. Almquist, A.J. Stewart, E.U. Kurz, A.M.V. Duncan and R.G. Deeley. Identification of a novel ATP-binding cassette transporter gene overexpressed in a multidrug resistant human lung cancer cell line. Gordon Research Conference on Cancer. Salve Regina University, Newport, RI. August 10-14, 1992.
57. R.G. Deeley, J.H. Gerlach, G. Bhardwaj and **S.P.C. Cole**. A novel ATP-binding cassette transporter gene overexpressed in a multidrug resistant human lung cancer cell line. 46th Annual Symposium of the Society of General Physiologists. Woods Hole, MA. September 10-13, 1992.
58. E. Atlas, P. Kerr, B. Savas, **S.P.C. Cole** and H. Pross. Expression of cell adhesion molecules associated with differences in NK and LAK cell sensitivity of the SCLC cell line H69 and a multidrug-resistant variant H69AR. Proc. 8th International Natural Killer Cell Workshop. October 4-6, 1992. *Nat. Immun.* 11: (1992).
59. M.L. Slovak, J. Ho, E.U. Kurz, R.G. Deeley and **S.P.C. Cole**. Amplification of the gene for a novel multidrug resistance associated protein (MRP) in non-P-glycoprotein mediated doxorubicin-selected solid tumor cell lines. Fifth International Workshop on Chromosomes in Solid Tumors. Tucson, AZ. January 10-12, 1993. *Cancer Gen. Cytogen.* 66: 148 (1993). Abstract 32 (*invited*).
60. **S.P.C. Cole**, S.E.L. Mirski, G. Bhardwaj, K.C. Almquist and R.G. Deeley. Altered drug distribution and elevated expression of a novel transporter gene (MRP) in a multidrug resistant lung cancer cell line. 4th IASLC Lung Tumor Biology Workshop, Airlie, VA. April 13-16, 1993 (*invited speaker*).
61. M.L. Slovak, J. Ho, R.G. Deeley and **S.P.C. Cole**. Localization of a novel multidrug resistance associated gene in two non-P-glycoprotein mediated doxorubicin-selected cell lines. *Proc. Amer. Assoc. Cancer Res.* 34: 136 (1993).

62. S.E.L. Mirski, C.D. Evans, K. Sparks, **S.P.C. Cole**. Altered topoisomerase II α gene, mRNA and protein in a VP-16 resistant small cell lung cancer cell line. *Proc. Amer. Assoc. Cancer Res.* 34: 1946 (1993).
63. P.W. Feldoff, S.E.L. Mirski, **S.P.C. Cole** and D.M. Sullivan. Role of subcellular distribution of topoisomerase II (topo II) in the drug resistance of human small cell lung cancer (SCLC). *Proc. Amer. Assoc. Cancer Res.* 34: 1970 (1993).
64. **S.P.C. Cole**, G. Bhardwaj, J.H. Gerlach, K.C. Almquist and R.G. Deeley. A novel ATP-binding cassette transporter gene overexpressed in multidrug-resistant human lung tumour cells. *Proc. Amer. Assoc. Cancer Res.* 34: 579 (1993) (RM2001) (*invited speaker*).
65. M.A. Barrand, P.R. Twentyman, A.C. Heppell-Parton, P.H. Rabbitts, K.A. Wright, **S.P.C. Cole**, R.G. Deeley and E.U. Kurz. Expression of the novel transporter (MRP) gene in non-P-glycoprotein-mediated MDR lung tumour cells containing the resistance-associated 190k protein. General Motors Cancer Research Foundation International Symposium on "Resistance Against Anticancer Drugs: Molecular Mechanisms and Clinical Opportunities". Toronto, ON. May 6-8, 1993.
66. **S.P.C. Cole**, K.C. Almquist, S.E.L. Mirski, E.U. Kurz, G. Bhardwaj and R.G. Deeley. MRP: A novel ATP-binding cassette transporter gene identified in a multidrug resistant lung cancer cell line. General Motors Cancer Research Foundation International Symposium on "Resistance Against Anticancer Drugs: Molecular Mechanisms and Clinical Opportunities". Toronto, ON. May 6-8, 1993 (*invited speaker*).
67. S.E.L. Mirski, C.D. Evans, K. Sparks and **S.P.C. Cole**. A novel topoisomerase II α in the drug resistant small cell lung cancer cell line H209/V6. General Motors Cancer Research Foundation International Symposium on "Resistance Against Anticancer Drugs: Molecular Mechanisms and Clinical Opportunities". Toronto, ON. May 6-8, 1993.
68. P.S. Meltzer, X-Y Guan, M. Ray, M. Slovak, **S. Cole** and J. Trent. Detection and cloning of amplified DNA in drug resistant cells by chromosome microdissection. General Motors Cancer Research Foundation International Symposium on "Resistance Against Anticancer Drugs: Molecular Mechanisms and Clinical Opportunities". Toronto, ON. May 6-8, 1993.
69. J.H. Gerlach, **S.P.C. Cole** and R.G. Deeley. MRP: A new member of the ABC superfamily of transporters. General Motors Cancer Research Foundation International Symposium on "Resistance Against Anticancer Drugs: Molecular Mechanisms and Clinical Opportunities". Toronto, ON. May 6-8, 1993.
70. M.L. Slovak, J. Ho, G. Bhardwaj, R.G. Deeley, and **S.P.C. Cole**. Localization of a novel multidrug resistance associated gene in two non-P-glycoprotein mediated doxorubicin-selected cell lines. General Motors Cancer Research Foundation International Symposium on "Resistance Against Anticancer Drugs: Molecular Mechanisms and Clinical Opportunities". Toronto, ON. May 6-8, 1993.
71. **S.P.C. Cole**, C.E. Grant, K.C. Almquist, D.R. Hipfner, G. Valdimarsson and R.G. Deeley. MRP: A novel ATP-binding cassette transporter gene isolated from a multidrug resistant small cell lung cancer cell line. 3rd International IASLC Workshop on Lung Tumor and Differentiation Antigens. Zürich, Switzerland. Sept. 8-11, 1993 (*invited speaker*).
72. **S.P.C. Cole**, S.E.L. Mirski, B.G. Campling, J.E. Mackie, R.G. Deeley, K.A. Krebes and H.F. Pross. Low molecular weight antigens detected by MAb 2.54 associated with multidrug resistance in a small cell lung cancer cell line. 3rd International IASLC Workshop on Lung Tumor and Differentiation Antigens. Zürich, Switzerland. Sept. 8-11, 1993 (*invited speaker*).
73. R.G. Deeley, C.E. Grant, K.C. Almquist, D. Hipfner, G. Valdimarsson and **S.P.C. Cole**. Multidrug resistance mediated by MRP, a novel ATP-binding cassette transporter gene. New Directions in Cancer Research. A Symposium in Honour of P.G. Scholefield. Honey Harbour, ON. September 24, 1993 (*invited*).

74. A.J. Stewart, **S.P.C. Cole**, R.G. Deeley and E. Baracchini. Inhibition of the expression of the Multidrug Resistance-Associated Protein (MRP) using antisense phosphorothioate oligonucleotides. IBC Conference on Commercializing Oligonucleotide-based Therapeutics. San Diego, CA. December 5-7, 1993.
75. **S.P.C. Cole**, C.E. Grant, K.C. Almquist, D.R. Hipfner, G. Valdimarsson, D.W. Loe and R.G. Deeley. Multidrug resistance mediated by MRP, a 190 kDa transmembrane protein. *Biochem. Cell Biol.* 71: Aiii (1993) (*invited speaker*).
76. J. Jirsch, D. Loe, **S.P.C. Cole**, R.G. Deeley and D. Fedida. ATP-dependence of volume regulated Cl⁻ channels in small cell lung cancer cells. Meeting of the Canadian Physiological Society. Lake Louise, AB. January, 1994.
77. R.G. Deeley, C.E. Grant, K.C. Almquist, D.R. Hipfner, G. Valdimarsson, E.U. Kurz, B. Stride, D.W. Loe and **S.P.C. Cole**. Multidrug resistance mediated by MRP, a novel ATP-binding cassette transporter. Keystone Symposia on Molecular and Cellular Biology. Molecular Basis of Cancer Therapy. Tamarron, CO. March 4-10, 1994 (*invited*).
78. C.E. Grant*, G. Valdimarsson, D.R. Hipfner, K.C. Almquist, **S.P.C. Cole** and R.G. Deeley. Overexpression of Multidrug resistance-associated protein and resistance to natural product drugs. *Proc. Amer. Assoc. Cancer Res.* 35: 54 (1994). (**recipient of a AACR Travel Award*)
79. S.E.L. Mirski and **S.P.C. Cole**. A 3' deletion in topoisomerase II α mRNA is associated with VP-16 resistance in a small cell lung cancer cell line. *Proc. Amer. Assoc. Cancer Res.* 35: 2700 (1994).
80. R.G. Deeley, C.E. Grant, K.C. Almquist, D.R. Hipfner, G. Valdimarsson, D.W. Loe, D.F. Callen, B. Kuss and **S.P.C. Cole**. Multidrug resistance mediated by the 190 kDa MRP, a novel member of the ATP-binding cassette transporter superfamily. *Proc. Amer. Assoc. Cancer Res.* 35: 698 (1994). (RM 2178) (*invited*).
81. B.G. Campling, K.A. Baer, E.J. Graham, L.C. Lazaruk, Y-M. Lam, A.M. Keightley, **S.P.C. Cole**, R.G. Deeley and J.H. Gerlach. Expression of the *MDR1* and *MRP* multidrug resistance genes by small cell lung cancer cell lines. 7th World Conference on Lung Cancer. Colorado Springs, CO. June 26-July 1, 1994.
82. S.E.L. Mirski, K. Sparks, R.A. Comley, **S.P.C. Cole**. Nuclear localization function of the COOH-terminus of human topo II α is revealed by a mutation in a drug-resistant cell line. Fifth Conference on DNA Topoisomerases in Therapy. New York University Medical Center, New York. October 3-6, 1994.
83. **S.P.C. Cole**, K.C. Almquist, C.E. Grant, G. Bhardwaj, D.R. Hipfner, G. Valdimarsson, B.J. Kuss, D. F. Callen and R.G. Deeley. Multidrug resistance mediated by the 190 kDa product of the MRP gene. XVI International Cancer Congress. New Delhi, India. October 30-November 5, 1994 (*invited speaker*).
84. **S.P.C. Cole**, K.C. Almquist, D.W. Loe, D.R. Hipfner, B. Stride, C.E. Grant, I. Leier, G. Jedlitschky, D. Keppler, R.G. Deeley. MRP-mediated multidrug resistance in human tumor cells. Modern Developments in Cancer Therapeutics - Joint Conference of the American Association for Cancer Research and the Institute of Biomedical Sciences (Taiwan). Taipei, Taiwan. November 7-11, 1994 (*invited speaker*).
85. **S.P.C. Cole**, A.J. Stewart, Y. Canitrot, E. Baracchini, R.G. Deeley. Modulation of multidrug resistance protein (MRP) mRNA in human cells by antisense oligonucleotides. Molecular Biology of Cancer: Implications for Prevention and Therapy. 3rd Joint AACR/JCR Conference. Maui, HI. February 13-18, 1995.
86. E.U. Kurz, C.E. Grant, M.Z. Vasa, R.A. Burtch-Wright, **S.P.C. Cole**, R.G. Deeley. Analysis of the proximal promoter region of the multidrug resistance protein (MRP) gene in three small cell lung cancer cell lines. *Proc. Amer. Assoc. Cancer Res.* 36: 1917 (1995).
87. D.W. Loe, K.C. Almquist, D.R. Hipfner, J.E. Mackie, **S.P.C. Cole**, R.G. Deeley. Characterization of the 190 kDa multidrug resistance protein (MRP) in drug-selected and transfected human tumor cells. *Proc. Amer. Assoc. Cancer Res.* 36: 1915 (1995).

88. D.R. Hipfner, G. Valdimarsson, K.C. Almquist, R.G. Deeley, **S.P.C. Cole**. Monoclonal antibodies for detection of the 190 kDa multidrug resistance protein, MRP. *Proc. Amer. Assoc. Cancer Res.* 36: 1916 (1995).
89. D.D. Ross, L.A. Doyle, C.A. Schiffer, E.J. Lee, C.E. Grant, **S.P.C. Cole**, R.G. Deeley, W-D Yang, Y. Tong. Expression of multidrug resistance-associated protein (MRP) mRNA transcripts in blast cells from acute myeloid leukemia (AML) patients. *Proc. Amer. Assoc. Cancer Res.* 36: 3793 (1995).
90. M.L. Slovak, J. Ho, R.G. Deeley, **S.P.C. Cole**, E.G.E. de Vries, H. Broxterman, G.L. Scheffer, R.J. Scheper. The drug resistance related protein LRP maps proximal to MRP on the short arm of chromosome 16. *Proc. Amer. Assoc. Cancer Res.* 36: 114 (1995).
91. H.S.L. Chan, G. Haddad, T. Grogan, D.R. Hipfner, R.G. Deeley, **S.P.C. Cole**. Sensitive detection of the multidrug resistance protein (MRP) in malignant cells by multilayer immunoperoxidase. *Proc. Amer. Assoc. Cancer Res.* 36: 1941 (1995).
92. L.C. Lazaruk, B.G. Campling, K.A. Baer, Y-M Lam, **S.P.C. Cole**, R.G. Deeley, J.H. Gerlach. Drug resistance and expression of MRP and MDR1 in small cell lung cancer cell lines. *Proc. Amer. Assoc. Cancer Res.* 36: 1953 (1995). (*recipient of AACR Best Poster Award*)
93. I. Brock, D. Hipfner, **S.P.C. Cole**, B.S. Nielsen, P.B. Jensen, R. Deeley, M. Sehested. Sequential co-expression of MRP and *mdr1* genes and gene products in VP-16 selected H69 small cell lung cancer cells. *Proc. Amer. Assoc. Cancer Res.* 36: 1966 (1995).
94. I. Leier, G. Jedlitschky, U. Bucholz, K. Barnouin, M. Center, **S.P.C. Cole**, R.G. Deeley, D. Keppler. Transport function and substrate specificity of the multidrug resistance-associated protein. *Proc. Amer. Assoc. Cancer Res.* 36: 1911 (1995).
95. **S.P.C. Cole**, D.W. Loe, K.C. Almquist, D.R. Hipfner, R.G. Deeley. Multidrug resistance mediated by the 190 kDa MRP. 19th International Congress of Chemotherapy. *Can. J. Infect. Dis.* 6: 5C (1995) (*invited speaker*).
96. S.E.L. Mirski, Q. Yu, K.E. Sparks and **S.P.C. Cole**. Molecular analysis of a mutant topoisomerase II α predominantly localized in the cytoplasm. The Sixth Conference on DNA Topoisomerases in Therapy. Amsterdam, The Netherlands. September 6-8, 1995.
97. **S.P.C. Cole**. Multiple drug resistance in lung cancer. Lung Cancer: Strategies for the 21st Century. Toronto, ON, September 29, 1995 (*invited speaker*).
98. N. Jain, **S.P.C. Cole**, R.G. Deeley, D.W. Loe, J.H. Gerlach, B.G. Campling. Increased expression of a 190 kDa membrane protein in a cisplatin resistant human cell lung cancer cell line, H209/CP. OCTRIF 15th Clinical Cancer Conference. Lake Couchiching, ON, October, 1995.
99. **S.P.C. Cole** and R.G. Deeley. MRP: An alternative cause of multidrug resistance. AACR Special Conference, "Novel Strategies Against Resistant Cancers". Ft. Myers, FL. November 20, 1995 (*invited speaker*).
100. V. D'Hondt, M. Caruso, M. Ward, C. Grant, **S. Cole**, R. Deeley and A. Bank. Expression of the multidrug resistance protein (MRP) gene using retroviral vectors. American Society of Hematology. 87th Annual Meeting, Seattle, WA. December 1-5, 1995.
101. D.W. Loe, K.C. Almquist, **S.P.C. Cole**, and R.G. Deeley. ATP-dependent transport of steroid glucuronides and chemotherapeutic agents by the multidrug resistance protein, MRP. *Proc. Amer. Assoc. Cancer Res.* 37: 2115 (1996).

102. D.R. Hipfner, K.C. Almquist, B.D. Stride, R.G. Deeley and **S.P.C. Cole**. Identification of the epitope of multidrug resistance protein (MRP)-specific monoclonal antibody QCRL-1. *Proc. Amer. Assoc. Cancer Res.* 37: 2114 (1996).
103. B.D. Stride*, G. Wilson, J.H. Gerlach, **S.P.C. Cole** and R.G. Deeley. Identification of the murine homologue of the multidrug resistance protein (MRP). *Proc. Amer. Assoc. Cancer Res.* 37: 2112 (1996). (**recipient of a AACR Travel Award*)
104. I. Neverova, A.J. Stewart, Y. Canitrot, E. Baracchini, N.M. Dean, R.G. Deeley and **S.P.C. Cole**. Reduced expression of the multidrug resistance protein, MRP, in human tumour cells by antisense oligonucleotides. *Proc. Amer. Assoc. Cancer Res.* 37: 2113 (1996).
105. Q. Yu, S.E.L. Mirski, K. Sparks and **S.P.C. Cole**. Characterization of a novel 6.2 kb topoisomerase II α mRNA in a VP-16 selected lung cancer cell line. *Proc. Amer. Assoc. Cancer Res.* 37: 2926 (1996).
106. K.C. Almquist*, D.W. Loe, D.R. Hipfner, R.G. Deeley and **S.P.C. Cole**. Inhibition of leukotriene C₄ binding and transport by MRP-specific monoclonal antibodies. *Proc. Amer. Assoc. Cancer Res.* 37: 2111 (1996). (**recipient of a AACR Rhone-Poulenc Travel Award*)
107. M.D. Norris, S.B. Bordow, P.S. Haber, G.M. Marshall, M. Kavallaris, J. Madafiglio, S.L. Cohn, M.L. Schmidt, D.R. Hipfner, R.G. Deeley, **S.P.C. Cole** and M. Haber. Evidence that the N-*myc* oncogene regulates MRP gene expression in neuroblastoma. *Adv. Neuro. Res.* (1996).
108. B.G. Campling, K.A. Baer, J.H. Gerlach, Y-M. Lam, **S.P.C. Cole** and S.E.L. Mirski. Levels of topoisomerase II isoforms: correlation with drug response in small cell lung cancer. Fourth International Conference on Small Cell Lung Cancer. Ravenna, Italy. May 1996.
109. **S.P.C. Cole** and R.G. Deeley. Multidrug resistance associated with overexpression of MRP. International Symposium "Anticancer Targets and Strategies for the Twenty-first Century". Castres, France. October 10, 1996 (*invited speaker*).
110. R.G. Deeley, M. Gao, D.W. Loe and **S.P.C. Cole**. Development of a baculovirus system for studying the structure and function of MRP multidrug resistance protein (MRP). International Symposium "Anticancer Targets and Strategies for the Twenty-first Century". Castres, France. October 10, 1996.
111. **S.P.C. Cole**, D.W. Loe, R.K. Stewart, T.E. Massey and R.G. Deeley. Role of GSH in the transmembrane transport of xenobiotics by the multidrug resistance protein, MRP. International Conference on Glutathione and Glutathione-linked Enzymes in Human Cancer and Other Diseases. Hilton Head, SC. November 1, 1996 (*invited speaker*).
112. D.R. Hipfner, K.C. Almquist, E. Leslie, M. Gao, J.H. Gerlach, R.G. Deeley and **S.P.C. Cole**. Glycosylation and membrane topology of the multidrug resistance protein, MRP. *Proc. Amer. Assoc. Cancer Res.* 38: 2944 (1997).
113. N. Jain, J.H. Gerlach, L.C. Young, **S.P.C. Cole**, R.G. Deeley and B.G. Campling. Increased expression of a 190 kDa membrane protein in a cisplatin resistant cancer cell line. *Proc. Amer. Assoc. Cancer Res.* 38: 2959 (1997).
114. D.W. Loe*, R.K. Stewart, T.E. Massey, R.G. Deeley and **S.P.C. Cole**. ATP-dependent transport of aflatoxin B₁ (AFB₁) and its glutathione (GSH) conjugates by the multidrug resistance protein, MRP. *Proc. Amer. Assoc. Cancer Res.* 38: 36 (1997). (**recipient of a AACR-AFLAC Young Investigator Travel Award*).
115. I. Neverova, Y. Canitrot, N.M. Dean, P. Villiet, R.G. Deeley and **S.P.C. Cole**. Reversal of MRP-associated resistance by 2'-modified antisense oligonucleotides. *Proc. Amer. Assoc. Cancer Res.* 38: 2943 (1997). (RM3985)

116. E.U. Kurz, **S.P.C. Cole** and R.G. Deeley. Comparative analysis of DNA-protein interactions in the 5' flanking region of the multidrug resistance protein (MRP) gene in three small cell lung cancer cell lines. *Proc. Amer. Assoc. Cancer Res.* 38: 3222 (1997).
117. B.D. Stride, C.E. Grant, D.W. Loe, D.R. Hipfner, **S.P.C. Cole** and R.G. Deeley. Pharmacological characterization of the murine and human multidrug resistance proteins (MRP) in HEK 293 cells. *Proc. Amer. Assoc. Cancer Res.* 38: 2627 (1997).
118. S.E.L. Mirski, Q. Yu, K. Sparks and **S.P.C. Cole**. Two C-terminal truncated cytoplasmic forms of topoisomerase II α in a VP-16 selected lung cancer cell line result from partial gene deletion and alternative splicing. *Proc. Amer. Assoc. Cancer Res.* 38: 4184 (1997).
119. C.E. Grant, E.U. Kurz, **S.P.C. Cole** and R.G. Deeley. Analysis of the intron-exon organization of the human multidrug resistance protein (MRP) gene and alternative splicing of its mRNA. *Proc. Amer. Assoc. Cancer Res.* 38: 3221 (1997).
120. I. Wessel, P.B. Jensen, J. Falck, S.E.L. Mirski, **S.P.C. Cole**, M. Sehested. Alternative splicing leading to deletion of bp 4468-76 coding for lys-ser-lys in topoisomerase II α (topo II) in small cell lung cancer H69/VP cells resistant to etoposide (VP-16) results in an extranuclear enzyme localization. *Proc. Amer. Assoc. Cancer Res.* 38: 4183 (1997).
121. D.W. Loe, R.K. Stewart, T.E. Massey, R.G. Deeley and **S.P.C. Cole**. ATP-Dependent transport of aflatoxin B₁ and its glutathione S-conjugates by the multidrug resistance protein, MRP. FEBS Advanced Lecture Course "ATP-Binding Cassette (ABC) Transporters: From Multidrug Resistance to Genetic Disease". Gosau, Austria. February 1997.
122. M. Gao*, D.W. Loe, K.C. Almquist, M. Yamazaki, **S.P.C. Cole** and R.G. Deeley. Structure and function of human multidrug resistance protein, (MRP). FEBS Advanced Lecture Course "ATP-Binding Cassette (ABC) Transporters: From Multidrug Resistance to Genetic Disease". Gosau, Austria. February 1997. (*recipient of a FEBS Travel Award)
123. R.G. Deeley and **S.P.C. Cole**. Multidrug Resistance Protein, MRP. FEBS Advanced Lecture Course "ATP-Binding Cassette (ABC) Transporters: From Multidrug Resistance to Genetic Disease". Gosau, Austria. February 1997.
124. G.M. Marshall, M.D. Norris, S.B. Bordow, P.S. Haber, M. Kavallaris, J. Madafiglio, S.L. Cohn, M.L. Schmidt, D.R. Hipfner, R.G. Deeley, **S.P.C. Cole**, M. Haber. Mechanisms of multidrug resistance in neuroblastoma. FEBS Advanced Lecture Course "ATP-Binding Cassette (ABC) Transporters: From Multidrug Resistance to Genetic Disease". Gosau, Austria. February 1997.
125. **S.P.C. Cole** and R.G. Deeley. Structure/function studies of the multidrug resistance protein, MRP. 6th European ISSX Meeting. Gothenburg, Sweden. June 30, 1997.
126. P.B. Jensen, I. Wessel, I.J. Falck, S. Mirski, **S.P.C. Cole** and M. Sehested. Sequential co-expression of all 3 multidrug resistance (MDR) phenotypes in a single human small cell lung cancer (SCLC) cell line exposed to etoposide, H69/VP. An illustration of the complex progression of drug resistance. 8th World Conference on Lung Cancer. Dublin, Ireland. August 1997.
127. S.E.L. Mirski, Q. Yu, K. Sparks and **S.P.C. Cole**. Two C-terminal truncated cytoplasmic forms of topoisomerase II α in the VP-16 selected lung cancer cell line, H209/V6, have lost bipartite nuclear localization signal(s) and result from partial gene deletion and alternative splicing. 8th World Conference on Lung Cancer. Dublin, Ireland. August 12, 1997.
128. B.G. Campling, N. Jain, **S.P.C. Cole**, R.G. Deeley and J.H. Gerlach. Energy dependent reduction of cisplatin accumulation in a cisplatin-resistant human small cell lung cancer (SCLC) cell line. 8th World Conference on Lung Cancer. Dublin, Ireland. August 1997.

129. B.G. Campling, S.R. Wright, **S.P.C. Cole**, R.G. Deeley and A.H. Boag. Immunohistochemical detection of the multidrug resistance protein (MRP) in human lung cancer. 8th World Conference on Lung Cancer. Dublin, Ireland. August 1997.
130. **S.P.C. Cole** and R.G. Deeley. Biology of MRP in drug resistance of lung cancer. 8th World Conference on Lung Cancer. Dublin, Ireland. August 14, 1997. (*invited speaker*)
131. **S.P.C. Cole**. Drug resistance in lung cancer. Symposium on Lung Cancer - New Aspects. Vienna University, Vienna, Austria. September 22, 1997. (*plenary speaker - sponsored by Novartis*)
132. S.L. Olsen, E.M. Leslie, D.W. Loe, A.L.-J. Ooi, R.G. Deeley and **S.P.C. Cole**. Site-directed mutagenesis of vicinal cysteine residues in human multidrug resistance protein, MRP. *Proc. Amer. Assoc. Cancer Res.* 39: 1145 (1998). (RM4010)
133. S.E.L. Mirski, H.J. Cummings, J.H. Gerlach and **S.P.C. Cole**. Analysis of potential bipartite nuclear localization signals in human topoisomerase II α . *Proc. Amer. Assoc. Cancer Res.* 39: 553 (1998).
134. L.C. Young, T. Voskoglou-Nomikos, **S.P.C. Cole**, R.G. Deeley, B.G. Campling and J.H. Gerlach. A comparison of *MDR1*, *MRP*, *cMOAT*, *MRP3*, *MRP4*, and *MRP5* in a panel of unselected SCLC and NSCLC cell lines. *Proc. Amer. Assoc. Cancer Res.* 39: 1457 (1998).
135. **S.P.C. Cole** and R.G. Deeley. Multidrug resistance protein (MRP) and related ABC transporters: their functions in health and disease. 8th Fisher Winternational Symposium on Cellular and Molecular Biology. Banff, AB. April 5, 1998. (*invited speaker*)
136. E.M. Leslie*, D.W. Loe, R.G. Deeley and **S.P.C. Cole**. The effects of flavonoids on the transport function of the multidrug resistance protein, MRP. 1st Annual Meeting for Basic and Clinical Research Trainees. Faculty of Health Sciences, Queen's University. Kingston, ON. May 27, 1998. (**Honourable Mention*)
137. **S.P.C. Cole**. MRP: Pharmacology and clinical relevance. 10th Meeting of the NCI-EORTC Symposium on New Drugs in Cancer Therapy. Amsterdam, The Netherlands. June 16, 1998. (published) (*invited speaker*)
138. A.J. Lang*, Q. Yu, H. Cummings, S.E. L. Mirski, J.H. Gerlach and **S.P.C. Cole**. Structural organization of the human *TOP2A* and *TOP2B* genes. *Naunyn-Schmied. Arch. Pharmacol.* 358 (Suppl.1): R155 (1998). XIIIth International Congress of Pharmacology. Munchen, Germany. July 1998. (**Recipient of a PSC Student Travel Award*)
139. **S.P.C. Cole** and R.G. Deeley. Recent advances in understanding the function of the MRP gene. *Naunyn-Schmied. Arch. Pharmacol.* 358 (Suppl.1): R25 (1998). XIIIth International Congress of Pharmacology. Munchen, Germany. July 27, 1998. (*invited speaker*)
140. B. Savas, L. Undar, **S.P.C. Cole** and H.F. Pross. Lymphokine-activated killer (LAK) cell susceptibility and multidrug resistance (MDR) in B cell carcinogenesis. 4th International Symposium on Predictive Oncology & Therapy. Nice, France, October 24-27, 1998.
141. S.E.L. Mirski, J.H. Gerlach, K. Sparks and **S.P.C. Cole**. Nuclear localization signals in human topoisomerase II α and β . Ninth Conference on DNA Topoisomerases in Therapy. New York. October 5-7, 1998
142. **S.P.C. Cole**, A.J. Lang, S.E.L. Mirski, H.J. Cummings, Q. Yu and J.H. Gerlach. Structural organization of the human TOP2 genes. Ninth Conference on DNA Topoisomerases in Therapy. New York. October 5 -7, 1998.
143. E.M. Leslie, R.G. Deeley and **S.P.C. Cole**. Effect of dietary flavonoids on the transport function of the 190 kDa multidrug resistance protein, MRP. 31st Annual Symposium of the Society for Toxicology of Canada. Montreal, QC. December 3-4, 1998.

144. **S.P.C. Cole** and R.G. Deeley. Mechanistic and structural features of multidrug resistance protein, MRP. FEBS Advanced Lecture Course "ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease". Gosau, Austria. February, 1999. (*plenary speaker*)
145. E.M. Leslie, R.G. Deeley and **S.P.C. Cole**. Effect of dietary flavonoids on the transport function of the 190 kDa multidrug resistance protein, MRP. *Proc. Amer. Assoc. Cancer Res.* 40: 4537 (1999).
146. B.G. Campling, I. Kosatka, **S.P.C. Cole**, R.G. Deeley and A.H. Boag. Immunohistochemical detection of the multidrug resistance protein, MRP, in human prostate carcinoma. *Proc. Amer. Assoc. Cancer Res.* 40: 1541 (1999).
147. D.D. Ross, W. Yang, L.V. Abruzzo, W.S. Dalton, E. Schneider, H. Lage, M. Dietel, L. Greenberger, **S.P.C. Cole** and L.A. Doyle. Breast cancer resistance protein (BCRP) mRNA is overexpressed in atypical multidrug-resistant human cancer cell lines selected with mitoxantrone. *Proc. Amer. Assoc. Cancer Res.* 40: 2092 (1999).
148. M. Gao, H.R. Cui, C.E. Grant, **S.P.C. Cole**, and R.G. Deeley. Structure and function analysis of the first nucleotide binding domain of multidrug resistance protein. *Proc. Amer. Assoc. Cancer Res.* 40: 4400 (1999).
149. V. D'Hondt, J.P. Machiels, A.S. Govaerts, **S.P.C. Cole**, R. Deeley, A. Bank and M. Symann. *In vivo* chemoprotection and selection after retroviral gene transfer of the multidrug resistance-associated protein (MRP) cDNA. *Proc. Amer. Assoc. Cancer Res.* 40: 3909 (1999).
150. R.G. Deeley and **S.P.C. Cole**. Molecular biology of efflux pumps in cancer therapy. 21st International Congress of Chemotherapy. Birmingham, UK. July 4-7, 1999.
151. **S.P.C. Cole** and R.G. Deeley. Structural and functional aspects of the human multidrug resistance protein, MRP1. 2nd FASEB Conference on Transport ATPases. Snowmass, CO. July 7, 1999. (*invited speaker*)
152. Q. Mao, E.M. Leslie, R.G. Deeley and **S.P.C. Cole**. ATPase activity of purified and reconstituted multidrug resistance protein MRP1 from drug-selected H69AR cells. 2nd FASEB Conference on Transport ATPases. Snowmass, CO, July, 1999.
153. **S.P.C. Cole** and R.G. Deeley. MRP1: An ABC transporter of xenobiotics and conjugated organic ions. 1999 American Association of Pharmaceutical Scientists Annual Meeting and Exposition. New Orleans, LA. November 15, 1999. (*invited speaker*)
154. S.E.L. Mirski, K.E. Sparks, Q. Yu, A.J. Lang, N. Jain, B.G. Campling and **S.P.C. Cole**. TOP2A exon deletion results in a truncated cytoplasmic topoisomerase II α in a drug resistant lung cancer cell line. Annual Meeting of the American Society for Cell Biology. Washington, DC. December, 1999. *Mol. Biol. Cell* 10: 442A (1999).
155. **S.P.C. Cole** and R.G. Deeley. Structural and mechanistic studies of MRP1. International Symposium on the Role of Transporters in the Host Defense Mechanism. Tokyo, Japan. January 18-19, 2000. (*invited speaker*)
156. R.G. Deeley and **S.P.C. Cole**. Structure/function studies of partial and hybrid MRPs. International Symposium on the Role of Transporters in the Host Defense Mechanism. Tokyo, Japan. January 18-19, 2000.
157. R.G. Deeley, and **S.P.C. Cole**. Structure/function relationships of human and murine MRP1/mrp1. Molecular Mechanisms in Intracellular Transport Symposium. Heidelberg, Germany. February 23, 2000.
158. K.-i. Ito, E.M. Leslie, K.E. Weigl, C.J. Oleschuk, R.G. Deeley and **S.P.C. Cole**. Site-directed mutagenesis of proline residues in human multidrug resistance protein (MRP). *Proc. Amer. Assoc. Cancer Res.* 41: 4295 (2000).

159. Q. Mao, R.G. Deeley and **S.P.C. Cole**. Functional reconstitution of substrate transport by purified MRP1 in proteoliposomes. *Proc. Amer. Assoc. Cancer Res.* 41: 2528 (2000).
160. L.C. Young, B.G. Campling, **S.P.C. Cole**, R.G. Deeley and J.H. Gerlach. Multidrug resistance proteins MRP1, MRP2 and MRP3 in lung cancer cell lines. *Proc. Amer. Assoc. Cancer Res.* 41: 4297 (2000).
161. **S.P.C. Cole** and R.G. Deeley. MRP-related ABC transporters: Defining their roles in drug sensitivity and resistance. *Proc. Amer. Assoc. Cancer Res.* 41: 2528 (2000). (*invited speaker*)
162. W. Qiu, D.R. Hipfner, Q. Mao, R.G. Deeley and **S.P.C. Cole**. Epitope mapping of the transport-inhibiting MRP1-specific monoclonal antibody QCRL-3. American Society for Biochemistry and Molecular Biology and American Society for Pharmacology and Experimental Therapeutics Joint Meeting with French Pharmacological Society and Pharmacological Society of Canada - ASBMB/ASPET 2000. Boston, MA, June 4-8, 2000. *FASEB J.* 14: A1339 (2000).
163. E.M. Leslie*, Q. Mao, C.J. Oleschuk, R.G. Deeley and **S.P.C. Cole**. Modulation of multidrug resistance protein 1 (MRP1) transport and ATPase activities by interaction with dietary flavonoids. Gordon Research Conference on Chemotherapy of Clinical and Experimental Cancer. Oxford, UK. September 17-22, 2000. (**recipient of a GRC travel award*)
164. K. Weigl*, D. Hipfner, W. Qiu, R.G. Deeley and **S.P.C. Cole**. Glycosylation and topology studies of the multidrug resistance protein 1, MRP1. Gordon Research Conference on Chemotherapy of Clinical and Experimental Cancer. Oxford, UK. September 17-22, 2000. (**recipient of a GRC travel award*)
165. R.G. Deeley and **S.P.C. Cole**. Mechanisms and substrate specificity of MRP1-mediated transport. *Drug Metab. Rev.* 32 (suppl. 2): 138 (2000). ISSX Meeting. Indianapolis, IN. October 25, 2000.
166. **S.P.C. Cole**. Resistance to chemotherapy. Québec Symposium on Breast Cancer. Montréal, QC. October 27, 2000. (*invited speaker*)
167. R.G. Deeley and **S.P.C. Cole**. Transport by human and murine MRP1, structural determinants of substrate specificity and functional differences between nucleotide binding domains. 3rd FEBS Advanced Lecture Course "ATP-Binding Cassette (ABC) Proteins From Multidrug Resistance to Genetic Disease". Gosau, Austria. March 3-10, 2001.
168. E.M. Leslie*, K. Ito, P. Upadhyaya, S.S. Hecht, R.G. Deeley and **S.P.C. Cole**. Active transport of the beta-O-glucuronide conjugate of the tobacco-specific carcinogen NNAL by MRP1/ABCC1: Requirement for GSH or a non-sulfur-containing analog. 3rd FEBS Advanced Lecture Course "ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease". Gosau, Austria. March 3-10, 2001. (**recipient of a NCIC Student Travel Award; recipient of a FEBS conference bursary; recipient of a FEBS Young Investigator Award*)
169. K. Ito, W. Qiu, R.G. Deeley and **S.P.C. Cole**. Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport activity. 3rd FEBS Advanced Lecture Course "ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease". Gosau, Austria. March 3-10, 2001.
170. C. Westlake, M. Gao, **S.P.C. Cole** and R.G. Deeley. Structure and function analysis of the MRP1 cytoplasmic loop 3. 3rd FEBS Advanced Lecture Course "ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease". Gosau, Austria. March 3-10, 2001.
171. D. Zhang, **S.P.C. Cole** and R.G. Deeley. Identification of an amino acid residue in multidrug resistance protein (MRP1) critical for conferring resistance to anthracyclines. 3rd FEBS Advanced Lecture Course "ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease". Gosau, Austria. March 3-10, 2001.

172. P.W. Causey, M.C. Baird, **S. Cole** and K. Sparks. In search of titanium-based anticancer agents. 84th Canadian Society for Chemistry Conference Exhibition. Montréal, QC. May 26-30, 2001.
173. **S.P.C. Cole** and R.G. Deeley. MRP1: An ABC transporter of drugs and toxins. 3rd FASEB Conference on "Transport ATPases". Snowmass, CO. July 18, 2001. (*invited speaker*)
174. A. Ilhan, O. Tomris, A. Hakan, S. Yenisooy, B. Savas and **S.P.C. Cole**. Multidrug resistance-associated protein (MRP1) gene transfection confers resistance to doxorubicin, etoposide and vincristine, but not to paclitaxel and cisplatin in kidney cells. *Balkan J. Clin. Lab.* VIII: pp-061. 9th Meeting of the Balkan Clinical Laboratory Federation. Ioannina, Greece. September 12-15, 2001.
175. **S.P.C. Cole**. ABC transporters and drug resistance. Symposium on "Children's Cancer: From Mechanisms to Therapeutics". Sydney, Australia. October 8, 2001 (*Keynote speaker*).
176. **S.P.C. Cole**. MRP-related ABC transporters: defining their roles in drug sensitivity and resistance. 33rd Meeting of the International Society of Paediatric Oncology (SIOP). Brisbane, Australia. October 11, 2001 (*Keynote speaker*).
177. E.M. Leslie*, R.J. Bowers, R.G. Deeley and **S.P.C. Cole**. Structure activity studies of glutathione analogues that stimulate estrone 3-sulfate transport by the multidrug resistance protein, MRP1. Society for Toxicology of Canada Annual Symposium, Montréal, QC. December 6-7, 2001. (**recipient of an STC travel award*).
178. C.J. Oleschuk, K-i. Ito, C. Westlake, M. Vasa, R.G. Deeley and **S.P.C. Cole**. Modulation of substrate specificity by mutation of Trp¹²⁵⁴ in the apical membrane transporter MRP2. Society for Toxicology of Canada Annual Symposium. Montréal, QC. December 6-7, 2001.
179. **S.P.C. Cole** and R.G. Deeley. Human MRP1 and MRP2: broad spectrum ABC transporters of toxicological relevance. CSBMCB 45th Annual Meeting and 12th Winternational Symposium. Banff, AB. March 22-24, 2002. (*invited speaker*)
180. C.J. Oleschuk*, K. Ito, R.G. Deeley and **S.P.C. Cole**. Substitution of Trp¹²⁴² in transmembrane segment 17 alters the substrate specificity of human multidrug resistance protein, MRP3 (ABCC3). CSBMCB 45th Annual Meeting and 12th Winternational Symposium. Banff, AB. March 22-24, 2002. (**Honorable Mention for Best Graduate Student Poster Competition*).
181. E.M. Leslie, I. Létourneau, K.E. Weigl, R.G. Deeley and **S.P.C. Cole**. Functional and structural consequences of cysteine substitutions in the NH₂-proximal region of human multidrug resistance protein 1 (MRP1). CSBMCB 45th Annual Meeting and 12th Winternational Symposium. Banff, AB. March 22-24, 2002.
182. A. Haimeur*, R.G. Deeley and **S.P.C. Cole**. Role of charged amino acids on the substrate specificity and transport of the ABC transporter MRP1 (ABCC1). CSBMCB 45th Annual Meeting and 12th Winternational Symposium. Banff, AB. March 22-24, 2002. (**Honorable Mention for Best Postdoctoral Fellow Poster Competition*).
183. D-W. Zhang, **S.P.C. Cole** and R.G. Deeley. Determinants of the substrate specificity of multidrug resistance protein 1 (MRP1): role of amino acid residues with hydrogen bonding potential in predicted transmembrane helix 17. CSBMCB 45th Annual Meeting and 12th Winternational Symposium. Banff, AB. March 22-24, 2002.
184. C.J. Westlake, Y. Qian, M. Gao, **S.P.C. Cole** and R.G. Deeley. Identification of the structural and functional boundaries of the multidrug resistance protein cytoplasmic loop3. CSBMCB 45th Annual Meeting and 12th Winternational Symposium. Banff, AB. March 22-24, 2002.

185. K-i. Nunoya, C. Grant, H. Imawaka, Y. Miyata, **S.P.C. Cole** and R.G. Deeley. Molecular cloning and pharmacological characterization of rat multidrug resistance protein (MRP) 1. CSBMCB 45th Annual Meeting and 12th Winternational Symposium. Banff, AB. March 22-24, 2002.
186. M. Muredda, K-i. Nunoya, R.A. Burtch-Wright, **S.P.C. Cole** and R.G. Deeley. Comparative analysis of the promoter regions of the human and rodent multidrug resistance protein 1 (ABCC1) genes. CSBMCB 45th Annual Meeting and 12th Winternational Symposium. Banff, AB. March 22-24, 2002.
187. M. Adachi, K-i. Nunoya, J. Sampath, D. Sun, G. Du, M. Leggas, C. Stewart, **S. Cole**, R. Deeley and J. Schuetz. The MRP4 gene transports cyclic nucleotides and is directly regulated by the PKA signaling pathway: implications for biological role. *Proc. Amer. Assoc. Cancer Res.* 43: 2463 (2002).
188. S. Conrad, H.M. Kauffmann, K. Ito, E.M. Leslie, R.G. Deeley, **S.P.C. Cole** and D. Schrenk. Identification and characterization of human multidrug resistance protein 1 (MRP1) mutations. *Naunyn-Schmied. Arch. Pharmacol.* 365: R161 (2002).
189. **S.P.C. Cole** and R.G. Deeley. Transport of xenobiotic and endobiotic metabolites by the MRP-related transporters, IUPHAR XIVth World Congress of Pharmacology. San Francisco, CA. July 8, 2002. (*invited speaker*)
190. **S.P.C. Cole**. Structure-function studies of the human multidrug resistance protein (MRP) genes. 22nd International Symposium on "Xenobiotics and Host Responses", University of Occupational and Environmental Health. Kitakyushu, Japan. September 24, 2002. (*invited speaker*)
191. C.J. Oleschuk, R.G. Deeley and **S.P.C. Cole**. Substitution of Trp¹²⁴² in predicted transmembrane segment 17 alters the substrate specificity of the human bile salt transporter, MRP3 (ABCC3), 53rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA. November 1-5, 2002. (Abstract # 101257)
192. **S.P.C. Cole**. Structure-function studies of MRP1 and GSH-stimulated organic anion transport. Joint meeting Symposium on "ABC Proteins" and the "5th Conference on ABC Proteins and Ion Channels - From Gene to Disease". Kyoto, Japan. January 24-26, 2003. (*invited speaker*)
193. **S.P.C. Cole** and R.G. Deeley. Structure-function studies of the human multidrug resistance protein, MRP1/ABCC1. 4th FEBS Advanced Lecture Course "ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease". Gosau, Austria. March 4, 2003. (*plenary speaker*)
194. G. Conseil, R.G. Deeley and **S.P.C. Cole**. Importance of two adjacent cytosolic tyrosine residues for MRP1 (ABCC1) transport activity. 4th FEBS Advanced Lecture Course "ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease". Gosau, Austria. March 1-8, 2003.
195. A. Haimeur, R.G. Deeley and **S.P.C. Cole**. Charged amino acids in the second membrane spanning domain of multidrug resistance protein MRP1 are important for transport activity and substrate specificity. 4th FEBS Advanced Lecture Course "ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease". Gosau, Austria. March 1-8, 2003.
196. K. Koike, E.M. Leslie, C.J. Oleschuk, R.G. Deeley and **S.P.C. Cole**. Contribution of proline residues in or near the transmembrane helices to the transport activity of MRP1 (ABCC1). 4th FEBS Advanced Lecture Course "ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease". Gosau, Austria. March 1-8, 2003.
197. L. Payen, M. Gao, **S.P.C. Cole** and R.G. Deeley. Structural basis of functional differences between the nucleotide binding domains of multidrug resistance protein (MRP1). 4th FEBS Advanced Lecture Course "ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease". Gosau, Austria. March 1-8, 2003.

198. C.J. Westlake, **S.P.C. Cole** and R.G. Deeley. Structure and function analysis of the multidrug resistance protein (MRP)1 COOH-terminal regions. 4th FEBS Advanced Lecture Course "ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease". Gosau, Austria. March 1-8, 2003.
199. I.J. Létourneau, E.M. Leslie, J.C. Hall, R.G. Deeley and **S.P.C. Cole**. Modulation of multidrug resistance protein 1 (MRP1), MRP2 and MRP3 transport by herbicide glutathione conjugates. *Proc. Amer. Assoc. Cancer Res.* 44: 3680 (2003).
200. K. Koike, E.M. Leslie, C.J. Oleschuk, R.G. Deeley and **S.P.C. Cole**. Contribution of proline residues in or near the transmembrane helices to the transport activity of MRP1 (ABCC1). *Proc. Amer. Assoc. Cancer Res.* 44: 3682 (2003).
201. L.F. Payen, M. Gao, **S.P.C. Cole** and R.G. Deeley. Structural basis of functional differences between the nucleotide binding domains of multidrug resistance protein 1 (MRP1). *Proc. Amer. Assoc. Cancer Res.* 44: 3684 (2003).
202. C.J. Westlake, **S.P.C. Cole** and R.G. Deeley. Identification of C-terminal regions important for multidrug resistance protein (MRP)1 function and trafficking. *Proc. Amer. Assoc. Cancer Res.* 44: 3687 (2003).
203. A. Haimeur, R.G. Deeley and **S.P.C. Cole**. Charged amino acids in the second membrane spanning domain of multidrug resistance protein MRP1 are important for transport activity and substrate specificity. *Proc. Amer. Assoc. Cancer Res.* 44: 3688 (2003).
204. K.E. Weigl, D.R. Hipfner, R.G. Deeley and **S.P.C. Cole**. Glycosylation of human MRP1 (ABCC1) affects both the conformation of membrane spanning domain 3 as well as the efficiency of E₂17βG transport. *Proc. Amer. Assoc. Cancer Res.* 44: 3689 (2003).
205. D-W. Zhang, H. Gu, **S.P.C. Cole** and R.G. Deeley. Characterization of wild-type and mutant human multidrug resistance protein (MRP) 3: role of polar amino acid residues within predicted transmembrane helix 17 in determining the substrate specificity of MRP3. *Proc. Amer. Assoc. Cancer Res.* 44: 3692 (2003).
206. S.E.L. Mirski, J.C. Bielawski and **S.P.C. Cole**. Identification of functional nuclear export sequences in human topoisomerase II α and β. *Proc. Amer. Assoc. Cancer Res.* 44: 4718 (2003).
207. S.E.L. Mirski, J.C. Bielawski, and **S.P.C. Cole**. Identification of functional nuclear export sequences in topoisomerase II α and β. Gordon Research Conference on Molecular Therapeutics of Cancer, Queen's College. Oxford, UK. July 13-18, 2003.
208. E.M. Leslie*, **S.P.C. Cole** and M.P. Waalkes. Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1): evidence that a tri-glutathione conjugate is required. 4th Annual Fellows and Young Investigators Retreat, NCI Center for Cancer Research. Williamsburg, VA. March 9-11, 2004. (*Outstanding Poster Presentation Travel Award).
209. E.M. Leslie*, **S.P.C. Cole** and M.P. Waalkes. Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1): evidence that a tri-glutathione conjugate is required. 43rd Annual Meeting of the Society of Toxicology. Baltimore, MD. March 21-25, 2004. (*Society of Toxicology Metals Specialty Section Postdoctoral Fellow Award).
210. **S.P.C. Cole**. Molecular determinants of the substrate specificity and transport functions of the human drug and organic anion transporter, MRP1 (ABCC1). Centre National de la Recherche Scientifique (CNRS) 9th Symposium, "Cancer: Targets, Molecules and Therapies". Gif-sur-Yvette, France. June 11, 2004. (invited speaker)
211. E.M. Leslie*, **S.P.C. Cole** and M.P. Waalkes. Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1): requirement for a tri-glutathione conjugate. 7th International ISSX Meeting.

- Vancouver, BC. August 29-September 2, 2004. (**3rd place Poster Award*). *Drug Metab. Rev.* 36: 176 (2004).
212. **S.P.C. Cole.** ABC transporters in cancer therapy: an update. Molecular Targets for Cancer Therapy, Third Biennial Conference, Moffitt Cancer Center. Tampa, FL. October 5, 2004. (*invited speaker*)
213. I.J. Létourneau, K. Koike, R.G. Deeley and **S.P.C. Cole.** Functional characterization of non-synonymous single nucleotide polymorphisms of human multidrug resistance protein 1 (MRP1). Pharmacogenomics Meeting. Cold Spring Harbor Laboratory, NY. November 18-21, 2004.
214. C.J. Westlake, **S.P.C. Cole** and R.G. Deeley. Protein processing and plasma membrane targeting functions of the multidrug resistance protein (MRP)1 N-terminal membrane spanning domain. Biophysical Society 49th Annual Meeting. Long Beach, CA. February 12-16, 2005.
215. J.P. Wyles, Z. Wu, S.E.L. Mirski and **S.P.C. Cole.** Nuclear interactions of DNA topoisomerase II and phospholipid scramblase I. CIHR Institute of Cancer Research (ICR) and the National Cancer Institute of Canada (NCIC), "Cancer Research Across the Spectrum: National Meeting for Trainees". Mont Tremblant, QC. May 9-11, 2005.
216. I.J. Létourneau*, R.G. Deeley and **S.P.C. Cole.** Functional characterization of non-synonymous single nucleotide polymorphisms of human multidrug resistance protein MRP1 (ABCC1). 8th Annual Meeting for Health Sciences Research Trainees. Queen's University, Kingston, ON. May 31, 2005. (**Award for Excellence in Research, Poster Presentation competition*).
217. **S.P.C. Cole.** Towards an understanding of the substrate specificity of the human ABC transporter, MRP1 (ABCC1). 12th Annual MDIBL Environmental Health Sciences Symposium, "Molecular evolution of chemical defense mechanisms". Salisbury Cove, ME. July 14, 2005. (*invited speaker*)
218. I.J. Létourneau, R.G. Deeley and **S.P.C. Cole.** Functional characterization of non-synonymous single nucleotide polymorphisms of the gene encoding human multidrug resistance protein (MRP1/ABCC1). Gordon Research Conferences, "Multidrug Resistance Efflux Systems". Oxford, UK. August 28 - September 2, 2005.
219. P. Wu, C.J. Oleschuk, Q. Mao, B. Keller, R.G. Deeley and **S.P.C. Cole.** Analysis of human multidrug resistance protein 1 (ABCC1) by mass spectrometry: towards identification of LTC₄ binding sites. 2nd Annual North American ABC Genetic Workshop, NCI-NIH. Frederick, MD. September 29, 2005.
220. G. Conseil, A.J. Rothnie, R.G. Deeley and **S.P.C. Cole.** Impact of mutating the cationic residues Arg¹¹³⁸, Lys¹¹⁴¹ and Arg¹¹⁴² at the cytosolic interface of TM15 on protein expression and transport activity of human MRP1 (ABCC1). 2nd Annual North American ABC Genetic Workshop, NCI-NIH. Frederick, MD. September 29, 2005.
221. I.J. Létourneau, R.G. Deeley and **S.P.C. Cole.** Comparison of SIFT and PolyPhen algorithm predictions with *in vitro* functional analysis of non-synonymous single nucleotide polymorphisms of multidrug resistance protein 1 (MRP1/ABCC1). 2nd Annual North American ABC Genetic Workshop, NCI-NIH. Frederick, MD. September 29, 2005 (*selected for oral presentation*).
222. A.J. Slot, I.J. Létourneau, R.G. Deeley and **S.P.C. Cole.** Mutation of proline 1158 to alanine in cytoplasmic loop 7 significantly alters the substrate specificity of human MRP2 (ABCC2). 2nd Annual North American ABC Genetic Workshop, NCI-NIH. Frederick, MD. September 29, 2005.
223. A.J. Rothnie, R. Callaghan, R.G. Deeley and **S.P.C. Cole.** The stimulatory role of GSH in MRP1 (ABCC1)-mediated transport. 2nd Annual North American ABC Genetic Workshop, NCI-NIH. Frederick, MD. September 29, 2005 (*selected for oral presentation*).
224. I.J. Létourneau*, R.G. Deeley and **S.P.C. Cole.** Comparison of SIFT and polyphen algorithm predictions with *in vitro* functional analysis of non-synonymous single nucleotide polymorphisms of multidrug

- resistance protein 1 (*MRP1/ABCC1*). Society of Toxicology of Canada (STC) 38th Annual Symposium, "The Impact of Toxicants on Child Health". Montreal, QC. December 5-6, 2005. (**recipient of a STC Travel Award*).
225. J.P. Wyles, Z. Wu, S.E.L. Mirski and **S.P.C. Cole**. Nuclear interactions of DNA topoisomerase II and phospholipid scramblase 1. 45th Annual Meeting of the American Society for Cell Biology. San Francisco, CA. December 10-14, 2005.
226. **S.P.C. Cole**. Structure function studies of the LTC₄ transporter, MRP1 (ABCC1). Keystone Symposium on Eicosanoids in Inflammation and Chronic Diseases. Park City, UT. January 11, 2006. (*invited speaker*) (*CME credit*)
227. A. Rothnie*, R. Callaghan, R.G. Deeley and **S.P.C. Cole**. The mechanism of GSH stimulated estrone sulphate transport by the multidrug resistance protein 1 (MRP1, ABCC). FEBS Special Meeting on ABC Proteins - ABC 2006. Innsbruck, Austria. March 5-9, 2006 (**recipient of a Steiner Travel Award*).
228. I.J. Létourneau*, A.J. Slot, R.G. Deeley and **S.P.C. Cole**. Role of a conserved cytoplasmic proline residue in signaling between the membrane spanning domains and nucleotide binding domains (NBDs) of MRP1, MRP2 and MRP3. FEBS Special Meeting on ABC Proteins - ABC 2006. Innsbruck, Austria. March 5-9, 2006 (**recipient of a NCIC Travel Award*).
229. G. Conseil, A.J. Rothnie, R.G. Deeley and **S.P.C. Cole**. Impact of mutating the charged residues in the cytoplasmic loop 7 on protein expression and transport activity of human MRP1 (ABCC1). FEBS Special Meeting on ABC Proteins - ABC 2006. Innsbruck, Austria. March 5-9, 2006.
230. M.F. Rosenberg, L. Zhang, P. Wu, Q. Mao, R.G. Deeley, **S.P.C. Cole** and R.C. Ford. Localization of the extra transmembrane domain of multidrug resistance protein 1. FEBS Special Meeting on ABC Proteins - ABC 2006. Innsbruck, Austria. March 5-9, 2006.
231. P. Bandler, C. Westlake, R. Burtch-Wright, **S.P.C. Cole** and R.G. Deeley. Identification of elements involved in plasma membrane targeting of human multidrug resistance proteins, MRP1 and MRP2. FEBS Special Meeting on ABC Proteins - ABC 2006. Innsbruck, Austria. March 5-9, 2006.
232. A. Theis, D. Zhang, **S.P.C. Cole** and R.G. Deeley. Functional characterization of a cysteine-less MRP1 in *Spodoptera frugiperda* 21 insect cells. FEBS Special Meeting on ABC Proteins - ABC 2006. Innsbruck, Austria. March 5-9, 2006.
233. **S.P.C. Cole**. ABC transporters: an update on the MRP1 drug efflux pump. Division of Drug Metabolism, Merck Pharmaceuticals. Westpoint, PA. April 18, 2006. (*invited speaker*)
234. **S.P.C. Cole**. ABC transporters: an update on the MRP1 drug efflux pump. Division of Drug Metabolism, Merck Pharmaceuticals. Rahway, NJ. April 19, 2006. (*invited speaker*)
235. Md. T. Hoque, G. Conseil and **S.P.C. Cole**. Differential localization of MRP4 in polarized kidney cell lines, MDCK and LLC-PK1. CSBMCB 49th Annual Meeting, "Membrane Proteins in Health & Disease". Niagara-on-the-Lake, ON. May 31 - June 4, 2006. *Biochem. Cell. Biol.* 84: 1065-1066 (2006)
236. P. Wu, B. Keller, R.G. Deeley and **S.P.C. Cole**. Functional purification and identification of LTC₄ binding sites of multidrug resistance protein 1 (ABCC1). CSBMCB 49th Annual Meeting, "Membrane Proteins in Health & Disease". Niagara-on-the-Lake, ON. May 31 - June 4, 2006.
237. A.J. Rothnie, R.G. Deeley and **S.P.C. Cole**. Mechanistic differences between GSH transport and GSH modulated transport by MRP1 (ABCC1). 3rd Annual North American Genetic ABC Workshop, NCI-NIH. Frederick, MD. September 21, 2006.
238. G. Conseil, A.J. Rothnie, R.G. Deeley and **S.P.C. Cole**. Mutation of charged residues in the cytoplasmic loop 7 of the multidrug and organic anion transporter MRP1/ABCC1 affects protein expression,

- localization and transport activity. 3rd Annual North American Genetic ABC Workshop, NCI-NIH. Frederick, MD. September 21, 2006.
239. I.J. Létourneau, A.J. Slot, R.G. Deeley and **S.P.C. Cole**. A conserved cytoplasmic proline residue plays a role in signaling between substrate binding sites and the nucleotide binding domains of MRP1, MRP2 and MRP3. 3rd Annual North American Genetic ABC Workshop, NCI-NIH. Frederick, MD. September 21, 2006.
240. P.E. Bandler, C.J. Westlake, R. Burtch-Wright, **S.P.C. Cole** and R.G. Deeley. Identification of elements involved in plasma membrane targeting of human multidrug resistance proteins, MRP1 and MRP2. 3rd Annual North American Genetic ABC Workshop, NCI-NIH. Frederick, MD. September 21, 2006.
241. L. Qin, **S.P.C. Cole** and R.G. Deeley. Identification of residues responsible for the asymmetric functionality of the nucleotide binding domains of MRP1. 3rd Annual North American Genetic ABC Workshop, NCI-NIH. Frederick, MD. September 21, 2006.
242. **S.P.C. Cole**. The MRP1 (ABCC1) drug efflux pump: validation studies of genetic variants. The 3rd International Symposium of Korea Biomedical Genomic Research Association and National Genome Research Institute". Seoul, Korea. December 15, 2006. (*invited speaker*)
243. **S.P.C. Cole**. MRP1 and related transporters. 7th Cerebral Vascular Biology International Conference. Ottawa, ON. June 25, 2007. (*invited speaker*)
244. Md. T. Hoque and **S.P.C. Cole**. Na⁺/H⁺ exchanger regulatory factor 1 (NHERF1) functionally interacts with the multidrug resistance protein 4 (MRP4) via a potential PDZ-interaction motif, ETAL. 4th Annual North American Genetic ABC Workshop, NCI-NIH. Frederick, MD. October 4, 2007.
245. A.J. Slot, D.D. Wise, R.G. Deeley, T.J. Monks and **S.P.C. Cole**. Modulation of human MRP1 (ABCC1) and MRP2 (ABCC2) transport activities by endogenous and exogenous glutathione-conjugated catechol metabolites. 4th Annual North American Genetic ABC Workshop, NCI-NIH. Frederick, MD. October 4, 2007.
246. M.K. DeGorter, G. Conseil, R.L. Campbell, R.G. Deeley and **S.P.C. Cole**. Molecular modeling of the human multidrug resistance protein 1 (MRP1/ABCC1) using the structure of *S. aureus* Sav1866 as template. 4th Annual North American Genetic ABC Workshop, NCI-NIH. Frederick, MD. October 4, 2007. (*selected for oral presentation*)
247. **S.P.C. Cole**. The MRP1 drug and organic anion transporter: structural determinants of its activity and substrate selectivity. "ABC Transport Proteins in Environmental Health and Toxicology" International Meeting. Siena, Italy. October 20, 2007. (*invited speaker*)
248. **S.P.C. Cole**. MRP1 (ABCC1): molecular determinants of its substrate transport and specificity. 2nd FEBS Special Meeting: "ATP-Binding Cassette (ABC) Proteins: from Multidrug Resistance to Genetic Diseases". Innsbruck, Austria. March 4, 2008. (*plenary speaker*)
249. A.J. Rothnie, G. Conseil, R.G. Deeley and **S.P.C. Cole**. Mechanistic differences between GSH, GSH-dependent and GSH-independent substrates on nucleotide and substrate binding by MRP1/ABCC1. 2nd FEBS Special Meeting: "ATP-Binding Cassette (ABC) Proteins: from Multidrug Resistance to Genetic Diseases". Innsbruck, Austria. March 1-8, 2008.
250. Md. T. Hoque and **S.P.C. Cole**. Na⁺/H⁺ exchanger regulatory factor 1 (NHERF1) functionally interacts with the multidrug resistance protein 4 (MRP4) via a potential PDZ-interaction motif, ETAL. 2nd FEBS Special Meeting: "ATP-Binding Cassette (ABC) Proteins: from Multidrug Resistance to Genetic Diseases". Innsbruck, Austria. March 1-8, 2008.

251. A.J. Slot, R.G. Deeley, T.J. Monks and **S.P.C. Cole**. Identification of multidrug resistance proteins (MRPs) as efflux transporters of GSH-conjugated estrogen metabolites. Gordon Research Conference on “Drug Metabolism”. Holderness, NH. July 6-11, 2008.
252. **S.P.C. Cole**. MRP1: structural basis for activity and substrate selectivity. Symposium on “Transporters: Relevance to Drug Disposition and Disease”, IXth World Conference on Clinical Pharmacology and Therapeutics - CPT2008. Québec City, QC. July 30, 2008. (*invited speaker*)
253. **S.P.C. Cole**. GSH and GSH conjugate transport by MRP1. “MRP and Membrane Transport”, Glutathione Transferase 2008 Conference (GST2008). Uppsala, Sweden. August 21, 2008. (*invited speaker*)
254. S.H. Iram, R.G. Deeley and **S.P.C. Cole**. Role of cytoplasmic loop 5 (CL5) in the expression and function of MRP1 (*ABCC1*). 5th Annual North American Genetic ABC Workshop, NCI-NIH. Frederick, MD. September 25, 2008.
255. Md. T. Hoque and **S.P.C. Cole**. Membrane localization of MRP4 is regulated by NHERF1 in polarized kidney epithelial cells. 5th Annual North American Genetic ABC Workshop, NCI-NIH. Frederick, MD. September 25, 2008. (*selected for oral presentation*)
256. K. Maeno, A. Nakajima, G. Conseil, A. Rothnie, R.G. Deeley and **S.P.C. Cole**. Analysis of *S*-methylGSH stimulated estrone sulfate transport and modulator sensitivity of TM6 and TM17 mutants of MRP1 (*ABCC1*). 5th Annual North American Genetic ABC Workshop, NCI-NIH. Frederick, MD. September 25, 2008.
257. M. Chan, G. Conseil, R.G. Deeley and **S.P.C. Cole**. Rescue of non-expressing mutants of multidrug resistance protein 1 (MRP1). 5th Annual North American Genetic ABC Workshop, NCI-NIH. Frederick, MD. September 25, 2008.
258. A.J. Slot, T.J. Monks, R.G. Deeley and **S.P.C. Cole**. Transport of GSH-conjugated catechol estrogen metabolites by MRP1/*ABCC1* and MRP2/*ABCC2*. 5th Annual North American Genetic ABC Workshop, NCI-NIH. Frederick, MD. September 25, 2008.
259. S.V. Molinski, G. Conseil, R.G. Deeley and **S.P.C. Cole**. Functional analysis of three acidic residues in the cytoplasmic α -helical region in COOH-proximal to TM17 in the multidrug transporter MRP1 (*ABCC1*). 5th Annual North American Genetic ABC Workshop, NCI-NIH. Frederick, MD. September 25, 2008. (*selected for oral presentation*)
260. A.J. Hampton, Y. Ji, G. Conseil, C.A. Ward, **S.P.C. Cole** and B.M. Bennett. Expression of the ATP-binding cassette transporter, ABCA3 and vascular nitrite distribution in rat aorta after treatment with glyceryl trinitrate. 5th Annual North American Genetic ABC Workshop, NCI-NIH. Frederick, MD. September 25, 2008.
261. A.J. Slot*, T.J. Monks and **S.P.C. Cole**. Transport of GSH-conjugated catechol estrogen metabolites by MRP1/*ABCC1* and MRP2/*ABCC2*. 40th Annual Symposium of the Society of Toxicology of Canada. Montréal, QC. December 1-2, 2008 (**recipient of a STC Travel Award*).
262. M. Chan*, G. Conseil and **S.P.C. Cole**. Temperature insensitivity of non-expressing TM16 mutants of MRP1 (*ABCC1*). 40th Annual Symposium of the Society of Toxicology of Canada. Montréal, QC. December 1-2, 2008 (**recipient of a STC Travel Award*).
263. S.V. Molinski*, G. Conseil and **S.P.C. Cole**. Functional analysis of an α -helical region proximal to transmembrane helix 17 in multidrug resistance protein 1. 40th Annual Symposium of the Society of Toxicology of Canada. Montréal, QC. December 1-2, 2008 (**recipient of a STC Travel Award*).
264. **S.P.C. Cole**. Molecular determinants of LTC₄ transport by MRP1/*ABCC1*. 5th Takeda Science Foundation Symposium on PharmaSciences: “Bioactive Lipid Molecules and Transporters”. Tokyo, Japan. May 26, 2009.

265. **S.P.C. Cole**. Molecular determinants of LTC₄ transport by MRP1/ABCC1. Fourth iCeMS International Symposium on Integrated Cell-Material Sciences, “Integrated Physical/Chemical Biology of the Cell: from Genes to Membrane Systems”. Kyoto, Japan. May 28, 2009.
266. **S.H. Iram*** and **S.P.C. Cole**. Functional analysis of CL5 amino acids at the interface of NBD2 for stable expression and activity of human MRP1 (*ABCC1*). 3rd FEBS Special Meeting “ATP-Binding Cassette (ABC) Proteins: from Multidrug Resistance to Genetic Diseases”. Innsbruck, Austria. February 27 – March 5, 2010 (**recipient of a FEBS Int’l Travel Award*).
267. **M. Chan***, **S. Iram** and **S.P.C. Cole**. R1202D and E1204K: rescue resistant TM16 mutants of MRP1 (*ABCC1*). 3rd FEBS Special Meeting “ATP-Binding Cassette (ABC) Proteins: from Multidrug Resistance to Genetic Diseases”. Innsbruck, Austria. February 27 – March 5, 2010 (**recipient of a CCSRI Travel Award*).
268. **A.J. Slot**, T.J. Monks and **S.P.C. Cole**. Complex inhibition of MRP1/ABCC1 transport function by glutathionylated benzene metabolites. 3rd FEBS Special Meeting “ATP-Binding Cassette (ABC) Proteins: from Multidrug Resistance to Genetic Diseases”. Innsbruck, Austria. February 27 – March 5, 2010.
269. **M.Z. Perry**, **G. Conseil** and **S.P.C. Cole**. Expression and transport of MRP1 processing mutants in insect cells. 7th Annual North American ABC Meeting, NCI. Frederick, MD. September 14-15, 2010.
270. **R.L. Myette**, **G. Conseil**, M.R. Detty and **S.P.C. Cole**. Chalcogenopyrylium derivatives as modulators of multidrug resistance protein 1 (MRP1/ABCC1) transport activity. 7th Annual North American ABC Meeting, NCI. Frederick, MD. September 14-15, 2010.
271. **S.P.C. Cole**. Molecular determinants of MRP/ABCC expression and transport. Symposium on “Multidrug Resistance and Transporters”, Joint Meeting of the Australian Society for Biophysics and Australian Physiological Society. Adelaide, Australia. November 29, 2010.
272. **A. Rothnie**, **K. Weigl**, **X. Wang**, **I. Létourneau**, **G. Conseil** and **S.P.C. Cole**. Understanding [³²P]azidoADP.V_i ‘trapping’ of MRP1. Biochemical Society Annual Symposium “Recent Advances in Membrane Biochemistry”, Robinson College. Cambridge, UK. January 5-7, 2011.
273. C.B. Shukalek, **G. Conseil**, **S.P.C. Cole** and E.M. Leslie. Regulation of arsenic triglutathione [As(GS)₃] transport by the human multidrug resistance protein 1 (MRP1/ABCC1) through post-translational modification. American Society for Pharmacology and Experimental Therapeutics 2011 Annual Meeting at Experimental Biology. Washington, DC. April 9-13, 2011.
274. **S.P.C. Cole**. Molecular determinants of human MRP1 and MRP4 expression. Symposium on “Frontiers in Epithelial Transport 2011”, Yonsei University. Seoul, Korea. April 15, 2011.
275. **S.P.C. Cole**. Molecular determinants of human MRP1 and MRP4 expression. Institute for Integrated Cell-Material Sciences, Kyoto University. Japan. April 22, 2011.
276. S.B. Cheepala, J. Bao, D. Nachagari, **G. Conseil**, A.P. Naren, D. Sun, T. Zhong, **S.P.C. Cole**, J. Zheng and J.D. Schuetz. Cytoplasmic loop 3 is critical for expression, function, and localization of human and zebrafish ABCC4/Abcc4. 8th Annual North American ABC Workshop. Frederick, MD. September 28-29, 2011.
277. **S.P.C. Cole** and R.G. Deeley. MRP1 (*ABCC1*): Two decades of intrigue... . 4th FEBS Special Meeting: “ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease”. Innsbruck, Austria. March 8, 2012. (*Keynote Speaker*)
278. **S.H. Iram*** and **S.P.C. Cole**. Mutations in cytoplasmic loop 5 cause misfolding in multiple domains of the multidrug and organic anion transporter MRP1 (*ABCC1*). 4th FEBS Special Meeting: “ATP-Binding

- Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease". Innsbruck, Austria. March 3-9, 2012. (**ABCC 2012 Young Investigator Award for Best Poster*).
279. A. Hernandez*, S. Iram, M. Chan and **S.P.C. Cole**. An aspartate residue located in the membrane-cytoplasm interface region of the third helix of MSD1 is crucial for expression of MRP1, MRP2, MRP3 and MRP4. 4th FEBS Special Meeting: "ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease". Innsbruck, Austria. March 3-9, 2012. (**recipient of a FEBS Young Investigator Travel Award*).
280. M.F. Miah and **S.P.C. Cole**. Expression of MRP4 (ABCC4) is downregulated by the NH₂-truncated CortBP1 isoform of SHANK2. 4th FEBS Special Meeting: "ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Disease". Innsbruck, Austria. March 3-9, 2012.
281. Y.I. Hassan, Md. T. Hoque and **S.P.C. Cole**. Phosphorylation of NHERF1 contributes to the membrane trafficking of human MRP4/ABCC4 in polarized epithelia cells. 9th Annual North American ABC Genetic Workshop. Frederick, MD. September 27-28, 2012.
282. A. Hernandez and **S.P.C. Cole**. Optimizing expression and purification of the functionally important COOH-terminal transmembrane helices TM16 and TM17 from human MRP1 (ABCC1) for biophysical studies. 9th Annual North American ABC Genetic Workshop. Frederick, MD. September 27-28, 2012.
283. M.F. Miah and **S.P.C. Cole**. Human multidrug resistance protein 4 (MRP4/ABCC4) is down-regulated by the NH₂-truncated CortBP1 isoform of SHANK2. 9th Annual North American ABC Genetic Workshop. Frederick, MD. September 27-28, 2012.
284. G. Conseil and **S.P.C. Cole**. Two non-synonymous single nucleotide polymorphisms (nsSNPs) - A989T and C1047S - in the organic anion transporter MRP1/*ABCC1* selectively alter drug resistance and efflux inhibition. 9th Annual North American ABC Genetic Workshop. Frederick, MD. September 27-28, 2012.
285. A. Hernandez and **S.P.C. Cole**. TM16/17 hairpin peptide: a model for substrate binding studies for the drug transporter MRP1. 5th Annual Resident/Post-Doctoral Research Day, Department of Pathology & Molecular Medicine, Queen's University. Kingston, ON. February 25, 2013.
286. G. Conseil, I.J. Létourneau and **S.P.C. Cole**. The 2965G>A non-synonymous single nucleotide polymorphism (nsSNP) in *ABCC1* leading to Ala989Thr mutation in the multidrug resistance protein 1 (MRP1) partially and selectively alters drug transport and resistance. 5th Annual Resident/Post-Doctoral Research Day, Department of Pathology & Molecular Medicine, Queen's University. Kingston, ON. February 25, 2013.
287. Y.I. Hassan, Md. T. Hoque and **S.P.C. Cole**. Functional interaction of human multidrug resistance protein 4 (MRP4/ABCC4) with Na⁺/H⁺ exchanger regulatory factor 1 (NHERF1) in polarized and non-polarized cells is dependent on the phosphorylation status of NHERF1-PDZ1-Ser77. 5th Annual Resident/Post-Doctoral Research Day, Department of Pathology & Molecular Medicine, Queen's University. Kingston, ON. February 25, 2013.
288. C. Gao, M. Chan, G. Conseil and **S.P.C. Cole**. Rescue of misfolded MRP1 mutants involving the highly conserved charged amino acids Arg¹²⁰² and Glu¹²⁰⁴ by expression in insect cells. 5th Annual Resident/Post-Doctoral Research Day, Department of Pathology & Molecular Medicine, Queen's University. Kingston, ON. February 25, 2013.
289. M.F. Miah and **S.P.C. Cole**. Cell-surface MRP4 (ABCC4) levels are down-regulated by the NH₂-truncated CortBP1 isoform of SHANK2. Gordon Research Conference on "Multi-Drug Efflux Systems". Ventura, CA. March 17-22, 2013.
290. C. Gao, G. Conseil, M. Chan and **S.P.C. Cole**. Rescue of misfolded MRP1 mutants involving the highly conserved charged amino acids Arg¹²⁰² and Glu¹²⁰⁴ by expression in insect cells. 16th Annual Meeting for Health Sciences Research Trainees, Queen's University. Kingston, ON. June 5, 2013.

291. A. Hernandez and **S.P.C. Cole**. TM16/17 hairpin peptide: a model for substrate binding studies for the drug transporter MRP1. 16th Annual Meeting for Health Sciences Research Trainees, Queen's University. Kingston, ON. June 5, 2013.
292. Y.I. Hassan*, Md. T. Hoque and **S.P.C. Cole**. Ser⁷⁷ in Na⁺/H⁺ exchanger regulatory factor 1 (NHERF1) plays a crucial role in membrane trafficking of multidrug resistance protein 4 (MRP4). 16th Annual Meeting for Health Sciences Research Trainees, Queen's University. Kingston, ON. June 5, 2013. (**recipient of a Poster Prize - 2nd place*).
293. M.F. Miah and **S.P.C. Cole**. CortBP1 isoform of SHANK2 adapter protein down-regulates cell-surface MRP4 (ABCC4) levels in HEK293 cells. 16th Annual Meeting for Health Sciences Research Trainees, Queen's University. Kingston, ON. June 5, 2013.
294. G. Conseil and **S.P.C. Cole**. Two non-synonymous single nucleotide polymorphisms (nsSNPs) – A989T and C1047S – in the organic anion transporter MRP1/ABCC1 selectively alter drug resistance and efflux inhibition. 16th Annual Meeting for Health Sciences Research Trainees, Queen's University. Kingston, ON. June 5, 2013.
295. **S.P.C. Cole**. Polymorphisms in the MRP1 (ABCC1) transporter: how important are they? European Union Conference “Role of MDR Proteins in Pharmacokinetics and Toxicology”. Ryn, Poland, September 3, 2013. (*Opening Lecture*)
296. Y.I. Hassan, Md. T. Hoque and **S.P.C. Cole**. Role of the PDZ domains of human NHERF1 in regulating surface expression and cellular trafficking of the multidrug resistance protein-4, MRP4 (ABCC4). 10th Annual North American ABC Meeting. Frederick, MD, September 19-20, 2013.
297. M.F. Miah and **S.P.C. Cole**. Cell-surface MRP4 (ABCC4) levels are down-regulated by the NH₂-truncated CortBP1 isoform of SHANK2. 10th Annual North American ABC Meeting. Frederick, MD, September 19-20, 2013.
298. **S.P.C. Cole**. Misfolding mutants of MRP1 (ABCC1): Useful tools for investigating domain-domain interactions of the transporter. 6th Annual SFB35 Symposium “Transmembrane Transporters in Health and Disease”, Vienna, Austria. September 23, 2013.
299. C. Gao, G. Conseil and **S.P.C. Cole**. Rescue of misfolded MRP1 mutants involving the highly conserved charged amino acids Arg¹²⁰² and Glu¹²⁰⁴ by heterologous expression in insect cells. 10th International Society for the Study of Xenobiotics Meeting, Toronto, ON. September 29-October 3, 2013. *Drug Metab. Rev.* 45: 268-269 (2014).
300. C. Gao*, M. Chan, G. Conseil and **S.P.C. Cole**. Heterologous expression in insect cells rescues expression but not function of misfolded MRP1/ABCC1 mutants. 5th FEBS Special Meeting “ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Diseases”. Innsbruck, Austria, March 8-14, 2014. (**recipient of a Queen's University Postdoctoral Travel Award*).
301. M.A. Csandl, G. Conseil and **S.P.C. Cole**. Effect of leukotriene modifiers on transport activity of multidrug resistance proteins (MRPs). Abstract #1449. Experimental Biology 2015, Boston, MA. March 28-April 1, 2015. *FASEB J.* 29: Suppl 939.4 (2015).
302. M.F. Miah, G. Conseil and **S.P.C. Cole**. N-linked glycans do not affect plasma membrane localization of multidrug resistance protein 4 (MRP4) but selectively alter its prostaglandin E₂ transport activity. 6th FEBS Special Meeting “ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Diseases”. Innsbruck, Austria, March 4-11, 2016.
303. G. Conseil and **S.P.C. Cole**. ABCC4 polymorphisms differentially affect levels and transport activity of the human organic anion transporter MRP4. 6th Special Meeting “ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Diseases”. Innsbruck, Austria, March 4-11, 2016.

304. K. Ziems, S. Bröderdorf, B. Rauch, **S.P.C. Cole**, and G. Jedlitschky. Transcriptional regulation of the MRP4 (ABCC4) transporter. 6th FEBS Special Meeting “ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Diseases”. Innsbruck, Austria, March 4-11, 2016.
305. B.D. Whitlock, D.P. Swanlund, X.C. Le, J.D. Schuetz, **S.P.C. Cole**, and E.M. Leslie. Differential specificity of the human and mouse multidrug resistance protein 4 orthologs for arsenic metabolites. Experimental Biology 2016, San Diego, CA. April 2-6, 2016. *FASEB J.* 30: Suppl 1, 1497 (2016).
306. E.E. Smith, G. Conseil and **S.P.C. Cole**. Exploring the consequences of mutating the hinge regions of the organic anion transporter, MRP1. 19th Annual Meeting for Health Sciences Research Trainees, Queen’s University. Kingston, ON. May 25, 2016.
307. C.B. Shukalek, D.P. Swanlund, R.K. Rousseau, K.E. Weigl, **S.P.C. Cole**, and E.M. Leslie. Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1) is selectively modified by phosphorylation and glycosylation. 16th IUBMB Conference, Vancouver, BC. July 17-21, 2016.
308. J.F. Power and **S.P.C. Cole**. Evaluation of drug resistance transfer via extracellular vesicles in human ovarian cancer cells. 6th Annual Meeting of the International Society for Extracellular Vesicles, Toronto, ON. May 18-21, 2017.
309. G. Conseil, K. Ziems, M. Banerjee, E.M. Leslie and **S.P.C. Cole**. Non-synonymous variants of the human organic anion transporter MRP4 (ABCC4) impair protein levels and trafficking to the plasma membrane. 60th Annual Conference of the Canadian Society for Molecular Biosciences. Ottawa, ON. May 16-20, 2017.
310. E.E. Smith*, G. Conseil and **S.P.C. Cole**. Functional analysis of the regions connecting the membrane spanning domains to the nucleotide binding domains of the 190 kDa multidrug resistance protein 1 (MRP1). 60th Annual Conference of the Canadian Society for Molecular Biosciences. Ottawa, ON. May 16-20, 2017. (**recipient of the Traffic-Wiley Publishing poster prize*)
311. J.F. Power and **S.P.C. Cole**. Evaluation of drug resistance transfer via extracellular vesicles in human ovarian cancer cells. 20th Annual Meeting for Health Sciences Research Trainees, Queen’s University. Kingston, ON. May 24, 2017.
312. G. Conseil, K. Ziems, M. Banerjee, E.M. Leslie and **S.P.C. Cole**. Non-synonymous variants of the human organic anion transporter MRP4 (ABCC4) impair protein levels and trafficking to the plasma membrane. 20th Annual Meeting for Health Sciences Research Trainees, Queen’s University. Kingston, ON. May 24, 2017.
313. E.E. Smith, G. Conseil and **S.P.C. Cole**. Functional analysis of the regions connecting the membrane spanning domains to the nucleotide binding domains of the 190 kDa multidrug resistance protein 1 (MRP1). 20th Annual Meeting for Health Sciences Research Trainees, Queen’s University. Kingston, ON. May 24, 2017.
314. E.E. Smith, G. Conseil and **S.P.C. Cole**. Differential importance of the connecting regions in the biosynthesis and function of multidrug resistance protein 1 (MRP1). Terry Fox Research Institute, Ontario Node Research Symposium, Toronto, ON. December 4, 2017.
315. G. Conseil and **S.P.C. Cole**. Reconciling the cryoEM structure of MRP1 with mutational analyses: The story of Met¹⁰⁹³. Terry Fox Research Institute, Ontario Node Research Symposium, Toronto, ON. December 4, 2017.
316. K.M. Hanssen, C.C. Gana, D.M.T. Yu, C.L. Flemming, A. DeFazio, C. Kennedy, R. Young, G. Wright, B. Solomon, G. Conseil, **S.P.C. Cole**, M.D. Norris, M. Haber, J.I. Fletcher. Modulator of MRP1 synergises with buthionine sulfoximine to chemosensitise and abolish clonogenic capacity of cancer cells. 7th FEBS

- Special Meeting “ATP-Binding Cassette (ABC) Proteins: From Multidrug Resistance to Genetic Diseases”. Innsbruck, Austria, March 6-10, 2018.
317. E.E. Smith*, G. Conseil and **S.P.C. Cole**. Regions connecting the membrane spanning and nucleotide binding domains of Multidrug resistance protein 1 (MRP1) are functionally distinct. 61st Annual Meeting of the Canadian Society for Molecular Biosciences on “Membrane Proteins in Health and Disease”. Banff, AB. April 11-15, 2018. *Recipient of a CSMB Travel Award (\$500)*
318. **S.P.C. Cole**. Protein-protein interactions and membrane localization of the ABCC4 multidrug and organic anion transporter. 61st Annual Meeting of the Canadian Society for Molecular Biosciences on “Membrane Proteins in Health and Disease”. Banff, AB. April 13, 2018. (*invited speaker*)
319. E.E. Smith, G. Conseil and **S.P.C. Cole**. Regions connecting the membrane spanning and nucleotide binding domains of multidrug resistance protein 1 (MRP1) are functionally distinct. 21st Annual Meeting for Health Sciences Research Trainees, Queen’s University. Kingston, ON. June 13, 2018.
320. A. Kragl, K. Ziemis, J. Glaubitz, S. Grammbauer, S. Broderdorf, **S.P.C. Cole**, M. Tzvetkov, G. Jedlitschky. Regulation of basal promoter activity of the human MRP4 (ABCC4) transporter. 4th German Pharm-Tox Summit, Stuttgart, Germany. February 25-28, 2019.
321. K.M. Hanssen, C.C. Gana, M.S. Wheatley, D.M.T. Yu, C.L. Flemming, R. Young, G. Wright, G. Conseil, C. Kennedy, A. DeFazio, B. Solomon, **S.P.C. Cole**, M.D. Norris, M. Haber, and Fletcher, J.I. Modulation of MRP1 activity reverses chemotherapy resistance in adult cancer cells. AACR Annual Meeting. Atlanta, GA. March 29 – April 3, 2019. *Proc. Amer. Assoc. Cancer Res.* 60: 4214 (2019).
322. G. Conseil and **S.P.C. Cole**. Structure-guided probing of the leukotriene C₄ binding site in the human MRP1 (ABCC1) transporter. 62nd Annual Conference of the Canadian Society for Molecular Biosciences. Montréal, QC. June 2-5, 2019.